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Abstract 
 
Extracellular ATP acts in an autocrine/paracrine manner influencing cellular responses via 
two classes of purinoreceptors: metabotropic P2Y and inotropic P2X receptors.  Recent 
observations have demonstrated a role for P2X receptors (P2X1-7) in calcium mediated 
hormone secretion from the pituitary. In the present study we used immortalised cell lines 
and primary pituitary cultures to investigate the effects of P2X receptors within the anterior 
pituitary. We used Reverse Transcriptase Polymerase Chain reaction (RT-PCR) to 
determine the expression of P2XR sub-types within pituitary cell lines and rat pituitary tissue. 
Our studies demonstrated similar expression of P2X receptors between rat pituitary tissue 
and cell lines. The expression of P2X1-7 receptors was identified in rat primary pituitary 
tissue.  In the lactotroph cell lines, MMQ and GH3 we found P2X2, 3, 4, 5, 7 and P2X3, 4, 7 
receptors, respectively.  In LβT2 gonadotroph type cells, P2X2, 3, 4, 7 were identified 
whereas the corticotroph cell line AtT20:D16 expressed P2X1,2.  Finally the murine cell line 
TtT/GF, which represent an in vitro model of the non-endocrine folliculostellate were profiled 
for P2X receptor expression. To our knowledge this is the first time this particular cell type 
has been examined for P2X receptor expression. Weak expression for P2X2, 4 was 
identified. The distribution pattern of P2X1-7 receptors within the rat pituitary was determined 
using double labelling immunoflourecscence and western blot. Protein expression for P2X4 
and P2X7 was confirmed by Western blot of rat pituitary lysates, but no signal for P2X3 
could be determined. Double immunofluorescence found P2X4 to be localised in 
corticotrophs, gonadotrophs, sommaotrophs, lactotrophs and thyrotrophs within a small 
group of cells.  P2X7 was only found localised in a small group of somaotrophs. 
We then undertook a more thorough characterisation of the functional significance of P2X 
receptor expression within the different mammalian pituitary subtypes. We began our 
investigation by establishing a rat primary pituitary culture model and utilised multiplexing 
technology to assess the effects of ATP on the secretion of multiple pituitary hormones 
(Adrenocorticotropic hormone (ACTH), Growth Hormone (GH), Prolactin (PRL) and Thyroid 
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Stimulating Hormone (TSH) ) simultaneously. ACTH and PRL were the most responsive to 
ATP stimulation. TSH and GH showed little response to ATP stimulation. We then went on to 
examine the effects of ATP on hormone secretion within our various cell lines. In AtT20:D16 
cells, ATP had a significant effect on ACTH release when applied alone and in combination 
with CRH following incubation for 7 and 12 hours. Using the lactotroph model GH3, we 
assessed the effects of ATP and various ATP analogues on PRL release in vitro. All 
concentrations of ATP tested (0.001-1000µM) had a significant effect of PRL release from 
cells. On the other hand both  analogues,  the non- hydrolysable form of ATP adenosine 5'-
O-(3-thio)triphosphate  (ATP--S) and the P2X selective  analogue,  2',3’-O-(4-benzoyl-
benzoyl) (BzATP) had no significant effect on PRL release. We then attempted to 
characterise P2XR function in the pituitary using highly specific P2 and P2XR antagonists. 
The P2 receptor antagonist pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS) 
significantly decreased both basal release of PRL and stimulated PRL secretion  in response 
to TRH (1nM), ATP, (1 and 100µM) and TRH and ATP in combination. A similar profile was 
observed after treatment with the selective P2X7R inhibitor, A438079. The selective P2X3R 
inhibitor failed to influence basal PRL secretion but did significantly attenuate the effect of 
TRH and ATP stimulated PRL release. Our results confirm previous investigations that ATP 
interactions with purinergic receptors expressed within the pituitary may play a role in 
modulating pituitary function.  Our data has also shown through the use of specific receptor 
antagonists, that P2X receptors, particularly P2X3 and P2X7 may be involved in regulating 
hormone secretion from lactotrophs. 
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1.1 The endocrine system 
 
In humans and other mammals, regulation of the internal environment and responses to the 
external environment are coordinated by signals derived from both the nervous and 
endocrine systems. The nervous system exerts its influence through a system of specialised 
cells or neurons, which convey messages from the brain directly to specific organs. In 
vertebrates, the endocrine system is composed of a collections of glands (e.g. thyroid, 
adrenal and pituitary), which function to produce chemical messengers which are secreted 
into the bloodstream and subsequently act to modify or control organ function. There are 
over 50 different types of “chemical messengers” or hormones secreted within the endocrine 
system.  These hormones can be grouped into three classes, and the germinal epithelium 
from which the gland is derived from, will determine the class of hormone secreted.  Glands 
derived from the ectoderm and endodermal layer will produce amine hormones which are 
derived from tyrosine residues, and peptide hormones which are composed of short chain 
amino acids. Glands made up of mesodermal tissue produce steroid hormones, which all 
share a common precursor – cholesterol.   
Protein hormone synthesis occurs  in the rough endoplasmic reticulum and golgi body of the 
secretory cells that compose the  endocrine gland and are secreted into the blood, where 
they bind to receptors  expressed on the surface or within the target organ. Receptor binding 
is coupled to an internal signalling mechanism which allows transduction of the signal to be 
initiated by the hormone. Hormones can act locally at the site of production (autocrine), on 
neighbouring cells (paracrine) or distally at sites located away from the gland transported via 
the circulation (endocrine), with hormone effects lasting from hours up to weeks. Variations 
in the amounts of hormone secreted coupled with alterations in the pattern of hormone 
secretion allow for fine control of numerous physiological functions including metabolism,  
reproduction and  sexual differentiation, growth and development,  sleep , mood  and 
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arguably most important,  the regulation of the internal environment (homeostasis). Co-
ordination of inputs from both the nervous system and endocrine system in order to maintain 
homeostasis is best exemplified by the regulation of the master gland or pituitary gland [[1], 
[2]]. 
1.2 The neuroendocrine system 
 
The neuroendocrine system describes the interactions between the brain (especially the 
hypothalamus) and the glands of the endocrine system, and includes the numerous 
neuroendocrine cells which receive direct neuronal input and subsequently release 
hormones into the blood. Together, their actions serve to regulate several major 
physiological functions within the body. Proper coordination between inputs from both the 
brain and the peripheral nervous system (PNS) are required to maintain normal homeostasis 
which is controlled by the hypothalamus, which I will describe in more detail in section 1.2.1. 
Hypothalamic control of the pituitary gland is also vital to ensure the system functions 
correctly as hormones released from here ultimately control all aspects of human physiology 
such as food intake, blood pressure and responses to stress or infection. The pituitary will be 
discussed in section 1.2.2 [2]. 
1.2.1 The hypothalamus- function and anatomy  
 
Homeostasis is a dynamic balance that must be maintained by all multi-cellular organisms in 
spite of changes to its external and internal environment. The hypothalamus plays a 
significant role in initiating an array of behavioural and physiological responses to maintain 
this equilibrium. The hypothalamus forms the connection between the central nervous 
system (CNS) and the rest of the body [1]. 
The hypothalamus is connected to the brain via the midbrain and telencephalon regions of 
the brain. It is composed of three parts; the periventricular, medial and lateral hypothalamus. 
Afferent and efferent neurones covey signals to and from the brain and inputs from distal 
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endocrine glands via the peripheral nervous system (PNS). Hypothalamic neurones connect 
with the brain in groups located in the third ventricle of the brain.  Neurones which emanate 
from the medial layer of the hypothalamus control pituitary gland function, forming a 
continuous link called the hypophyseal nerve tract.  Neurones sprouting from the lateral 
portion are involved in control of autonomic function. Blood supplied by the hypophyseal 
inferior and superior arteries facilitate control of the posterior and anterior pituitary 
respectively.  Hypothalamic nuclei secrete hormones directly into a capillary portal system 
that transports the hypothalamic hormones directly to the endocrine cells that constitute the 
pituitary gland. There are six hypothalamic hormones which regulate pituitary function (see 
figure 1.1 and table 1). These hormones possess either a stimulatory or inhibitory effect on 
hormones release from the anterior pituitary.  Pituitary hormones can control their own 
release via negative feedback. This feedback mechanism is illustrated in figure 1.1  [3]. 
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Figure 1.1: Role of hypothalamic hormones in controlling peptide hormone secretion from the anterior 
pituitary gland Hypothalamic neurones release six hormones: Gonadotrophin releasing hormone (GnRH),  
Growth Hormone releasing hormone (GHRH), Somatostatin (SS) Thyrotropin Relaseing hormone (TRH), 
Dopamine (DA) and  Corticotropin-releasing hormone  (CRH) which are transported to the 
adenohypophysis via the portal capillary system These substances can either facilitate pituitary hormone 
release (RH) or act to inhibit pituitary hormone release (IH) from the different pituitary cell populations. 
Pituitary hormones include: - Follicle stimulating hormone (FSH), Luteinising Hormone (LH), Growth 
hormone (GH), Thyroid stimulating hormone (TSH) , Prolactin (PRL) and Adrenocorticotropic hormone 
(ACTH). 
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1.2.3 The pituitary gland 
1.2.3.1 Pituitary gland –function and structure 
 
The adult pituitary gland is situated at the base of the brain just below the hypothalamus in a 
bony area called the sella turcica and is formed from both neural and oral ectodermal tissue. 
Invagination of the ectoderm early in development forms the primary structure of the pituitary 
gland known as Rathke’s pouch. The posterior lobe, also known as the neurohypophsis, is 
continuous with the hypothalamus via the hypophyseal portal connection.  The hypothalamic 
axons of supraoptic and paraventricular nuclei neurons comprise much of the posterior 
pituitary as well as the supportive cells called pituicytes. The hypothalamus secretes 
inhibitory and excitatory hormones into this area following electrical stimulation from the 
brain. 
The anterior lobe, also known as the adenohypophysis,  is anatomically separate from the 
hypothalamus, and   is composed of 6 different types of hormone secreting epithelial cells  
(see table 1).  Some 50% of these endocrine cells are sommatotrophs, 10-15% are 
lactotrophs, 15-20% are corticotrophs, 10-15% are gonadotrophs and 3 to 5 % are 
thyrotrophs [[4] [5]].  Interspersed amongst the hormone secreting cells are the non-
endocrine folliculo-stellate cells. These are glial like cells and play a supportive role [[6], [7]].  
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Table 1.1: Pituitary cell sub-types and their associated hormones  
    
 
Cell type 
 
Hormone secreted 
 
Hormone function 
 
Target tissue 
Corticotroph ACTH and POMC 
derivatives 
Controls synthesis 
and release of 
glucocorticoids 
from adrenal cortex 
Heart, immune 
cells, adipocytes, 
neurons 
Thyrotroph TSH Regulation of the 
thyroid gland and 
synthesis and 
release of thyroid 
hormone 
Muscle, heart, 
adipocytes, liver 
Somatotroph GH Liver synthesis of 
IGF1; bone and 
muscle growth 
Glucose, lipid 
immune cells 
Gonadotroph FSH, LH Regulates 
development of 
gonads and 
secretion of sex 
steroid hormones 
Gonads 
Lactotroph PRL Lactation Mammary glands 
Produced using the following reference: [1]  
Most of the hormones secreted by the adenohypohysis are polypeptide hormones formed 
from the post translational modification of a larger prohormone by proteolytic enyzymes 
located within the secretory granules. Anterior pituitary hormone secretion is driven at a 
cellular level by entry of extracellular calcium or calcium influx [Ca2+]i  and the frequency and 
amplitude of hormone secretion occurs in a pituitary cell subtype specific manner [8]. Gross 
anatomy of the interactions between the hypothalamus and pituitary can be seen in figure 
1.5. 
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1.2.3.2 The hypothalamo-pituitary axis 
 
Established at week 20 of gestation in humans, the hypothalamo-pituitary axis is vital for 
monitoring and maintenance of the internal environment and communicating any changes 
back to the central nervous system (CNS).  Pituitary function is also augmented by paracrine 
factors such as IL-6, insulin-like growth factor and acetylcholine [[9], [10], [7] [11]]. More 
recent observations have demonstrated that adenosine 5’-triphosphate (ATP) can be added 
to list of molecules that augment pituitary function [[12], [13], [14]]. 
1.3 Adenosine 5’-Triphosphate (ATP) and purinergic signalling 
  
The ability of adenosine 5’-triphosphate (ATP) to act as an extracellular signalling molecule 
was first observed over 80 years ago. Since then, investigations have increased our 
understanding into ATP behaviour as a paracrine and autocrine messenger. These effects 
are conveyed by interactions with its native receptors. We now appreciate that ATP is more 
than just a currency of energy and can influence a whole host of physiological events.  The 
aim of this following section is to give a brief history of ATP as a signalling molecule, then to 
introduce the concept of purinergic signalling and the physiological role of P2X receptors 
(P2XR), and then the importance of purinergic signalling in modulating pituitary function. 
1.3.1 Adenosine 5’-Triphosphate (ATP) - an extracellular signalling molecule 
 
In 1929 the pioneering work of Dury and Szent-GyÖrgyi first identified a role for extracellular 
purines, in this case adenosine and adenosine 5’-monophosphate (AMP), in regulating the 
cardiovascular system [15]. Gillespie, in 1934, demonstrated that ATP could stimulate 
contraction of both guinea pig ileum and uterus and was more potent than adenosine and 
AMP in this regard. During the 1940’s the role of ATP as an extracellular signalling molecule 
was confirmed in numerous tissues, and in 1948, Emmelin and Feldberg, working on cats, 
observed that ATP produced effects both within the peripheral and central nervous systems 
[15]. Holton and Holton’s work in the 1950’s identified ATP’s role as a neurotransmitter in 
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mediating vasodilation in the rabbit ear following stimulation of the auricular nerve [[16], [1]].  
The concept of ‘purinergic signalling’ was formally recognised due to the work of Burnstock 
in the 1970’s, who coined the term during investigations into non-andrenergic non-
cholinergic (NANC) nerves supplying the gut and the bladder [[15], [1]].  It is now accepted 
that ATP is an important neurotransmitter in both the central and peripheral nervous 
systems. Therefore, investigations into ATP and its interactions with native receptors have 
increased our understanding of the molecule’s significance in biological systems and we now 
appreciate that ATP is more than just a currency of energy and can influence a whole host of 
physiological events. 
1.3.2 Structure and synthesis 
 
ATP is a purine molecule, composed of an adenine molecule bound to a ribose sugar via a 
glycosidic bond. As shown in figure 3, attached to the 5’ carbon of the ribose sugar are three 
charged phosphate group. Eukaryotic organisms have evolved tightly regulated mechanisms 
for the synthesis of ATP which include oxidative phosphorylation, the citric acid/Krebs cycle 
and within the mitochondria during anaerobic glycolysis [19]. ATP is a ubiquitous molecule 
which can be found stored in both the organelles and cytoplasm of a cell. Energy generated 
from the enzymatic breakdown of the molecule is vital to a range of biochemical reactions 
crucial to cellular survival [[19],[[20]]. ATP is released by both living and dying cells by a 
range of mechanisms which include exocytosis, transmembrane channels such as 
hemichannels,  and anion channels and by protein transporters such as  the ATP-binding 
cassette transporters (ABC-transporter) [[21],[22]]. In the mammalian pituitary gland, a clear 
mechanism for ATP release has yet to be fully characterised. However a family of gap 
junction proteins called pannexins have been identified in the rat pituitary tissue and pituitary 
cell lines. Investigations have demonstrated that inhibition of pannexin protein function 
caused a decrease in basal ATP release from AtT20 cells and it is now believed  that 
pannexins facilitate  ATP release from pituitary cells [23]. In animal cells, extracellular ATP 
participates in a range of physiological processes via its actions as a signalling molecule. 
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AMP, as well as uracil triphosphate (UTP) and uracil diphosphate (UDP). Purinergic 
receptors can be found distributed in a variety of tissues and more than one receptor type 
can be found in any given organ or biological system [[25], [26], ([27], [27]]. Figure 1.3 
provides a schematic overview of how ATP and it derivatives interact with P1 and P2 
receptors. 
1.4.1 Overview of P1 receptors 
 
Adenosine (P1) receptors are G-coupled protein receptors. To date four mammalian P1 
receptors have been cloned: A1R, A2AR, A2BR and A3R [[15], [26], ([27], [27]].  ATP released 
from both excitatory and non-excitatory cells is subject to degradation by ectonucleotidases 
which break down ATP into its precursors, thus providing a source of adenosine which can 
then bind to P1 receptors located on the plasma membrane of cells. Ligand binding of 
adenosine to A1R (& potentially A3R) has been shown to have an inhibitory effect on target 
cells. This occurs primarily via the down regulation of adenylate cylclase and subsequent 
reduction in activity of the cyclic adenosine monophosphate (cAMP) dependent protein 
kinase [15]. Other signalling mechanisms associated with A1R include both an increase in 
Ca2+ mobilization due to activation of phospholipase C (PLC), as well as down regulation of 
calcium (Ca2+) mediated signalling primarily via the activation of potassium (K+) channels. In 
contrast, A2AR and A2BR are positively linked to adenylate cylclase (via Gs and Gq pathway) 
and activation of these receptors also causes modulation of Ca 2+ channels. Activation of the 
mitogen activated protein (MAP) kinase pathway is associated with all P1 receptors [[28] 
[29][30]]. 
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The binding of ATP to P2X receptors (P2XRs) causes a change in conformation which 
favours the passage of cations (Na2+, K+ and Ca2+) through the protein pore.  There are 7 
receptors (P2X1-7) which can be found expressed homo- and hetero-metrically in a variety of 
organisms [[26],[31]]. An overview of the molecular structure and agonist selectivity of 
purinergic receptors is shown in Figure 1.3. 
1.5 P2X receptors 
1.5.1 Structure 
 
 P2XRs  represent a novel class of ligand gated channels which in response to ATP, non-
selectively facilitate the passage of divalent cations such as Ca2+ and monovalent  ions such 
as K+ [[32],[33]]. P2XR are structurally distinct from other members of the ligand gated ion 
channel family, which include glutamate receptors (e.g. N-methyl-D-aspartate receptor) and 
the nicotinic acetylcholine receptor [[29],[34],[35]].  P2XRs are described as calcium 
channels since they show a preference for the passage of Ca2+ allowing a greater influx of 
Ca2+ compared to other family members. P2X receptors are most similar in structure to the 
acid–sensing ion channel family (ASIC), however studies have found there to be no amino 
acid sequence homology between the two families.  Following cloning of P2 receptor 
encoding genes in 1994, seven human P2XR have been identified to date. Receptors can 
be found expressed in eukaryotic organisms in either the homo- or hetero-meric form. 
Recombinant expression of murine and rat derived P2X subunits have found. P2X6 is 
exceptional as it does not form functional homomeric receptors and can only be found as 
part of a functional heteromer with P2X2 and P2X4. P2X7 on the other hand does not form 
functional heteromers with other P2XRs and can only be found expressed as a homomer 
[33]. 11 different heteromeric receptors may be assembled from the 7 P2X subunits, 
however far fewer than this have been documented in vivo. Currently P2X2/3, P2X2/6, 
P2X4/6, and P2X1/5 are the only functional heteromultimers to have been identified [36]. 
Therefore comprehensive comparative pharmacology data on heteromeric receptors and 
homomeric receptors is not currently available [[34] ,[37],[36]].  
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1.5.2. Receptor topology and subunit interactions 
 
Receptors have a size range of 379-595 amino acids. Residues associate to form a trimeric 
structure [[34], [21]].  Two membrane spanning units (TM1 & TM2) form the pore/gate of the 
receptor which allow for binding of up to three ATP molecules at any given time. TMs adopt 
an -helical structure and hydrophobic regions within connect the two units via disulphide 
bridges formed from the cross linking of cysteine residues.  These intramolecular disulphide 
bridges are a defining feature of P2X receptors. They form the ectodomain (ec) of the 
receptor which represents 70% of the overall structure of the P2XR. N-glycosylation of the 
ec domain, as shown in figure 1.4, is essential for expression of functional receptors on the 
cell surface membrane [[28], [34],[35]]. The amount of glycosylation varies between receptor 
subtypes and both the disulphide bridge and glycosylation contribute to formation of the 
secondary and tertiary structure of the protein [34].  
In 2009, Kawate and colleagues published the first 3D crystal structure of a P2X receptor [2]. 
A construct of the wild type zebrafish P2X4.1 (zfP2X4.1) was resolved to 3.1ºA and has 
confirmed much of the previous information on the structure and function of P2X receptors 
derived from mutagenesis studies. This crystalograph study also confirmed that TM2 plays a 
greater role in the gating of the pore with TM1 having more of a supportive role. Substitution 
studies of conserved sequences in the ec domain of P2X1,2,3,4  demonstrated that  aromatic 
amino acids within the ec domain bind to the adenine ring in ATP. Positively charged lysine 
residues in TM2 can interact with the negatively charged phosphates in the ATP tail. The  
sensitivity of P2X receptors to divalent cations such as Ca2+ may be a consequence of the 
polar regions in TM2  formed by  threonine and serine  and sub-units in the TM  which 
behave in an aqueous manner [[28], [39]]. 
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Figure 1.4 Schematic of P2X topology in the plasma membrane. This diagram shows essential internal 
interactions (formation of disulphide bridge and glycosylation sites) in the ec domain required for proper 
receptor expression. The two TM units span the lipid membrane while the amino and carboxy groups are 
located intracellularly. 
 
1.5.3 Signal transduction 
 
The selective filtration of cations by P2XRs is a dynamic process. The longer that ATP is 
docked to the receptor, the greater the dilation of the pore and the larger the size of cation 
that can pass through the pore. Studies have shown this process can occur whilst 
simultaneously inhibiting the entrance of anions [34]. Pharmacological characterisation of 
both human and rat receptors have been conducted using recombinant protein expressed in 
both mammalian (such as the human astrocytoma cell line 1321N1) and non-mammalian 
systems (Xenopus oocytes). Combined with mutagenesis data, these studies have provided 
a wealth of information on receptor sensitivity to agonist, antagonist and rates of 
desensitisation.  Although there are some discrepancies depending on the expression 
TM2 TM1 
NH+3 
COO- 
Ectodomain 
Transmembrane 
domain 
Cytosolic 
domain 
N-linked 
glycosylation 
Disulphide 
bonds 
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system used, particularly with regard to ATP analogues, such as α,β-meATP and BzATP, it 
is generally the case that  P2XR  kinetics are primarily dependant on the subtype structure 
and differ for hetero- and homo- polymerized receptors [[22], [40],[41]]. 
 
1.5.4 Tissue distribution and biological effects 
 
As a consequence of the diverse expression of P2XR within mammalian cellular 
microenvironments, it is essential that receptor expression is tightly regulated in order to 
ensure that receptor mediated responses occur in a coordinated manner [[30], [42]]. A list of 
the different tissues which express P2X channels are shown in table 1.2. Constitutive cycling 
of inotropic P2XRs is one of the mechanisms by which these receptor mediated responses 
can be regulated in order to maintain homeostasis [43]. For example, P2X4R are up-
regulated on the surface of activated macrophages as required from a readily available pool 
of receptors in the lysosomal compartment and P2XR density can also be readily altered in 
presynaptic neurons within the olfactory bulb [44].  
In general, P2XR appear to act as “cellular sensors” within the different microenvironments 
that the receptors have been observed within [[21] [30]]. The large extracellular domain 
significantly contributes to the modulation of local tissue responses. The receptor is sensitive 
to subtle changes in the microenvironment including changes in the levels of proton ions 
(H+), trace metal ions (Zn2+, Cu2+), calcium ions and, of course, ATP. Receptors convey 
these fluctuations by rapidly increasing or decreasing the passage of Ca2+ down its 
electrochemical gradient which then controls the activity of calcium dependent secondary 
messengers within the cell and therefore the overall response of the cells [[21] [45],[2]].  
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Table1.2 Widespread physiological expression of P2X receptors in mammalian systems 
 
 Produced using the following reference: [[19][2] [47][26] [29]]. 
1.6 Purinergic signalling in the neuroendocrine system 
 
Recent observations have demonstrated a role for purinergic signalling in regulated 
exocytosis [48].  In exocrine organs such as the pancreas, it has been established that ATP 
(and zinc) are co-released with insulin, and act in an autocrine and paracrine manner to 
increase glucose induced insulin hormone release. These studies have been extended to 
other secretory tissues, including endocrine organs such as the pituitary, where studies have 
shown that fully functioning purinergic signalling is expressed, and operates  in a similar 
manner [[49] [29]; [27]]. 
 
  
P2X Receptor subtype Principle tissue distribution 
P2X1 Smooth muscle , sympathetic & 
parasympathetic ganglia, cerebellum, 
platelets, pituitary 
P2X2 Central and peripheral nervous system, 
brain,  smooth muscle, pituitary 
P2X3 Sensory neurons, sympathetic neurons, 
pituitary 
P2X4 Brain, Teste , epithelial cells, pancreas, 
pituitary 
P2X5 Brain, spinal cord, skin cells, heart, thymus, 
pituitary 
P2X6 Cerebellum, hippocampus, skeletal muscle,  
pituitary 
P2X7 Microglia,  Macrophages,  Apoptotic cells 
skin, pituitary 
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1.6.1 P2X signalling in the hypothalamus  
 
 All nuclei of the neuronal fibres which stem from the hypothalamus and terminate at the 
pituitary express more than one type of purinergic receptor. P2X2 receptors expressed in 
these nuclei aid in the controlled release of vasopressin from the posterior pituitary [50]. 
Recently, investigation of purinergic signalling in the hypothalamus has shown that ATP 
stimulates increased levels of intracellular calcium within hypothalamic neurons in the rat 
[47].  In vitro, the pulsatile release of luteinising hormone releasing hormone  (LHRH) from 
cultured LHRH neurons is augmented by ATP activation of P2XR2 and P2XR4 and Ca2+ [51]. 
Purinergic receptors are also expressed in the supportive cells of the hypothalamus 
including microglial cells and astrocytes [52]. Although studies have indicated that functional 
homo- and heteromeric P2X2 receptors play a role in CRH release, their potential role in the 
HPA axis and localised responses to stress require further investigation. 
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Figure 1.5 The Hypothalamo-Pituitary Axis and P2X Expression in the Anterior Pituitary (Adapted from 
[49]).  Magnocellular neurons of the supraoptic and paraventricular nuclei project to the posterior 
pituitary where they release vasopressin and oxytocin into the capillaries.  Hypophysiotropic neurons 
from the hypothalamus release trophic hormones into the hypophysial portal system, where they travel 
to the anterior pituitary and control hormone release from secretory cells.  TSH: thyroid-stimulating 
hormone; ACTH: adrenocorticotropic hormone; LH: luteinizing hormone; FSH: follicle-stimulating 
hormone; GH: growth hormone; PRL: prolactin. 
 
1.6.2 Purinergic signalling in the pituitary 
 
Characterisation studies have established that the pituitary gland expresses all forms of 
purinergic receptors as well as the machinery required for purinergic signalling. P2Y 
metabotropic receptors (predominantly P2Y4,6,12),  P2X-ligand gated ion channel ( P2X2,3,4,7) 
and adenosine receptors (A1,A2a/b) can be found distributed within the different pituitary 
subtypes to varying degrees [[53]; [49] ,[96]]. Figure 1.5 illustrates our current understanding 
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of expression of P2X receptors amongst the pituitary subpopulations. Exploitation of 
mammalian  expression systems  such as HEK cells using membrane expressed luciferase 
have shown internal concentrations of ATP to reach concentrations of up to 200uM at the 
plasma membrane [[54] [33]]. This involves incubating cells in Krebs Ringer  buffer at room 
temperature and  assaying samples  for ATP release using a luminometer [2]. 
Pharmacological studies have shown that concentrations within this range are sufficient to 
elicit a response at purinergic receptors. Enzymes to control the activity of ATP are also 
expressed in the plasma membrane of pituitary cells with mRNA for the ecto-nucleotideases, 
ectonucleoside triphosphate diphosphohydrolases 1, 2 and 3 (E-NTPDases) detected in 
whole pituitary [[33, 55]]. 
 
1.6.2.1 Overview of P2X mediated hormone release 
In the pituitary, binding of ATP to P2X allows the passage of calcium down its 
electrochemical gradient inside the cell. This causes a depolarisation of the plasma 
membrane and stimulation of action potentials. These action potentials generate large 
influxes of intracellular calcium [Ca]I which penetrate all areas of the cell [56]. This global 
signalling allows calcium to span the gap between hormone loaded vesicles and calcium 
channels, which is vital for regulated hormone secretion [[57], [1]]. 
 
1.6.3. P2XRs and pituitary subtypes 
Our current understanding concerning the influence of purinergic signalling within specific 
pituitary cell populations has been derived from a combination of electrophysiological and 
molecular based investigations, using both pituitary cell lines and primary tissue.  
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1.6.3.1 Corticotrophs 
Our current understanding of purinergic signalling within corticotrophs is limited. In 1989, 
work from two separate laboratories demonstrated adenosine signalling played a functional 
role in regulating ACTH secretion from pituitary corticotrophs. More recently Zhao and co-
workers have identified that both P2 receptor families are expressed within the mouse 
corticotroph cell line, AtT-20s. The same study demonstrated that ATP stimulation of the 
cells increased the production of POMC by a mechanism which did not involve protein 
kinase A (PKA). Although this pituitary subtype appears more sensitive to adenosine, it has 
been suggested that both P2Y and P2X receptors may be involved in the production of 
POMC [[59], [60], [61]] 
1.6.3.2 Gonadotrophs  
Data from studies utilising embryonic, neonatal and adult rat pituitary tissue have suggested 
that ATP and P2X interactions are responsible for the spontaneous changes in membrane 
potential observed within gonadotrophs. P2X receptors are believed to control basal release 
of hormone from these cells and therefore act as pacemaking channels in gonadotrophs. 
Zemkova and colleagues demonstrated in primary gonadotroph cultures that ATP acting on 
P2X2 receptors induce depolarising currents (via the influx of calcium through these 
channels) and initiate spontaneous action potentials in cells. A combination of patch clamp 
studies and RT-PCR have demonstrated that these channels serve to synchronise electrical 
activity across the membrane and to amplify calcium mobilising activity initiated by 
hypothalamic gonadotropin-releasing hormone and the release of LH [[62];  [34]]. 
1.6.3.3 Lactotrophs  
Investigations have demonstrated that approximately 90% of pituitary lactotrophs are 
responsive to ATP. He and colleagues demonstrated that lactotrophs express functional 
receptors that are able to generate depolarising currents when treated with ATP. Patch 
clamp analysis of cells pretreated with thasigargin (which blocked internal calcium 
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mobilisation by P2Y channels) and subsequently treated with P2XR agonists demonstrated 
an increased calcium influx through these channels of sufficient magnitude to stimulate 
prolactin release. Pharmacological profiling with various P2XR ligands and subsequent RT-
PCR analysis suggested that P2X4 was the most likely candidate responsible for the calcium 
mediated release in these cells. Further work utilising electrophysiology and pharmacological 
profiling of TRH responsive cells confirmed these findings that direct interactions between 
ATP and P2X4 were responsible for prolactin release from cells. These cells were also 
sensitive to the P2X4 modulator ivermectin (IVM), which increases both pore dilation and 
sensitivity of receptors for ATP [[63]; [64],[65], [13]. A summary of purinergic receptor 
expression within the different pituitary subtypes is shown in table1. 3. 
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Table 1.3: The distribution of purinoceptors within the pituitary gland  
Cell type P1 receptor P2Y receptor P2X receptor References 
Folliculostellate 
cells 
A2b 
Stimulation 
triggers the 
release of IL-6 
and VEGF and   
aids the formation 
of gap junction for 
intercellular 
communication 
 
P2Y2 
Binding of UTP 
and ATP 
mobilises 
intracellular Ca2+ 
stores and 
stimulate hormone 
secretion  
 
No evidence of 
functional 
receptors 
[66],  
 
[67] 
 
[2] 
 
Corticotrphs A1 and A2 
-stimulation of all 
purinergic 
receptors induced 
production of 
POMC  but did 
not increase 
secretion of 
ACTH; additive 
effect on CRH 
mediated ACTH 
release  
P2Y1,2,4 
-Receptors 
identified by RT-
PCR 
-Physiological 
significance is still 
under 
investigation 
 
P2X1,3,7 
-Receptors 
identified by RT-
PCR 
-Physiological 
significance is 
still under 
investigation  
[61] 
Lactotrophs A1 
-Coupled to 
adenylate 
cyclase, PLC  
where can inhibit 
Ca2+ channels  
P2Y2 
Evidence from 
studies on mixed 
pituitary 
population  
suggested this 
subtype is 
expressed 
P2X4,7 
Pace making 
channels 
 
[69] 
 
[50] 
 
Gonadotrophs A1 
- as above 
P2Y2 
stimulation 
increases 
cytosolic 
Ca2+,production of 
IP3  and release of 
LH  
 
P2X2 
Pace making 
channels 
 
[34] 
[70] 
[14] 
[48] 
 
The co-release of ATP (and possibly bivalent ions such as zinc) seemingly potentiates the 
effects of hypothalamic neurohormones by signalling in an autocrine/paracrine manner to 
modulate calcium signalling [[71], [1]]. The duration and pattern of P2X signalling is 
controlled by ectonucleases found in the pituitary, which sequentially break down ATP into 
its metabolites for recycling back into the cell and the stimulation of adenosine receptors 
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which are generally negatively coupled to calcium mobilising G-protein coupled receptors 
[[73] [2]; [75] ] 
 
1.7 Summary of aims of thesis 
 
 Purinergic signalling is evolutionarily highly conserved and has been demonstrated to play a 
role post-development in a range of organs, including the mammalian pituitary gland. 
Previous investigations have demonstrated a role for ATP interactions with P2X1-7   family to 
play a role in hormone release from the pituitary gland. However investigations into the role 
to which individual receptors contribute to pituitary function has been inhibited by the limited 
range of specific ATP analogues and/or antagonist. 
The overall concept behind the work presented in this thesis was to further examine the role 
of purinergic signalling in the propagation and amplification of pituitary hormone release, and 
also the mechanism by which individual P2X receptors contribute to hormone release from 
the different pituitary cells. To do this, highly specific P2X antagonists were used to 
determine the contribution made by each family member, along with a range pituitary cell 
lines so that each cell type can be assed in isolation. 
With detailed histological characterisation available for  P2Y expression in the rat pituitary 
gland [76], emphasis was also placed on determining the distribution patterns of the P2X 
receptors expressed in the pituitary . Although functional expression of the P2X receptors 
has been demonstrated using electrophysiology and Q-PCR, confirmation of which receptors 
reside in the pituitary subtypes by immunostaining has yet to be achieved. This branch of the 
investigation would provide evidence of co-localisation between individual P2X receptors 
and pituicytes. 
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Chapter 2 Material and Methods 
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2.1 Materials 
    2.1.1. Chemicals and reagents 
Chemicals and reagents used in the experiments were summarized in the following table 
 
Table 2.1   Chemicals and reagents 
   
Abbreviation Name Supplier 
Agarose --------- Sigma-Aldrich, UK 
ATP Adenosine 5’-triphosphate Sigma-Aldrich, UK 
ATPγS Adenosine 5´-O-(3-thiotriphosphate) Sigma-Aldrich, UK 
A-438079 
3-[[5-(2,3-Dichlorophenyl)-1H-
tetrazol-1-yl]methyl]pyridine 
hydrochloride 
Sigma-Aldrich, UK 
AF-353 
5-[5-iodo-4-methoxy-2-(1-
methylethyl)phenoxy]-2,4-
pyrimidinediamine hydrochloride 
Sigma-Aldrich, UK 
BzATP 2’(3’)-O-(4-Benzoylbenzoyl) Sigma-Aldrich, UK 
CRF Corticotropin Releasing Factor  Sigma-Aldrich, UK 
DAPI 
4',6-Diamidino-2-Phenylindole, 
Dihydrochloride Invitrogen, UK 
DMSO Dimethyl sulfoxide  Sigma-Aldrich, UK 
NDS 
Normal Donkey serum 
 
Sigma-Aldrich, UK 
DMP904 
 
4-(3-pentylamino)-2,7-dimethyl-8-
(2-methyl-4-methoxyphenyl)-
pyrazolo-[1,5-a]-pyrimidine 
 
Gift from Pfizer-neusentis 
EDTA 
Ethylenediaminetetraacetic acid 
 
Sigma-Aldrich, UK 
EtBr ethidium bromide Sigma-Aldrich, UK 
FCS Foetal Calf Serum Invitrogen, UK 
NGS Normal Goat Serum Sigma-Aldrich, UK 
HCl Hydrochloric acid 
 
Sigma-Aldrich, UK 
HS Horse Serum Invitrogen, UK 
H2O2 
 
 
Hydrogen peroxide solution 
 Sigma UK 
LDS Sample Buffer (4X) 
 
-- 
Thermo Scientific, UK 
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Milk Powder --- VWR,UK 
MOPs buffer 3-(N-morpholino)propanesulfonic 
acid, 
Invitrogen, UK 
Mounting Medium 
(Hardset) --- Vector labs, UK 
PBS Phosphate buffered saline  Sigma, UK 
 PFA Paraformaldehyde Sigma, UK 
PPADS 
Pyridoxal phosphate-6-
azo(benzene-2,4-disulfonic acid) 
tetrasodium salt hydrate 
 
Sigma-Aldrich, UK 
phosphatase inhibitor 
cocktail 1 
--- Sigma-Aldrich, UK 
phosphatase inhibitor 
cocktail 2 
--- Sigma-Aldrich, UK 
protease inhibitor 
cocktail 
--- Roche 
R121919 
 
3-[6-(dimethylamino)-4-methyl-
pyrid-3-yl]-2,5-dimethyl-N,N-
dipropyl-pyrazolo[2,3-a]pyrimidin-
7-amine 
 
Gift from Pfizer-neusentis 
TBE Tris-Borate-EDTA buffer Sigma-Aldrich, UK 
TNP-ATP 
 
2′,3′-O-(2,4,6-Trinitrophenyl) 
adenosine 5′-triphosphate 
monolithium trisodium salt 
 
Tocris, UK 
TRH Thyrotropin releasing hormone  Sigma-Aldrich, UK 
Triton-X 100 
4-(1,1,3,3-
Tetramethylbutyl)phenyl-
polyethylene glycol 
Sigma-Aldrich, UK 
0.25% Trypsin-EDTA 
 
-- Invitrogen, UK 
Trypsin inhibitor 
from Glycine 
max (soybean) 
 
--- 
 Sigma , UK 
Tween 20 Polyethylene glycol sorbitan monolaurate, Sigma , UK 
nuclease free water ---- VWR, UK 
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2.1.2. Buffers and solutions 
 Recipes of Buffers used in the experiments were summarized in the following table 
 
Table 2.2 Solutions and Buffers 
  
Buffer Recipe 
ACTH RIA- Assay Buffer EDTA: 12.7mM, 
Na2HPO4: 68.2mM 
sodium azide : 3mM 
Triton x-100: 0.1%, 
DTT:0.01% 
BSA:0.033% 
 
ACTH/PRL RIA-Separating buffer 18% PEG 
0.05M P04 
Distilled water 
 
 TBE buffer 50 mM Tris-Cl, pH 7.5 
150 mM NaCl 
 
RIPA buffer 50 mM NaCl,  
1.0% IGEPAL,  
0.5% sodium deoxycholate 
0.1% SDS 
50 mM Tris, pH 8.0 
 
1x LDS Sample Buffer  
 
40% glycerol 
4% lithium dodecyl sulfate (LDS) 
4% Ficoll*-400 
0.8 M triethanolamine-Cl pH 7.6 
0.025% phenol red 
0.025% coomassie G250 
2mM EDTA disodium 
 
1X MOPS buffer 50 mM MOPS 
50 mM Tris Base 
0.1% SDS 
 1 mM EDTA- pH 7.7  
 
5% non-fat milk in TBS-tween 5% w/v Marvel milk powder 
50 mM Tris-Cl, pH 7.5 
150 mM NaCl 
0.05% Tween 20 
 
TBS-Tween 50 mM Tris-Cl, pH 7.5 
150 mM NaCl 
0.05% Tween 20 
 
 
 
5% BSA in TBS-tween 
 
 
5% w/v BSA 
50 mM Tris-Cl, pH 7.5 
150 mM NaCl 
0.05% Tween 20 
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Dispersion Medium 1x PBS  
1x, streptomycin mix 
 0.3%  BSA 
 
Odyssey® Blocking Buffer Licor 
 
PBS 
 
2.7mM KCL 
1.5mM KH2PO4 
137mM NaCl  
 6.5mM NaHPO4 
 
PRL RIA- assay buffer  1.9mM NaH2 PO4 
 0.7mM Na2HPO4 
 0.5mM EDTA 
 30 % BSA 
 1% Thermalsal 
 
PRL –separating buffer ( Triton-X) 0.1% Triton X 
Distilled water 
 
2.1.3. Antibodies 
 All antibodies used in the experiments were summarized in the following table 
 
Table 2.3. Antibodies 
  
Antibody Supplier  
Anti-rat ACTH Abcam, UK 
Anti-rat ACTH National Hormone and Peptide Program, US 
 
Alexa Fluor® 488 Donkey Anti-Rabbit IgG 
(H+L) 
Invitrogen, UK 
Alexa Fluor® 568 Goat Anti-Rabbit IgG (H+L), 
 
Invitrogen, UK 
Guinea pig anti-rabbit IgG Fab fragment 
polyclonal antibody 
Cusabio, China 
Anti- rat FSH National Hormone and Peptide Program, US 
 
Anti-rat GH National Hormone and Peptide Program, US 
 
Anti-rat PRL  National Hormone and Peptide Program, US 
 
Anti-rat PRL Millipore , UK 
 
P2X3 Abcam, UK 
 
P2X3 Alomone Labs, Ltd, Jeruselum, Isriel 
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P2X4 
 
Alomone Labs, Ltd, Jeruselum, Isriel 
P2X7 
  
Alomone Labs, Ltd, Jeruselum, Isriel 
Anti-rat TSH National Hormone and Peptide Program, US 
 
IRDye 800CW Donkey anti-Rabbit IgG (H + L) Licor, UK 
 
2.1.4. Kits 
 All kits used in the experiments were summarized in the following table 
 
Table 2.4 Kits 
  
Kit Supplier 
RETROscript® Kit Ambion Incorporation,USA 
MILLIPLEX MAP Rat Pituitary Magnetic 
Bead Panel - Endocrine Multiplex Assay 
#RPTMAG-86K 
 
Merck, Millipore, USA 
 
 
 
2.1.5. Cell culture Media  
 List of medium used in the experiments were summarized in the following table 
 
Table 2.5 Cell culture medium- All cells were supplemented with Penicillin-Streptomycin 
mix [100 units/mL penicillin, and 100 µg/mL strptamycin] 
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2.1.6. Cell lines    
2.1.6.1AtT20 D16:16 cells 
D16:16 cells (a gift from S Guild, UK) are adherent sub clones of the parental AtT-20 cell line 
which were derived from an ACTH producing mouse pituitary tumour [48]. These cells are 
typically used as an ex vivo model of anterior pituitary corticotrophs, responding to 
stimulation by CRH by secreting both ACTH, β-endorphin from the pro-hormone POMC [77]. 
2.1.6.2TtT/GF cells 
TtT/GF cells (a kind gift from Dr C McArdle, University of Bristol, UK) are adherent mouse 
anterior pituitary folliculo-stellate cells, derived from a radiothyroidectomy induced thyrotropic 
pituitary tumour [80] and secrete IL-6 and macrophage migration inhibitory factor [78] 
 
 
 
   
Cell line/primary cells  Media  Supplements 
AtT:20 :D16 and TtT/GF DMEM 10 % heat inactivate FSC  
5mg/Iinsulin,5mg/I transferrin, 
166µM sodium selenite (ITS) 
30pM T31 x NEAA  
 
GH3 DMEM 2.5% FCS, 15% HS  
MMQ F12  medium + glutamax  2.5% FCS, 15% HS  
LβT2 and αT3-1 DMEM 10% FCS 
Primary pituitary cells M16 10% HS  
57 | P a g e  
 
2.1.6.3 GH3 cells 
GH3 cells are a non-adherent sub-clone of the parental GH1 cell line which was derived 
from the rat MtT/W5 pituitary tumour .Cells have the ability to secret both PRL and GH in 
response to stimulation with TRH, which has led to them begin referred to as a 
‘somatolactotrope’, in terms of their cellular phenotype [1]. 
2.1.6.4 MMQ cells 
MMQ cells (a kind gift from Dr Jack Ham, University of Cardiff, UK) are a non-adherent 
model of pituitary lactotrophs which were derived from the rat pituitary tumour 7315a. They 
possess functional dopamine and oxytocin receptors and secrete PRL [[80], [81]] 
 
2.1.6.5 LβT2 cells 
LβT2 cells (a kind gift from Dr Pamela Mellon, University of California, USA via Dr Rob 
Fowkes, The Royal Vet College, London, UK) are an adherent model of mature pituitary 
gonadotrophs which were derived from tumour tissue within transgenic mice possessing an 
altered LHb-subunit promoter [1]. These cells express GnRH receptors and secrete LH and 
FSH in response to stimulation with GnRH [[83],[84]] 
2.1.6.6 αT3-1 cells 
αT3-1 cells (a  kind gift from Dr Pamela Mellon, The Salk Institute, USA via Dr Rob Fowkes, 
The Royal Vet College, London, UK)  are an immortalised adherent mouse cell line derived 
from a tumour produced within a transgenic mouse line using oncogene SV40 T antigen and 
the human glycoprotien α-subunit gene promoter [1]. Cells express GnRH receptors, but 
secrete immature gonadotrophins in response to GnRH. Hence cells are regarded as having 
a phenotype akin to immature precursor pituitary cells [[86],[87]]. 
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2.2 Methods 
2.2.1 Maintenance of cell lines 
 
All cells were grown in 75ml ventilated flasks (Cellstar , Griner Bio-one GmGH, Germany) at 
37ºC and 5% CO2 (Binder incubator GmbH, Tuttlingen, Germany). Media used (included 
required supplements) for individual cell lines can be found in table 6.  All cells were 
supplemented with Penicillin-Streptomycin mix [100 units/mL penicillin, and 100 µg/mL 
strptamycin]  
2.2.2 Passage of cells 
 
Upon reaching confluency (~80-90%) adherent cells (AtT20 D16:16, TtT/GF, LβT2,   αT3-1) 
were first washed with Dubbecco’s phosphate –buffered saline (PBS) containing 2.7mM 
KCL, 1.5mM KH2PO4, 137mM NaCl and 6.5mM NaHPO4 (Invitrogen Ltd,UK) and then cells 
were subjected to trypsinisation via incubation with 0.25% trypsin (Invitrogen Ltd,UK) for 5 
minutes at 37ºC and 5% CO2.  Trypsin was neutralised by addition of an equal volume of cell 
media and cells were resuspended into T175 flasks with fresh media. For RIA, cells were 
seeded at a density of 2x10-5 cells per well in 48 well plates (Cellstar, Greiner Bio-One, 
UK)(see section 3.4.3) or for western blot cells were seeded at a density of 2x106 cells per 
well (see section 3.3.2).  Cell suspensions (GH3, &MMQ) were pelleted from medium by 
spinning at 1100g for 5 minutes at room temperature. Medium was then aspirated and cells 
were washed in PBS and spun for a further 5 minutes.  PBS was then aspirated and 
replaced with 10ml of fresh medium to resuspend cells. This was either transferred to a fresh 
T175 with additional medium or cell counts were performed and cells seeded into 24 well 
plates for RIA or western blot in the same manner as described above for adherent cells. 
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2.2.3 Determination of the functional expression of P2X receptors in pituitary cell lines 
2.2.3.1 Treatment of cell line (AtT:20 :D16) with native secretagogue 
 
Cells were seeded (2x105 well-1) into 48 well plates (Cellstar, Greiner Bio-One, UK) and 
incubated with a range of  doses ( 0.1,1,10,100nM) of native pituitary agonists, CRF (Sigma, 
Poole, UK) for various lengths of time (1,4,7 and 12 hours).  Each concentration was tested 
n= 6 wells. Errors shown are ± SEM. Medium was collected on ice and stored at -80ºC until 
assayed for hormone release by radioimmunoassay (RIA).   
2.2.3.2 Treatment of cell line (AtT:20 :D16) with native P2X agonist 
 
Cells were seeded (2x105 well-1) into 48 well plates (Cellstar, Greiner Bio-One, UK) and 
incubated with a single dose of ATP (100µM) (Sigma, Poole, UK) for various lengths of time 
(1,4,7 and 12 hours). Concentration was tested n=6 replicates/well. Errors shown are ± 
SEM. Medium was collected on ice and stored at -20ºC until assayed for hormone release 
by RIA.   
2.2.3.3 Treatment of cell line (AtT:20 :D16) with native agonist CRF and ATP 
 
AtT20:D16 (2x1051.well-1) cells were incubated with a single dose of CRH [100nM](Sigma, 
Poole, UK) for 1, 4, 7 and 12 hours, alone and in the presence  of ATP 
[100µM](Sigma,Poole,UK). Medium was collected on ice and stored at -80ºC until assayed 
for hormone release by RIA. 
2.2.3.4 Treatment of cell line (GH3) with native secretagogue 
 
GH3  cells were seeded (2x105 well-1) into 48 well plates (Cellstar, Greiner Bio-One, UK) and 
incubated with a range of  doses (1,10,100, and 1000nM) of native pituitary agonists, TRH  
(Sigma, Poole, UK) for various lengths of time (5,10,15,20,30,60 minutes). Each 
concentration was tested n=6 replicates/wells.  Errors shown are ± SEM. Medium was 
collected on ice and stored at -80ºC until assayed for hormone release by RIA.   
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2.2.3.5 Treatment of cell line (GH3) with native P2X agonist and analogues 
 
GH3  cells were seeded (2x105 well-1) into 48 well plates (Cellstar, Greiner Bio-One, UK) and 
incubated with a range of  doses (0.001,0.01,0.1,1,10,100,1000µM) of native pituitary 
agonists, ATP or analogues ATP--S and BzATP (Sigma, Poole, UK) for various lengths of 
time (5,10,15,20,30,60 minutes).  Each concentration was tested n=6 replicates/wells.  
Errors shown are ± SEM. Medium was collected on ice and stored at -80ºC until assayed for 
hormone release by RIA.   
2.2.3.6 Treatment of cell line (GH3) with native agonist TRH and ATP 
 
GH3 (2x1051.well-1) cells were incubated with a single dose of TRH [1nM](Sigma, Poole, UK) 
for 30 minutes alone and in the presence of ATP [1µM or 100µM](Sigma,Poole,UK). Medium 
was collected on ice and stored at -80ºC until assayed for hormone release by RIA. 
2.2.3.7 Treatment of GH3 cells with P2X receptor antagonists PPADS, TNP-ATP,AF-353                      
A-438079 
 
Using conditions previously described for GH3 cells (see table 2.6 for details), cells were 
seeded into 48 well plates (Cellstar , Griner Bio-one GmGH, Germany) at a density of 
2x105.ml-1.well-1. After 48h cultures were serum starved [F12 medium containing 0.1% FCS, 
0.1%HS and streptomycin mix:] for a further 24h. Cells were then treated with 1nM TRH 
(Sigma-Aldrich, UK), 1µM or 100µM ATP (Sigma-Aldrich, UK), either alone or in combination 
with ATP. Cells were also treated with TRH and/or ATP in combination with P2X receptor 
antagonists PPADS (1, 5, 10, 50,100,500,1000µM), TNP-ATP, AF-353 and A-438079 
(1,5,10,50,100,500,1000,5000nM). Medium was collected after 30 minutes and stored at -
80ºC for measurement of PRL release. Table 2.1 contains the list of PX2 receptor 
antagonists used. 
 
 
61 | P a g e  
 
2.2.4. Primary rat pituitary culture 
2.2.4.1 Animals 
 
All experiments were carried out in accordance with the United Kingdom Animals (Scientific 
Procedures) Act 1986 under the project licence PPL 70/5593.  Male Sprague –Dawley rats 
were obtained from a commercial supplier (Charles River Laboratories, Inc., Margate, UK) 
and maintained in standard, wire top cages in the Comparative Biology Services unit at 
Hammersmith Hospital (Faculty of Medicine, Imperial College London). Animals were 
housed 5 rats per cage in a room with controlled lighting (lights were on between 0.800h & 
20.00h) temperature (21ºC-23 ºC) and humidity (60-65%) with standard rat chow provided 
ad libitum. Rats were handled daily for a week prior to experiments. 
2.2.4.2 Generation of primary pituitary cultures 
 
Primary rat pituitary cultures were carried out according to previous studies [(Tomić, Jobin et 
al. 1996), ([96]Tomić et al. 2000)]. Pituitaries were excised from male Sprague–Dawley rats 
and immediately transferred to Dispersal media (DM) [1x PBS supplemented with 1x, 
streptomycin mix, 0.3%  BSA]. Tissue was then washed in medium to remove blood and cut 
into 0.5mm blocks. Tissues were then centrifuged in 10ml of DM at 700g at 4ºC and the cell 
pellet retained. The pituitary cells were incubated in T75 flasks containing 30ml of 0.25% 
trypsin for 60 min at 37ºC on a shaking incubator (Inferign Ltd, UK) followed by 30ml of DM 
supplemented with 0.1mg/ml trypsin inhibitor (Sigma,,UK) and 0.01% DNase (Sigma,,UK) for 
10 minutes at 37ºC. The cell suspension was then centrifuged (700g, 5 minutes at 4ºC), the 
supernatant aspirated and the cells filtered through a nylon mesh (Becton, UK) to obtain a 
single cell suspension. The cells underwent repeated centrifugation in fresh medium (4x 
700g, 4ºC, 5 min) following which cells were resuspended and a cell count was taken. Cells 
were then plated into 48 well plate at the appropriated density in M199 medium containing 
10% horse serum and pen/strep 100u/mL. 
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2.2.4.3 Treatment of primary cultures with CRH and CRH receptor antagonists, 
R121919 and DMP904 
 
Using conditions previously described for AtT-20 cells (see table 1 for details), primary 
pituitary cells were seeded into 24 well plates (Cellstar, Griner Bio-one GmGH, Germany) at 
a density of 1x105.ml-1.well-1. After 48h cultures were serum starved [DMEM containing 0.5% 
FCS, T3: and streptomycin mix:] for a further 24h. Cells were then treated with 100nM CRH 
(Sigma, UK) either alone or in combination with CRH receptor antagonists, R121919 or 
DMP904 (1, 5, 10, 50 or 100nM). Medium was collected after 4h and stored at -20ºC for 
measurement of ACTH release. 
2.2.3 RadioimmunoAssay  (RIA) 
 
The radioimmunoassay was first developed in the 1950’s by Solomon A Berson and Rosalyn 
Yalow. This in vitro binding assay exploits the immune reaction between an antibody (Ab) 
and an antigen (Ag) to measure/quantify the amount of substance in a biological sample. Ag 
is labelled with radioactivity (I125) and incubated with a fixed amount of antibody and 
unlabelled Ag, which is provided by the sample under investigation. This sets up a 
competition between radioactive labelled Ag and unlabelled Ag for limited amount of binding 
sites on the Ab. To allow enough time for Ag-Ab complexes to occurs, the reaction is allowed 
to incubate and go to completion. 
 
 
*Ag + Ab + Ag ↔x *AgAb + AgAb 
 
Ag = unlabelled antigen 
 
 
*Ag = radiolabelled antigen 
 
Ab = antibody 
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Unlabelled Ag in the form of Standards are also incubated alongside the reaction. During 
incubation period the amount of radiolabelled Ag will be displaced by the unlabelled Ag, 
in unknown amounts, in the sample being measured. Unbound antigen is removed by 
incubating  samples with 2° ab, directed to the species which the primary ab was raised 
in, and centrifugation to precipitate out the Ab-Ag complex. The pellet formed will contain 
Ag-ab complexes and the free Ag will be in the supernatant. Both the bound and the free 
Antigens are read on a γ –counter. The intensity of the radioactivity measure following 
separation of ab bound Ag from free, unbound Ag, is inversely proportional to the 
amount of Ag in the sample under investigation. The results from the standards can be 
used to construct a standard curve from which the unknown samples can be interpolated 
from. Inter-assay variation can be calculated by assaying aliquots of the same sample in 
each assay performed and comparing the concentrations obtained in each. To measure 
and correct for baseline drift, tubes with no sample (‘zero’ tubes) are placed at regular 
intervals throughout the assay and standard curves are performed at the beginning and 
end of each assay.  A table to show the general set up of an RIA can be found in 
appendices 1. 
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2.2.3.1 ACTH Radioimmunoassay 
2.2.3.1.1 Iodination of ACTH 
 
All iodinations of ACTH peptide were carried out by Professor MA Ghatei (Professor of 
Regulatory Peptides, Metabolic Medicine, Faculty of Medicine, Imperial College) according 
to the following method.  Synthetic ACTH was iodinated using the iodogen method [88]. The 
oxidising agent, 1,3,4,6,-tetrachloro-3, 6-diphenylglycoluril (iodogen reagent) is evaporated 
onto the walls of a polypropelene tube from a solution in methylene chloride. The peptide to be 
iodinated and 125I are then added. The reaction is terminated when the mixture is removed from 
the tube, thus negating the need for a reducing agent.  
To iodinate ACTH, 10μg of peptide in 10μl of 0.2 M phosphate buffer pH 7.2 were reacted with 
37 MBq of Na 125I (Perkin Elmer) and 23 nmol (10 μg) of iodogen reagent (Pierce Chemical 
Co.) for 4  minutes at 22oC.  The 125I-peptide was purified by reversed-phase high performance 
liquid chromatography using an ACN/ H2O /0.05 % TFA gradient of 20 % to 25 % over 50 min. 
The fractions were collected using a Frac-100 fraction collector (Pharmacia). The specific 
activity (SA) of an iodinated peptide is the amount of radioactivity per mole of hormone. It is 
measured in Bequerel (Bq) which is an SI unit of radioactivity and is equivalent to 1 
disintegration per second. The purified label was found to have a SA of 60.6 Bq/fmol as 
measured by self-displacement in the assay. 
2.2.3.1.2 Radioimmunoassay for ACTH 
 
The concentration of hormones released into the medium of primary pituitary cultures and 
pituitary cell lines was determined using RIA with reagents supplied by the National Institute 
of Diabetes and Digestive and Kidney Disease (NIDDK, California). Details of antibodies can 
be found in table 2.3.  Reference standards were prepared for each hormone in triplicate, via 
serial dilution of stock standard (ACTH 2µg/ml) in assay buffer [see table 2.2, section 2.1.2].  
This produced standards ranging from 10,000pg/ml to 10pg/ml.  200µl of peptide specific 
antibody (diluted 1:60,000) was added to 100µl of sample in duplicate. Control tubes were 
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included in triplicate consisting of iodinated/labelled peptide (100µl) and assay buffer (300µl) 
to determine non-specific binding and separate tubes with label (100ul), antibody (200ul) and 
buffer (300ul) to determine specific binding. Standard and sample tubes were each 
administered 100ul of radio labelled peptide (which had been diluted to give 2000 counts per 
minute) and 200ul antibody and all assay tubes were then mixed and left to incubate for 4 
days at 4ºC. 
On the fourth day, separation of bound and free peptide began with the addition of 200ul 
horse serum: 0.9% saline (1:1 mix) to all tubes at room temperature for 30minutes. 600ul of 
separating buffer [see table 2] were then added to the tubes and centrifuged at 3000 rpm at 
8ºC for 30 minutes. The supernatant was aspirated and the bound fraction counted on an 
automatic gamma counter (Perkin-Elmer LAS Ltd, Beaconfield, UK) for 120 seconds. 
Hormone concentrations within assayed samples were derived from the respective standard 
curves. The detection limit of assay is 40pg/ml. 
2.2.3.2 PRL Radioimmunoassay 
2.2.3.2.1 Iodination of PRL 
 
All iodination of PRL peptides was carried out by Dr Chris John according to the following 
method. 2µg/20µl of PRL peptide in 0.05M phosphate buffer, pH 7.4. was reacted with 
27.75MBq of Na 125I (Amersham) and 10µl of  N-Chloro-p-toluenesulfonamide sodium salt 
hydrate (chloramine-T;1.5mg/ml in 0.05M phosphate buffer, pH 7.4)(Sigma-Aldrich, UK) for 
30s at room temperature after which time the reaction was stopped by addition of 10µl 
sodium metabisulphate (2.5mg/ml in 0.05M phosphate buffer). The resulting mixture was 
immediately pipetted on to the surface of a sephadex G50 column which had been 
previously equilibrated with 0.05M phosphate buffer containing 0.5% w/v bovine serum 
albumin (BSA, Sigma, UK). The mixture was then eluted through the column using the 
phosphate buffer containing 0.5% BSA and 1ml fractions were collected, stoppered and the 
radioactive content of each was determined. The first fractions containing the highest counts 
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of radioactivity (usually fractions 4- 6) contained the 125I-labelled.  The 125I-peptide was 
assessed for use in RIA by constructing a standard curve and zero tubes and the 
percentage binding determined. Labelled peptide that gave at least 60% binding in zero 
were used in PRL-RIAs. 
2.2.3.2.2. Radioimmunoassay for PRL 
 
PRL was determined in duplicate by radioimmunoassay using reagents supplied by the 
National Hormone and Pituitary Programme (Bethesda, USA). The PRL antibody (NIDDK-
anti-rPRL-S-9) had negligible cross reactivity with rat-GH, -TSH, -FSH and -LH and was 
stored at -80°C. Solutions of the prolactin standard (NIDDK-rat-PRL-RP-3) were prepared by 
serial dilution of a stock standard (10µg/ml in distilled water stored at -80°C) in assay buffer 
(see table 2.2), to produce solutions ranging from 0.049-50ng/ml.  Tubes containing 50µl 
aliquots of standard or test solution and 100µl PRL antibody (diluted 1 in 3200) were 
prepared in duplicate.  Tubes containing 150µl assay buffer or 100µl PRL antibody and 50µl 
assay buffer were also set up to determine non-specific and specific binding, respectively. In 
addition, 250µl of the tracer 125I-labelled PRL, diluted in assay buffer to give approximately 
10000 counts/min/250µl was added to each tube. The tubes were then vortexed and 
incubated for 2 days at room temperature.  Separation of the bound and free peptide was 
achieved using a mixture of anti-rabbit precipitating serum raised in donkey (IDS, 
Washington, England), diluted 1 in 24 v/v and non-immune rabbit serum, diluted 1 in 200 v/v, 
both in assay buffer.  100µl of this mixture was added to each tube (except total count tubes) 
which were then vortexed and incubated for 2h at room temperature, after which time 500µl 
4% w/v polyethylene glycol (PEG, BDH Chemicals, Dagenham, UK) was added to each 
tube. The tubes were then centrifuged at 4000g at 4°C for 30 minutes.  Following 
centrifugation, the supernatant was then aspirated and the radioactivity of the remaining 
pellet was counted on Bound and free label were separated and both the pellet and 
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supernatant counted for 180 seconds in a γ-counter (model NE1600, Thermo Electron 
Corporation).   
2.2.4 Protein expression Analysis 
2.2.4.1 Protein extraction 
 
 Protein was extracted from cells and rat tissue (brain and pituitary) according to a previously 
published protocol (Zemkova et al. 2010).  Cells were washed twice in cold PBS and then 
resuspended in 100µl of RIPA buffer (Sigma,UK) which was supplemented with 
phosphatase inhibitor cocktail 1 and 2 (Sigma Poole) and a protease inhibitor cocktail 
(Roche). Samples were lysed on ice for 60 minutes following which cells were then 
centrifuged at 13,000 rpm for 60 minutes at 4ºC. Rat tissue was washed twice in cold PBS to 
remove any residual blood, and then homogenised in RIPA buffer using a micropestle 
(VWR, International Ltd, Leicester, UK). Tissue was then incubated in buffer for 60min on ice 
and then centrifuged at 14,000 rpm at 4ºC for 1hr. The supernatant was retained and stored 
at-20ºC. 
2.2.4.2 Protein quantification (Bradford assay) 
 
This colorimetric assay was used to assess the protein content in samples using coomassie 
blue dye in solution.  The binding of the coomassie dye to protein within samples causes a 
shift in absorbance from 465nm to 595nm which can be detected using a 
spectrophotometer.  This is measured against a standard curve of bovine serum albumin 
(0.1-1mg/ml). Samples were diluted (tissue-1:100) and both samples and standards were 
added in duplicate to 96 well plates and incubated with G250/coomassie solution [100mg 
G250 (Sigma, Poole, UK) 95% ethanol, 85% orthophosphoric acid] for 2 minutes.  The 
amount of protein in each sample was determined by reading the absorbance (Anthos 
Labtec, UK) at 595nm.  Concentration of protein was then estimated by linear regression of 
the standard curve. 
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2.2.4.3 Electrophoretic separation of proteins on 10% SDS-PAGE gels 
 
 Protein was resuspended in 1x sample buffer (Invitrogen Ltd, UK) and protein denatured at 
100ºC for 5 minutes. 100µg of protein was separated by electrophoresis following application 
to pre-cast, polyacrylamide 10% Bis-Tris Gels (Invitrogen, UK).  Non denaturing conditions 
were used for separation, using 1x MOPs buffer (Invitrogen Ltd, UK), running at 200v for 
40min (Invitrogen, Ltd, UK). 
Following separation, gels were transferred onto PVDF membrane iBlot® western blotting 
system (Invitrogen, UK) for 7 minutes. The membrane was transferred to 5% non-fat milk 
powder (Marvel,Stafford, UK) in Tris–buffered saline [50mM Tris HCL pH 7.4,150mM Nacl] 
supplemented with 0.05% Tween (Sigma, Poole, UK) (TBS-T) for 1h. Following 3 x 10min 
washing cycles with 50ml TBS-T, blots were incubated overnight at 4°C with P2XR 
antibodies in 5% BSA in Tris–buffered saline. The following day the blot was washed 1 x 
30min and 2 x 15min with TBS-T. Deposition of the antibody was visualised by 
using   Odyssey Imaging System (Licor, UK). Firstly the blot was incubated with IRDye 
antibody, a fluorescently-labelled secondary antibody in Odyssey Blocking Buffer for 1h 
(1:10000;Licor, UK)  at room temperature.  The membrane was then washed 4 times in TBS-
T for 15 min. Specific antibody binding to protein was visualised and documented on the 
Odyssey Imaging System, by excitation of the fluorescent signal on the membrane in the 
appropriate channel according to the manufacturers guidelines. 
2.2.5 Immunohistochemistry 
2.2.5.1 Animals and Tissue handling 
 
All experimental procedures, used in immunohistochemistry were performed in accordance 
with the UK Animal (Scientific Procedures) Act 1986. Male Sprague–Dawley rats (200-250g) 
(Charles River, UK) were sacrificed by non-schedule 1 decapitation. The pituitaries were 
dissected out and fixed in 4% paraformaldehyde in 0.1 mol/l phosphate buffer pH 7.4 for 1 h, 
then transferred to 5, 15 and then finally 30%- sucrose in PBS and kept in the solution until 
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they sank to the bottom. Tissue was then removed from sucrose and emended in OCT 
embedding media (Thermo scientific, UK) and frozen at -80oC. Sections were cut (10 μM in 
thickness) using a Leica cryostat (CM3050) and mounted onto superfast slides (Thermo 
scientific, UK). Slides were stored at -80oC until further use. 
2.2.5.2 Immuostaining 
 
To determine the expression of P2X protein within the rat pituitary tissue, staining of 
receptors using fluorescently labelled P2X antibodies was undertaken. Antibodies raised for 
different pituitary hormones (ACTH, FSH, GH, PRL and TSH) were also used to identify the 
different pituitary subpopulations, and thus allowed co-localisation of both target proteins to 
be assessed. Antibodies for both P2X receptors and the pituitary hormones were raised in 
the same species and required a sequential,  double staining method which had been 
applied previously [[76], [89], [90],[91]]. Following thawing of slides for 2 hours at room 
temperature (temp), Slides were then washed twice in PBS (Sigma, UK) for 5 minutes.  
Slides were then permeabilised in PBS with 0.1% triton x-100 for 20 minutes. Slides were 
washed in PBS (2X 5 minutes) and then blocked in IHC buffer with  5% donkey serum 
(Sigma,UK) for 30 minutes ( see table for recipe of IHC buffer) to reduce nonspecific binding 
of the  fluorescent secondary donkey antibody.  Block was removed and rabbit polyclonal 
P2X antibodies (Alomone, Israel) added in 5% NDS in IHC buffer at the following 
concentration: P2X3 (1:10,000), P2X4 (1:8,000) and P2X7 (1:1000). Slides were allowed to 
incubate in a humidified chamber at 4°C overnight. The next day slides were washed in PBS 
with 0.1% Tween-20 (3 x 15 minutes). To enhance the signal of P2X antibodies, a biotin-
conjugated tyramide signal amplification (TSA) kit (Invitrogen, UK) was utilised in a manner 
previously described [[76], [89],[91]]. This was allowed to incubate with tissue for 10 minutes 
and excess removed by PBS washes (3 x 5 minutes). Then tissue was  incubated with Alexa 
Fluor® 488 Donkey Anti-Rabbit IgG (H+L) (Invitrogen, UK) (1:400 dilution ) and the nuclear 
stain DAPI (1:1000) (Invitrogen,UK) for 30 minutes at room temperature and  then washed in 
PBS with 0.1% tween 20 ( 3X5 mins).  
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To facilitated combination with second primary antibodies, which were also raised in same 
species, slides were then incubated with polyclonal guinea pig anti-rabbit IgG Fab fragment 
to block any any unbound rabbit binding sites on the 1st primary antibody (1:100 in PBS for 2 
hours). Excess Fab fragments were removed through PBS washes (3 X2 minutes). Tissue 
was then blocked in IHC buffer with 5% NGS (Sigma,UK) for 30 minutes to reduce 
nonspecific binding of the  fluorescent secondary goat antibody.  Block was removed and 
rabbit polyclonal pituitary hormone antibodies (see table for details of manufactures) were 
added in 5% NGS in IHC buffer at the following concentration:ACTH (1:2000), FSH 
(1:10,000), GH (1:1000), PRL (1:1000) and TSH (1:10,000). Slides were allowed to incubate 
in a humidified chamber at room temp. for 1 hour. Slides were washed in PBS with 0.1% 
Tween-20 (3 x 15 minutes). Then tissue was  incubated with Alexa Fluor® 568 Goat Anti-
Rabbit IgG (H+L), (Invitrogen, UK) (1:400 dilution) and the nuclear stain DAPI (1:1000) 
(Invitrogen,UK) for 30 minutes at room temperature and  then washed in PBS with 0.1% 
tween 20 ( 3X5 mins).  After a final wash was (3 X 5 minutes in PBS), sections were 
mounted in fluromount (Thermo scientific, UK) and stored in dark until visualisation. 
Negative controls were performed by substituting primary antibodies for IHC block in both 
the 1st and 2nd part of immunostain.  To check that no cross reactivity occurred between 
consecutive stains with the two rabbit antisera, the results of single and double staining was 
compared. Pictures were obtained using a confocal scanning microscope (Zeiss, Microscope 
Axio Observer.Z1) which allowed image reconstruction (AxioVision 4 Documentation). All 
images taken at 20X magnification.  Only cells that demonstrated the same morphology and 
position when viewed under the two different filters (in the same focal plane) were deemed 
to co-localise both P2X receptor and pituitary hormones. These slides were then taken at 
40x magnification.  
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2.2.6 MILLIPLEX MAP rat pituitary panel kit 
 
The Millipore MILLIPLEX MAP rat pituitary panel kit was used for the simultaneous 
quantification of the following rat pituitary hormones: ACTH, PRL, TSH and GH. Samples of 
supernatant were collected on ice from primary culture experiments and stored at-80°C. On 
the day of assay, samples were thawed on ice and then centrifuged 10, 000 rpm for 10 mins 
at 4°C. Samples were then diluted in media (1:10 dilution) and subjected to high through 
analysis in according to the manufactures guidelines. This involved incubating hormone 
standards of varying concentrations, two controls and samples in a 96 well format with 
polystyrene microspheres (antibody immobilised beads) coated which two different 
fluorescent dye. Each hormone had its own set of beads and is allowed to bind with analyte 
in samples overnight at 4° C with continuous shaking (min rpm). The following day, the plate 
is washed using the Bio-Plex Pro Wash Station (Biorad,UK) 3 x with 200µL wash buffer.  
Samples were then incubated with detection antibody (50µl) and the reporter molecule, 
Streptavidin- phycoerythrin (PE) conjugate (50µl) (Merck-Millipore, UK) at room temperature 
for a total of 1 hour. Further washing of the plate occurs before the plate is then filled with 
100µL sheath fluid to resuspend beads and then read on the Bio-Plex® MAGPIX™ Multiplex 
Reader (Biorad, UK). Lasers in the plate reader excite an internal dye in the bead and the 
PE, thus allowing identification of each individual bead, creating a profile for each hormone. 
Data was captured in Bio-Plex Data Pro software manger (Biorad, UK) and the exported to 
Prism 5.01 program (GraphPad Software Inc. San Diego, USA) for statistical analysis. 
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2.2.7 Detection of P2XR mRNA by reverse transcriptase polymerase  
chain reaction (RT-PCR) 
2.2.7.1 Total RNA extraction 
 
Total cellular RNA was extracted from all cell lines for RT- PCR for detection of P2X receptor 
1-7 and GAPDH (internal control). Cells were cultured in T75 flasks and removed from 
media. Cells were counted under a light microscope using a haemocytometer (Sigma, Poole 
UK).  Approximately 1x 107 cells were used for extraction using the Qiagen RNeasy mini kit 
(Qiagen, West Sussex, and UK). RNA was also extracted from whole tissue. Rats were 
killed by decapitation and brain, pituitary, kidney and eye were removed. Brain and kidney 
were cut into 0.5cm pieces, and then all tissue was placed in 3-5ml of RNAlater RNA 
stabilisation reagent (Qiagen, West Sussex, UK) to protect the RNA. Tissues were then 
incubated in reagent at 4ºC overnight, and then kept at -20ºC until required.  
Approximately 30mg of tissue (pituitary, brain and kidney) was placed in liquid nitrogen and 
disrupted using a pestle and motor. RNA was then extracted using the Qiagen RNeasy mini 
kit.  Tissue/cells were resuspended in 600µl of RTL® buffer which was supplemented with 
100mM β-mercaptoethanol and placed in the Qiagen shredder column and centrifuged at full 
speed for 3 minutes. Supernatant was mixed with 1ml 70% ethanol (Sigma Poole, UK). 
Successive aliquots of sample were spun through an RNeasy spin column at 10,000rpm for 
15s. 700µl of RW1® buffer was then added to the samples, which were then spun at 
10,000rpm for 15s. An on-column DNase digestion was then performed using an RNase–
Free DNase set (Qiagen, West Sussex, UK). Samples were incubated with 1U DNase I in 
buffer RDD® for 15 minutes at room temperature.  
Following this, the column was subjected to two washes with 500µl of buffer RPE® by 
centrifuging at 10,000rpm for 15s, and then 2 minutes.  The column was then transferred to 
a 1.5ml collection tube and RNA was eluted from the spin column via addition of 50µl of 
nuclease free water (VWR International Ltd, Leicester, UK) and spun at 10,000 rpm for 1 
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minute. This step was repeated to ensure all RNA was eluted from the column. Neat aliquots 
of purified RNA (1µl) were quantified using spectrophotomery (NanoDrop Technologies,Inc, 
Wilmington,USA) by measuring the optical density at absorbance 260/280nm for 
measurement of the purity of RNA. A second reading at 260/230nm was also used to 
determine purity of nucleic acid and the concentration of samples was determined. RNA 
samples yielding a ratio value below 1.8 for both readings were not analysed. 
2.2.7.2 Reverse transcription 
 
 Extracted RNA was reversed transcribed using Moloney Murine Leukemia Virus (MMLV-
RT) as provided in the RETROscript® Kit (Ambion Incorporation, Texas, USA) to generate 
cDNA as follows. 1µg of RNA was denatured by incubation for 3 minutes at 85ºC with 
random decamers (at a final concentration 5µM) and nuclease free water (at final volume 
12ul) on a thermal cycler (Omigene thermal cycler Hybaid Ltd, Middlesex, UK), and 
subsequently placed on ice.  To this 12µl mixture , 1X RT buffer [50 mM Tris-HCl, pH 8.3,75 
mM KCl, 3 mM MgCl, 5mM DTT], dNTP mix [0.2mM of dATP,dCTP,dGTP,dTTP], RNase 
inhibitor [1 U/μL] and 5U/µl MMLV-RT were added. This was made up to 20µl with nuclease 
free water, mixed and incubated at 44ºC for 1hr  and then 92ºC for 10mins to inactivate 
MMLV. Samples were then stored at -20ºC until further use. 
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2.2.7.3 PCR of cDNA 
 
PCR was conducted on cDNA for the detection of P2X receptors using previously published 
primer sequences and cycling conditions  for P2X1, 2, 3, 6 and GAPDH [92] and P2X4,5,7 
[2]. For a list of primer sequences see appendix 2.  
5µl of RT reaction was added to 1x PCR buffer [10mM Tris-HCl, pH 8.3,5 0mM KCl, 1.5mM 
MgCl2], 0.2µM dNTP mix, 2mM MgCl (Invitrogen, Ltd,UK) , 0.04U/µl of Platinum®  Taq DNA  
polymerase (Invitrogen Ltd, UK). Primers [sense and antisense at a final concentration of 
0.2µM each] (Invitrogen Ltd, UK) specific for each reaction were added and volume made up 
to 50µl with nuclease free water. For detection and amplification of receptors 1, 2, 3, 6, PCR 
mixture was subjected to denaturation at 96 ºC for 5 minutes, then subjected to 48 cycles of 
94ºC for 45s, 58ºC for 45s  and 72ºC for 90s followed by a final extension for 10 minutes at 
72ºC. For the amplification of receptors 4, 5, 7, PCR mixture was subjected to denaturation 
at 94ºC for 2 minutes, then subjected to 35 cycles of 94ºC for 30s, 58ºC for 30s and 72ºC for 
60s followed by a final extension for 7 minutes at 72ºC.  Controls were included with the 
omission of MMLV-RT and RNA in the 1st round and the omission of Taq and cDNA in the 
second round. PCR product was stored at 4ºC. 
2.7.4 Visualisation of PCR product by agarose gel electrophoresis 
 
10µl of amplicon  was mixed with 2.5µl of loading buffer (Ambion, Texas, USA) and 
separated on a 1.5% agarose gel (Sigma Poole, UK) stained  with ~ 0.02% ethidium 
bromide (Sigma, Poole, UK).  To determine that the correct sequence was amplified, the 
size of product was determined by comparison with molecular weight bands (5µl loaded) 
which correspond to 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 and 1500 base pairs 
(BDH laboratories, Poole, UK). Electrophoresis was carried out for 90 minutes at 100V in 
Tris/Borate/EDTA (TBE) buffer (Sigma Poole, UK) following which product was visualized 
under UV light (Syngene, Cambridge, UK) and the image analysed and documented 
(Syngene, Cambridge, UK). 
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2.8 Statistical Analysis 
 
All data are expressed as the mean value ± S.E.M.. Rat pituitary peptide hormone levels 
were compared by one-way ANOVA followed by post-hoc Tukey’s correction.  Prism Version 
5.01 (GraphPad Software Inc. San Diego, USA) was used for statistical analysis. In all 
cases, values of p<0.05 were considered statically significant.  
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CHAPTER THREE 
P2X receptor expression within the anterior pituitary gland  
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3.1 INTRODUCTION 
3.1.1 An investigation of P2XR expression in whole pituitary and pituitary cell lines 
  
The endocrine function of the anterior pituitary consists primarily of regulated hormone 
secretion from multiple secretory cell types, with nonendocrine folliculo-stellate cells 
providing a supportive role [[94, 95]]. Characterisation studies have established that the 
pituitary gland expresses all forms of purinergic receptors as well as the machinery required 
for purinergic signalling. P2Y metabotropic receptors (predominantly P2Y4,6,12),  P2X-ligand 
gated ion channel( P2X2,3,4,7) and adenosine receptors (A1,A2a/b) can be found distributed 
within the different pituitary subtypes to varying degrees [[96][49]]. Enzymes to control the 
activity of ATP are also expressed in the plasma membrane of pituitary cells with mRNA for 
the ecto-nucleotideases, ectonucleoside triphosphate diphosphohydrolases 1, 2 and 3 (E-
NTPDases)  detected in whole pituitary tissue [[96], [97] ].  
The significance of ATP and the role of individual P2X receptors in the pituitary gland is not 
fully understood, Therefore, a study to determine expression of P2X receptors in relation to 
each other and subsequent location within pituitary subtypes is of importance as it will 
provide further information with regards to P2X receptor function, specifically with regard to 
the regulation of the pituitary under physiological, and potentially pathophysiological 
conditions.  
This chapter confirms the distribution of P2XRs expressed in rat anterior pituitary tissue, as 
determined by RT-PCR. Molecular characterisation was also carried out on a range 
immortalised pituitary cell lines (see table 3.1), with each in vitro model analysed for P2XR 
transcript, representing a subtype of the pituitary. This work supported subsequent 
investigations aimed at assessing the functional significance of blocking individual P2X 
receptors found expressed in the pituitary (See chapter 4). Double staining of the anterior 
pituitary gland has proved to be a useful tool for determining the pattern of expression of 
P2Y receptors, with subtype expression occurring to varying degrees within pituitary 
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subpopulations [[23], [76]].  We also present data from immunofluorescence experiments 
that also aimed to establish the distribution and localisation of P2XRs within rat anterior 
pituitary cells.  
Table 3.1: A summary of cell lines profiled by RT-PCR to P2XR1-7 expression 
  
Pituitary subtype In vitro model analysed 
Folliculo-stellate TtT-GF cells 
Corticotrophs AtT20 D16:16 
Lactotrophs GH3, MMQ 
Gonadotrophs LβT2 
 
3.1.2 Aims 
The aims of this investigation were as follows; 
(1) To confirm the expression of P2XR within the anterior pituitary and numerous 
pituitary cell lines. 
(2) To assess the pattern of expression of individual P2XRs within the different 
pituitary subpopulations of the rat anterior pituitary gland. 
 
Key findings from this part of the thesis are; 
(1) P2X receptors are widely expressed in both the rat anterior pituitary and pituitary cell 
lines. 
(2) P2X3, 4 and 7 are strongly expressed by all in vitro pituitary models. 
(3) Western blotting demonstrated expression of P2X4 and P2X7 in pituitary lysates. 
(4)  Double-labelling immunofluorescence of  P2X4, and 7 receptors show co-
localisation with small subpopulation of cells in the rat anterior pituitary 
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3.3 RESULTS 
3.3.1 Expression of P2X receptor transcripts in rat pituitary by RT PCR 
We first studied the expression of the various purinergic receptor mRNAs within rat pituitary 
tissue by RT-PCR. As shown in Fig 3.1, a strong signal for mRNA transcripts of P2X2 and 
P2X3, P2X4, P2X6 and P2X7 (Figure 3.1A.).   A weak signal for P2X1 and P2X5 was also 
detected (Figure 3.1A.). For a positive control we utilised rat brain tissue which contain P2X 
receptor subtypes 2-7 (Figure 3.1B) and rat kidney tissue was used as a positive control 
tissue for P2X1 (Figure 3.1A). The rat brain control tissues expressed the expected P2X 
receptor transcripts, in the pituitary however, mRNA transcripts for variants P2X2a and P2X2b 
were also detected. 
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(A) Anterior pituitary tissue: Spague Dawley rat 
 
 
 
 
 
 
(B) Control tissue (Kidney – P2X1; Brain P2X2-7) 
 
 
      
. 
 
 
 
 
 
Figure 3.1 A-B: Identification of P2X receptor transcripts: Rat pituitary tissue  
Expression of purinergic receptor subtypes in rat pituitary tissue was analysed by RT-PCR (A). Controls 
are from rat kidney (P2X1) and rat brain (P2X2-7 (b)). For negative controls, PCR was conducted using 
first strand cDNA samples without RT. Water was used for no template control (not shown, refer to 
appendix 2). GAPDH primers were used as an internal control to monitor quality of RNA preparation. Gels 
represent n=2 experiments, representative gel shown. 
 
 
 
 
 
 
 
 
                        Ladder     P2X1       2           3         4           5           6       7       GAPDH 
 
 
1. 100 bp Ladder  
2. P2X1 (493 bps) 
3. P2X2 (689 bps) 
4. P2X3 (556 bps) 
5. P2X4 (447 bps) 
6. P2X5 (418 bps) 
7. P2X6 (341 bps) 
8. P2X7 (354 bps) 
9. GAPDH (417 bps) 
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1. 1 kb Ladder  
2. P2X1 (493 bps) 
3. P2X2 (689 bps) 
4. P2X3 (556 bps) 
5. P2X4 (447 bps) 
6. P2X5 (418 bps) 
7. P2X6 (341 bps) 
8. P2X7 (354 bps) 
9. GAPDH (417 bps) 
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3.3.2 Expression of P2X receptor transcripts in pituitary cell lines 
Subsequent RT-PCR analysis studied the expression of the various purinergic receptor 
mRNAs within numerous anterior pituitary cell lines (see Fig 3.2A-F) (see Methods, section 
2.2).  
 
3.3.2.3 Expression of P2X receptor transcripts in a folliculostellate (TtT/GF) cell line 
Fig 3.2A illustrates the expression of purinergic receptor mRNAs within the FS cell like TtT-
GF cell line. Numerous P2X receptors were identified within the TtT-GF cell line, although it 
must be noted that expression levels were low. The transcripts for P2X2 and P2X4 were 
most strongly expressed, with the P2X2 splice variants P2X2a and P2X2b clearly identifiable. 
P2X1 and P2X3 were also identified whereas P2X5, 6 & 7 mRNA were not present in TtT-
GF cells.  
3.3.2.4 Expression of P2X receptor transcripts in a corticotroph (AtT-20 D16:16) cell 
line 
 
Fig 3.2B illustrates the expression levels of purinergic receptor mRNAs within the AtT20 
D16:16 corticotroph cell line.  The transcripts for P2X1 and P2X2 mRNA were strongly 
expressed with the AtT20 cell line, whereas P2X3, 4, 5, 6, and 7 demonstrated no 
expression at all.  
 
 
 
 
 
 
 
 
82 | P a g e  
 
(A) TtT-GF cells: Mouse 
               P2X1             2                3            4            5            6              7               GAPDH 
 
 
 
(B) AtT20 D16:16 cells: Mouse 
   
                   P2X1            2              3            4                5           6          7           GAPDH 
 
 
Figure 3. 2 (A-B): Identification of P2X receptor transcripts in pituitary cell lines: TtTGF and AtT20 D16:16 
Expression of purinergic receptor subtypes in immortalised pituitary cell lines was analysed by RT-PCR. 
Controls are from rat kidney (P2X1) and rat brain (P2X2-7). For negative controls, PCR was conducted 
using first strand cDNA samples without RT. Water was used for no template control. GAPDH primers 
were used as an internal control to monitor quality of RNA preparation. Expression of P2X2 and P2X4 
was found in the TtT-GF cells (A). P2X1 and P2X2 were detected in AtT20 D16:16 (B) Gels represent n=2 
experiments, representative gel shown. 
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3.3.2.5 Expression of P2X receptor transcripts in lactotroph (GH3 and MMQ) cell lines 
 
Figure 3.2C illustrates the expression levels of purinergic receptor mRNAs within the GH3 
‘somatolactotroph’ cells. Probing the GH3 cells revealed strong expression for P2X3, P2X4 
and P2X7 mRNAs (Fig 3.2C) whereas P2X1, 2, 5 and 6 were not detected. Fig 3.2D 
illustrates the expression levels of purinergic receptor mRNAs within the MMQ lactotroph-like 
cell line. In MMQ cells, P2X3, P2X4 and P2X7 mRNA were strongly expressed which 
correlates with expression in the GH3 ‘somatolactotroph’ cells. In contrast to GH3 cells, clear 
(albeit weak) expression of P2X2 and P2X5 mRNA was also identified in the MMQ cells (Fig 
3.2 D). P2X1 and P2X6 were not detected. 
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(C) GH3 cells: Rat 
                      P2X1          2             3             4            5            6             7          GAPDH 
 
 
 
 
 
 
(D) MMQ cells: Rat 
 
               P2X1      2          3             4             5          6         7         GAPDH 
 
 
Figure 3. 2 C-D: Identification of P2X receptor transcripts in pituitary cell lines: GH3 and MMQ 
Expression of purinergic receptor subtypes in immortalised pituitary cell lines was analysed by RT-PCR. 
Controls are from rat kidney (P2X1) and rat brain (P2X2-7). For negative controls, PCR was conducted 
using first strand cDNA samples without RT. Water was used for no template control  GAPDH primers 
were used as an internal control to monitor quality of RNA preparation . Expression of P2X2, P2X4 and 
P2X7 was found in the GH3 cells (C). P2X2, P2X3, P2X4, P2X5 and P2X7 were detected in MMQ (D) Gels 
represent n=2 experiments, representative gel shown. 
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3.3.2.6 Expression of P2X receptor transcripts in a gonadotroph (LβT2) cell line 
 
Finally, Fig 3.2E illustrates the expression levels of purinergic receptor mRNAs within the 
mouse LβT2 gonadotroph-like cell line. Transcripts for P2X2, P2X3, P2X4 and P2X7 were 
strongly expressed (Fig 3.2D-E) with P2X1 and P2X3 the most strongly expressed. P2X5 
and P2X6 were not detected. A summary of findings can be found in table 3.2. 
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(E) LβT2 cells: Rat 
 
          P2X1            2                3            4             5              6             7          GAPDH 
 
 
 
(B) Control tissue: (Kidney – P2X1; Brain P2X2-7) 
 
           P2X1      2               3             4             5          6         7       GAPDH 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 E: Identification of P2X receptor transcripts in pituitary cell lines: LβT2 
Expression of purinergic receptor subtypes in immortalised pituitary cell lines was analysed by RT-PCR. 
Controls are from rat kidney (P2X1) and rat brain (P2X2-7). For negative controls, PCR was conducted 
using first strand cDNA samples without RT. Water was used for no template control. GAPDH primers 
were used as an internal control to monitor quality of RNA preparation. (F) Transcripts for P2X1, P2X2, 
P2X3, P2X4 and P2X7 were detected in LβT2 cells (E). Gels represent n=2 experiments, representative gel 
shown. 
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Table3.2. Summary of P2X transcripts detected in rat pituitary tissue and pituitary cell lines 
 
       
P2X Rat 
Pituitary 
FS AtT20:D16 GH3 MMQ LβT2 
P2X1 + - + - - - 
P2X2 + W + - W + 
P2X3 + W - + + + 
P2X4 + - - + + + 
P2X5 W - - - - - 
P2X6 + - - - - - 
P2X7 + - - + + + 
 
Key 
Expression (+)     No expression (-)   Weak expression (W) 
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3.3.2 Characterisation of purinergic receptor expression in whole pituitary tissue 
using Western blot 
 
mRNA for P2X receptors 1 to 7 were identified in whole rat pituitary tissue using RT-PCR.  In 
order to verify expression of P2X receptors at the protein level, Western blot analysis (and 
immunoflouresces see section 3.3.3) of rat pituitary protein extracts was conducted. This 
was also to be used as a control experiment to validate the specificities of anti-P2X receptor 
antibodies to be used in later studies. We initially chose to validate the antibodies for P2X3, 
4, & 7 since these receptors were the most consistently expressed across the various 
pituitary cell lines investigated. 
We utilised protein extracts from rat brain as a positive control for the expression of P2X 
receptor protein for P2X3 (approximately 65 kDa), P2X4 (approximately 65 KDa) and P2X7 
(approximately 68KDa). Rat pituitary lysate that was also subjected to Western blot analysis 
showed the presence of P2X4 (figure 3.3B) and P2X7 (figure 3.3C) receptor protein within 
rat  pituitary. How P2X 3 (approximately 65 kDa) was identified in brain tissue but not in the 
pituitary gland (figure 3.3A). In all cases differences in glycosylation may explain differences 
in protein size between brain and pituitary lysates . Summary of results can be found in table 
3.3. 
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Figure 3.3:  Expression of P2XRs in Rat pituitary: Immunoblotting of P2X receptor protein using control 
tissue (Brain) and rat pituitary. Rabbit polyclonal antibodies to P2X receptors were utilized to probe 
tissue. Arrows indicate the respective P2XRs detected with anti-P2X3 (A) anti-P2X4 (B) and anti-P2X7 (C) 
at 1:200 dilutions
    Protein Marker     Brain      Pituitary 
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188 
 
P2X3 (A) 
P2X4 (B) 
P2X7  (C) 
49 
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Table 3.3:  Summary of P2XR immunoreactivity detected in rat pituitary tissue and brain 
tissue  
 
 
 
 
 
 
 
Key 
Expression (+); No expression (-) 
3.3.3 Optimisation of immunoflourescent techniques for the detection and 
characterisation of purinergic receptors in whole pituitary tissue: Co-expression of 
P2X receptors with pituitary hormones. 
 
 The only study currently in the literature characterising P2 receptor localisation in rat 
pituitary subtypes utilizes P2Y targeted antibodies. The following section includes our results 
from attempts to characterise pituitary P2X receptor expression in a similar fashion. P2X3 
antibody (alomone) showed no expression and was omitted from our study. Sprague Dawley 
rat pituitary tissue was incubated with antibodies for P2X4 or 7 and pituitary hormones 
ACTH, FSH, GH, PRL and TSH to determine colocalisation in the different pituitary 
subtypes.  
3.3.3.1 Coexpression of P2X4 receptor with ACTH, FSH, GH, PRL and TSH 
 Single staining showed P2X4 to have weak to moderate staining in pituitary tissue (Figure 
3.4 A). Double-labelling immunofluorescence showed no true immunoreactive for between 
ACTH (3.4A-B), GH (3.5E-F), PRL (3.4G-H) and TSH (3.4I-J), FSH (3.5 C-D) and P2X4.
   
P2X  Rat Brain Rat Pituitary  
P2X3 + - 
P2X4 + + 
P2X7 + + 
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(A)                                                                                                               (B) 
Figure 3.4 A-B: Double  staining to investigate colocalisation (yellow) of P2X4 receptor immunoreactivity (green) with ACTH (red) in the cells of 
the rat pituitary gland.  DAPI staining of nuclei (blue) also shown(X20)(A) and (40X) (B). 
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(C)                                                                                                                                                                
(D) 
Fig 3.4  C-D: Double staining to investigate  colocalisation (yellow) of P2X4 receptor immunoreactivity (green) with FSH  (red)  in the rat 
pituitary gland DAPI staining of nucei (blue) also (20x) (C) and (D). 
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(E)                                                                                                                        (F) 
 Figure 3.4 E-F: Double staining to show colocalisation (yellow) of P2X4 receptor immunoreactivity (green) with G H  (red) in the  cells of the 
rat pituitary gland with G H  (red) in the rat (20x) (E) and (40x) (F) DAPI staining of nuclei (blue) also shown. 
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(G)                                                                                                                                         (H) 
Figure 3.4 G-H: Double staining to show colocalisation (yellow) of P2X4 receptor immunoreactivity (green) with PRL (red) in the rat pituitary 
gland ( x20) (G) and (x40) (H). DAPI staining of nuclei (blue). 
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(I)                                                                                                                                   (J) 
Figure 3.4 I-J: Double staining to show colocalisation (yellow) of P2X4 receptor immunoreactivity (green) with TSH  (red) in the rat pituitary 
gland  at (x20) I and  (40X) (J).  DAPI staining of nuclei (blue) also shown). 
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3.3.3.2 Coexpression of P2X7 receptor with ACTH, FSH, GH, PRL and TSH 
 
P2X7 showed very low levels of staining in the anterior pituitary tissue (figure 3.5 A-F). 
Double staining with the nuclear stain DAPI showed P2X7 to be weakly immunoreactive in 
the pituitary tissue (Figure 3.5 A). Double-labelling immunofluorescence showed no 
colocalisation was seen with ACTH (3.5A), FSH (3.5 B), PRL (3.5 E), TSH (3.5 F), GH 
(3.5C-D). 
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(A)                                                                                                                                               (B) 
Figure 3.5 A–B: Double staining to investigate localisation of P2X7 receptor immunoreactivity (green) in the cells of the rat pituitary gland.  
With ACTH (red) A and FSH (red)(B) DAPI staining of nuclei (blue) also shown (x20). 
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(C)                                                                                                                                               (D) 
Figure 3.5 C-D:  Double staining to show colocalisation (yellow) of P2X7 receptor immunoreactivity (green) with GH (red)  in the rat pituitary 
gland  at 20X (c) and 40X (D) DAPI staining of nuclei (blue) also shown 
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(E)                                                                                                                                   (F)  
Figure 3.5 E-F:  Double staining to show colocalisation (yellow) of P2X7 receptor immunoreactivity (green) with PRL (red) E and TSH (red) (F)  
in the rat pituitary gland (20x).  DAPI staining of nuclei (blue) also shown.
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Figure 3.6: Negative controls used in immunostain of rat pituitary. Absence of P2X antibody 
and no pituitary hormone. 
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Table 3.4.: Coexistence between P2X receptors and pituitary hormones  
 
 
 
 
 
 
Key 
+ coexistence, − no coexistence 
 
 
 
 
 
 
 
 
 
 
 
      
P2X ACTH FSH GH PRL TSH 
P2X4 - - - - - 
P2X7 - - - - - 
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3.4 Discussion 
 
The results of the experiments presented in this chapter were designed to investigate the 
pattern of P2X receptor expression within the pituitary.  As demonstrated by RT- PCR 
analysis, transcripts for P2X1-7 were expressed in the rat pituitary gland. This confirms 
previous data concerning P2X receptor expression within the pituitary gland using Sprague 
Dawley rats [[98]], with the exception of P2X5  which we demonstrated was highly expressed 
in the pituitary, whereas the Koshimizu study failed to show P2X5  expression. We were also 
able to detect P2X7 within rat pituitary tissue using qualitative RT-PCR [[98] [1]]. This is 
significant, given a recent study using the more sensitive Q-PCR technique demonstrated 
that amongst the various P2XR subtypes expressed in the rat pituitary, P2X7 is one of the 
receptors with the lowest levels of expression [64]. Zemkova and colleagues used anterior 
pituitary tissue only to determine levels of P2X receptor expression. P2X5 has been identified 
in the posterior pituitary where it has been demonstrated to modulate oxytocyin release[[73]] 
In our study we used whole pituitary to subject to RT-PCR, therefore our detection of P2X5 
may represent expression of in the posterior pituitary.  In accordance with previous studies, 
our RT-PCR analysis identified two bands for P2X2 within the rat pituitary. The expression of 
the wild type channel, P2X2a, and the spliced variant, P2X2b, have been identified in pituitary 
tissue, as well as brain, kidney, spleen and intestine.  Identification of P2X2 variants within 
pituitary tissue is important, particularly with regard to subsequent functional analysis. 
Evidence suggests that the two variants show different rates of desensitisation to ATP [100], 
[92]], which would impact on the development of in vitro assays for pituitary function in 
relation to P2XR. We utilised whole pituitary tissue for our expression studies, which is 
consistent with previous investigations of purinergic receptors currently in the literature [[96]]. 
However, the failure to remove the posterior pituitary and to ensure the removal of 
contaminating blood cells could lead to the reporting of false positives. Upon reviewing our 
method for the preparation of pituitary tissue, although care was taken to remove blood prior 
to RNA extraction, traces of contaminates in samples could potentially remain and also be a 
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source of false positive due to expression of P2X receptors in the blood and immune cells 
contained within [1]. Perfusion of tissue with saline prior to extraction of pituitary would limit 
this and has been used to great effect [102]. 
 Our data demonstrate the expression of P2X1 and P2X2 mRNA within our corticotroph cell 
line. A previous study investigated the expression of P2XR within the AtT-20 corticotroph cell 
line, albeit using a different subclone (AtT-20 PL). RT-PCR analysis within this study 
identified the presence of P2X3, P2X4, P2X6 and P2X7 transcripts in the AtT-20 cells [61]. 
Whilst there are significant differences between the two subclones, specifically a much 
slower growth rate but a much quicker responsiveness of POMC promoter activity [103] this 
does not explain the contrasting expression data between the two cell lines. In the literature, 
the  D16 subclone has been more extensively used , particularly for in vitro investigations of 
stimulus induced ACTH release from corticotrophs [[104], [105]]. One could therefore 
speculate that the corticotroph model used in our study is a more representative model of 
this pituitary subtype.  Unfortunately, available functional data does not indicate the 
importance of individual P2X subtypes within corticotroph cells, since stimulation of P2XRs 
within these cell types with available agonists does not influence the endocrine secretion of 
ACTH [61]. 
As demonstrated by PCR analysis, transcripts for P2X2 and P2X4 were found to be 
expressed in the TtT/GF folliculostellate cell line. To our knowledge this is the first time that 
folliculstellate cells have been probed for P2XRs.  It is interesting to note that P2X4 is 
associated with immunological cells such as macrophages and stem cells [3], since 
folliculostellate cells are often regarded as pituitary tissue specific macrophage like cells 
derived from the lymphoid dendritic cell lineage. However, the fact that P2X2 and P2X4 are 
only weakly expressed in TtT/GF cells in our studies is suggestive of a minor role in 
regulating folliculostellate cell function. Current data concerning functional purinergic 
signalling within folliculostellate cells indicates that responses are primarily driven by 
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adenosine [2], with adenosine receptor activation linked with IL-6 secretion. In addition P2Y2 
receptors may also have a functional role in folliculostellate cells.  
Molecular identification of P2XRs expressed within the lactotroph cell lines, GH3 and MMQs, 
was also obtained by RT-PCR analysis. Transcripts encoding P2X3, P2X4 and P2X7 were 
detected in both cell lines.  With regard to GH3 cells, our data is in agreement with previous 
studies using this cell line as well as data from molecular profiling of enriched lactotroph cell 
populations [73]. RT-PCR analysis of the MMQ cell line also demonstrated weak expression 
for P2x2 and P2x5 mRNA. To our knowledge this is first time this specific lactotroph cell line 
has been probed for P2XR expression. MMQs are similar to primary tissue with regards to 
the expression of a functional dopaminergic system and receptors for oxytocin [81]. As in 
native pituitary tissue, secretions from MMQ cells are under the control of calcium and other 
secondary messengers such as cAMP [81]. GH3 cells are established in vitro models of 
lactotrophs, although its use as a direct model of the normal pituitary function is limited by 
the absence of dopamine receptors and observations suggesting an abnormal 
storage/release mechanism for PRL [4]. The difference in physiology may in part account for 
the differences in P2X expression [75]. P2X5 has been associated with a range of cancer 
states including prostate and skin cancer [108]. It is possible that expression of this receptor 
within the MMQ cell line is related to the fact that this cell line is derived from a pituitary 
adenoma [81]. This is an issue which of course is true for all immortalized cells lines used in 
this investigation . It is important that in vitro systems used to assess purinergic function 
within the pituitary are representative models of the native pituitary system we are trying to 
investigate. As the result for MMQ illustrates, molecular profiling of cancerous tissue is vital 
to ensure this is the case. Functional assays to assess purinergic function in the human 
pituitary system may utilise a mixture of normal and cancerous tissue and profiling will be 
conducted to ensure expression of receptors within dysregulated tissue is comparable to 
normal tissue. 
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RT-PCR analysis revealed that P2X3, P2X4, P2X7 and P2X2 (weakly) are expressed in the 
gonadotroph cell line, LT2. This is the first time that P2XR expression has been analysed 
within a specific population of gonadotroph cells. Although there is no direct PCR data on 
this cell line, our findings are in accordance with data from the characterisation of primary 
gonadotrophs  by Zemkova and co-workers who demonstrated P2X1, P2X2R, P2X3R, P2X4R 
and P2X7R expression in both neonatal and 7 day old rats [34].   Our western blotting data  
for P2X4 and P2X7 ( figure 3.3) was in accordance with previous studies [[64], [109]]. 
However in  this study we were able to demonstrate expression in native pituitary tissue as 
opposed to recombinant expression in an artificial system [109]. We detected double band 
for expression of P2X3 and P2X4 in our control tissue, rat brain lysates. P2X4 bands 
corresponding to ~ 50 and 65 kDa were detected in control tissue. These bands represent 
expression of the unglcosylated and glycosylated forms of the receptor in both tissues. This 
was also seen with P2X3 expression in the brain where two bands corresponding to ~60 and 
70 kDa represent the unglycosylated and glcosylated variants respectively.  Expression of 
multiple bands for individual receptors has been observed in a range of tissues and is a 
consequence of the variations in glycosylation and oligomerisation that occurs between 
P2XR subtypes. Predicted sizes for receptors range from 45- 64kDa for unglycosylated 
forms and 50-70kDa for the glycosylated forms [110]. Western blot analysis, along with 
immunoprecipitation has suggested  that a functional interaction between the two receptors 
may occur [111]. Whilst our study cannot support this finding, this does suggest that   
investigation of the level of colocalisation between different P2X receptors within the pituitary 
tissue is an important area to explore.  This could provide vital evidence as to the extent with 
which different P2XRs exert regulatory effects on one another – something that has been 
identified in other tissues, such as the smooth muscle  and salivary  glands [[112], [113], 
[114]]   Results from double immunoflourescence staining of P2XRs and the relevant 
pituitary hormone demonstrated that corticotrophs, gonadotrophs, lactotrophs and 
thyrotrophs express at least one member of the P2X family, but this is the first time that 
P2XRs have been investigated for co-localisation with specific pituitary hormones within 
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specific pituitary cell types and this has provided new insight into the pattern of P2X 
distribution within the pituitary. P2X4 was co-localised within the greatest number of pituitary 
cell types (figure 3.5) This is not surprising given that P2X4  demonstrates the highest level of 
expression in the rat pituitary  gland within other studies[64]. Histological staining has also 
identified  expression within the adrenal gland [115] and studies using immunoflouresence 
have indicated that P2X4 plays a fundamental role in the regulation of exocytosis of cellular 
contents [116].  Given that we also found P2X4 widely distributed amongst pituitary cells, it is 
possible that P2X4 possesses a similar role in the pituitary, although further 
electrophysiological studies would be required to confirm this. P2X7 showed the least 
immunoreactivity in the pituitary tissue (3.5).  Expression of P2X7 within other tissues is 
generally associated with apoptotic mechanisms, and the release of cytokines from immune 
derived cells  [[117], [118], [119], [120], [121], [122]] .Previous studies to identify a functional 
role for P2X7 in the pituitary have shown that  loss of  P2X7 expression, using P2X7 
knockout mice,  has been associated with no alteration in the release of the pituitary 
hormones, particularly the posterior pituitary hormones oxytocin and vasopressin [123].  The 
fact that we have only shown low levels of pituitary P2X7 expression in our studies coupled 
with low P2X7 expression demonstrated within the pituitary in previous studies [[64]] 
suggests that P2X7 may not play as significant a role within the anterior pituitary compared 
with the other P2X receptors expressed. Chapter 4 includes functional data that focuses on 
the influence of individual P2XRs on anterior pituitary function. 
We were unable to detected P2X3 after conducting western blot of rat pituitary lysates 
(3.3A).  This was surprising given that P2X3 had demonstrated to be expressed in the 
cellular subpopulations of other endocrine organs. Western blotting had identified P2X3 
expression in human islets and immunofluorescence techniques confirmed co-localisation of 
P2X3 within insulin secreting -cells in human tissue in vitro [[124]]. There is evidence to 
show that  expression of P2X3 receptors changes with age within the rat brain and the 
adrenal gland [[125], [115]]. Post-natally, expression of P2X3 is restricted to the bladder, 
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spinal cord and cerebellum of the rat [[126], [125]], This pattern of post-natal down regulation 
of P2X3 receptor within the CNS and other organs of the rat may explain our inability to 
detect P2X3 expression in our pituitary lysates . However, as we were able to detect P2X3 in 
our control lysate (brain) could suggest that protein expression of this receptor in the pituitary 
tissue used may be very low and beyond the detect limits of assay. This issue has been 
overcome by other groups that have used separate expression systems such as GT1 cells 
or xenapus oocytes, to artificially express receptor, thus ensuring a high levels expression 
[64]. However, as we were interested in expression of the receptor in the native system, the 
antibody may require further optimisation and/or increased amount of protein  for use in  
western blot.  
3.5 Conclusions 
Our investigations of P2XR expression in vitro support the published evidence and show that 
P2XRs is a highly expressed protein component of mammalian pituitary tissue which we has 
demonstrated to show species dependent differences (Rat, mouse). Characterisation of P2X 
receptor expression within the whole pituitary and numerous pituitary cell lines by RT-PCR, 
demonstrated that all P2XRs were expressed in pituitary tissue with P2X3, 4 and 7 most 
commonly expressed within the pituitary cell lines. In the future, expression profile studies of 
P2X receptors within the pituitary should also include investigations of human tissue. P2X 
receptors are proving to be viable site of intervention in human health, and further 
knowledge with regards to localisation and expression in the pituitary would be 
advantageous.  These expression profile studies provide the basis for future assessments of 
P2X receptor targeted agents, which should take into account these species differences in 
expression when assessing specificity and potency. 
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Chapter FOUR 
Investigation of P2X receptor antagonists: Effects on pituitary 
function  in vitro   
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4.1 Introduction 
Whilst it is the case that a range of ATP analogues have been developed which specifically 
target individual P2X receptors, most of these agents also act as partial agonists for other 
members of the P2X family. However, a number of specific P2X receptor antagonists have 
now been generated which might provide more conclusive evidence with regard to the 
importance of individual P2X receptors in regulating pituitary function.  I have demonstrated 
that the rat pituitary gland expresses all P2X family members, and that these receptors 
demonstrate co-localisation with hormones associated with the different pituitary subtypes to 
varying degrees (see chapter 3). In this chapter I investigated the functional significance of 
P2X receptors expressed in the pituitary gland using a range of ATP analogues and a 
number of specific P2X receptor antagonists in order to assess the contribution made by 
individual P2X receptors to pituitary hormone release in vitro. 
4.1.1 Investigation of P2X receptor pharmacology in vitro 
The native agonist of P2X receptors is ATP, however the development of ATP analogues 
have proved to be useful tools in the study of the functional significance of individual P2X 
channels. The majority of the data that has enhanced our understanding of P2X receptor 
physiology has come from studies that have compared the interaction of ATP to that 
observed with chemical ATP analogues such as αβ-methylene-ATP (αβmeATP) , 2',3'-O-(4-
benzoylbenzoyl)-ATP (BzATP) (See table 4.1 for list of ATP analogues ). ATP is susceptible 
to enzyme degradation, and the use of non-hydrolysable isoforms has also allowed for 
observations to be made over extended time points [[65], [127]]. The relative sensitivities of 
the P2XR subtypes for ATP and the various ATP analogues are summarised in Table 4.1. 
Table 4.2 Summarises IC50 data for ATP antagonists acting at the various P2XR subtypes. 
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Table 4.1: List of ATP analogues EC50 (µM)  
        
Receptor P2X1 P2X 2 P2X3 P2X4 P2X5 P2X6 P2X7 
Desensitisation Fast(<1s) slow fast slow slow slow slow 
Pore dilation No yes No yes yes - yes 
Agonist        
ATP 0.07-1 1.2 0.5 10 10 12 100 
2-meSATP 0.07-1 1.2 0.3 10 10 9 100 
αβ-MeATP 0.3-3 >300 0.8 >300 >300 >100 >300 
BzATP 0.003-30 0.75 0.08 7 >500 - 20 
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Table 4.2: List of P2X receptor antagonists with IC50 (µM) 
         
Receptor  P2X1 P2X 2 P2X3 P2X4 P2X5 P2X6 P2X7 
IC50         
PPADS P2 receptors  1 1 1 >500 3 >100 >50 
TNP-ATP  P2X antagonist 0.006 1 0.001 15 - - >30 
AF-353 hydrochloride potent antagonist 
of P2X3 
homotrimers and 
P2X2/3 
heterotrimers 
  0.0073 – 
0.0085 
    
5-BDBD potent P2X4 
receptor 
antagonist 
   0.5    
A-438079 hydrochloride 
hydrate 
selective P2X7 
purinoceptor 
antagonist 
      0.0069 
 
 
Table 4.1 and 4.2 produced using the following references: [128], [41],[129], [130].
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As can be seen in Table 4.1 each of the various ATP analogues is capable of activating all of 
the P2XR subtypes. These compounds have been  useful  tools in electrophysiology studies, 
highlighting the role of P2X receptor mediated (and P2Y) calcium release, and the 
associated depolarisation of the pituitary cell membrane prior to hormone 
release[[74][131];[132][96]]. However this lack of true specificity makes it difficult to delineate 
the role of individual receptors in hormone release within the pituitary subpopulation.  
In contrast, selective P2XR antagonists have been generated which provide a more useful 
tool for identifying the cell-specific physiological function of individual P2XRs. 
Pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS)  has been described in the 
literature as a broad spectrum P2 antagonist. It has the ability to block all members of the 
P2XR family, however it has also been reported to show activity at both P2Y4 and P2Y6 
[[133],[134, 135];[136]]. 2',3'-O-(2,4,6-Trinitrophenyl)adenosine-5'-triphosphate 
tetra(triethylammonium) (TNP-ATP) is the latest in the line of broad spectrum P2XR 
inhibitors, showing high affinity for all P2X receptors, albeit with some evidence for greater 
selectivity for P2X1, P2X3 and heterometric P2X2/3 [[137], [138], [139]] There is  mounting 
clinical evidence supporting the  importance of P2X receptors in a range human of 
pathologies. The pharmaceutical industry has therefore responded with the development of 
highly selective and highly potent P2X receptor antagonists [ [140],[141] [142]].  
Recent studies using Q-PCR and electrophysiology have determined receptor subtypes 
P2X2, P2X3 and heteromeric P2X2/3 play a key role in the relaying of painful stimuli to the 
brain [ [143, 144],  [145]], and thus the development of specific P2X3 inhibitors, e.g. AF-353 
generated by Roche [146] are specifically targeted to treat neuropathic pain. Considerable 
effort has been directed towards the development of selective P2X7 receptor antagonists 
due to the fact that ATP-induced activation of P2X7R has been associated with numerous 
disease pathophysiologies, for example P2X7R is believed to mediate some of the 
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neuroinflammation that contributes to the development of Alzheimer’s disease (AD)  [ [147], 
[148]]. 
Clearly the evidence supports the use of drugs that modulate P2XR activity as a therapeutic 
intervention in a range of situations. As we have shown in the previous chapter, the pituitary 
gland demonstrates the highest level of P2XR expression and therefore it is extremely 
important that we understand how interference with purinoceptor function may potentially 
influence homeostasis via actions within the hypothalamo-pituitary system.  
The data presented in this chapter focuses on the effects of P2XR antagonists on pituitary 
function, using primary pituitary cells and an established pituitary cell line model of 
corticotrophs, AtT20:D16s and in vitro model of lactotrophs, GH3, which have both been 
used by investigators to assess the contribution of ATP on pituitary hormone function 
[[131],[61]]. 
4.2 Aims 
The studies in this chapter aim to investigate the following:- 
1. To determine the effects of P2XR stimulation on hormone release in vitro using  
primary  pituitary cultures and cell lines (AT20:D16 and GH3). 
2. To evaluate the in vitro the effects specific P2XR antagonists on pituitary cell 
function. 
 
Key findings from this study are; 
1.  ATP stimulated the release of pituitary hormone from primary rat pituitary cultures 
and pituitary cell lines in vitro in a dose dependant manner. 
2. Effects of pituitary secretagogues, CRH and TRH were constantly potentiated when 
administered with 100µM ATP. 
3. Effects of secretagogue and/or ATP on hormone release from GH3 cells were 
significantly decreased when pretreated with P2X antagonists PPADS, TNP-ATP, 
AF-353 and A-438079. 
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4.3 Results 
4.3.1 Validation of rat primary pituitary culture by RIA 
 
We generated a rat primary pituitary culture and carried out preliminary studies to validate 
this system with an assessment of the functional response to a well-established pituitary 
stimulant. In this regard, the pituitary cultures were treated with CRF in the presence and 
absence of the CRF antagonists R121919 and DMP904.   
4.3.1.1 Effects of the CRF inhibitor R121919 on ACTH release from primary pituitary 
culture 
 
ACTH secretion from primary rat pituitary cultures was significantly increased following 4hr 
incubation with CRF (100nM CRF, p<0.001 vs control  figure 4.1). Pre-incubation with the 
CRF receptor antagonist R121919 or DMSO alone did not significantly influence basal 
ACTH release. The CRF receptor antagonist, at all concentrations tested (1,5,10, 50 and 
100nM), significantly decreased CRF induced ACTH release from primary pituitary cultures 
(P<0.05 vs CRF and P<0.001 vs CRF ;figure 4.1A), with a maximal seven-fold decrease in 
ACTH release (50nM R121919). 
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Figure 4.1 Effects of CRF receptor antagonist R121919 on CRF stimulated ACTH release from primary 
anterior pituitary cultures. Cultures (1X105 cells /well) treated with CRF (100nM) alone or in combination 
with increasing concentrations of antagonist (1, 5, 10, 50, 100nM) for 4h. Each experiment was performed 
twice, representative graphs shown.  Bars represent mean (n=6 replicate) ± SEM. *** P> 0.001 vs control.  
$$$ (**P<0.001 vs CRF alone) and $ (P<0.05 vs CRF alone). Data compared one way ANOVA followed by 
Tukey’s post hoc.  
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4.3.1.2 Effects of CRF inhibitor DMP904 on ACTH release from primary pituitary 
culture. 
ACTH secretion from primary rat pituitary cultures was significantly increased following 4hr 
incubation with CRF (100nM CRF, P<0.001 vs control figure 4.2). Pre-incubation with the 
CRF receptor antagonist DMP90 or DMSO alone did not significantly influence basal ACTH 
release. The CRF receptor antagonist, at all concentrations tested, significantly decreased 
CRF induced ACTH release from primary pituitary cultures (P<0.001 vs CRF; figure 4.2), 
with a maximal five-fold decrease in ACTH release (100nM DMP90). 
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Figure 4.2: Effects of CRF receptor antagonist DMP904 on CRF stimulated ACTH release from primary 
anterior pituitary cultures.  Cultures (1X105 cells /well) treated with CRF (100nM) alone or in combination 
with increasing concentrations of antagonist (1, 5, 10, 50, 100nM) for 4h. Each experiment was repeated 
twice, representative graphs shown. Bars represent mean (n=6 replicates) ± SEM. *** P> 0.001 vs control.  
$$$ (**P<0.001 vs CRF alone). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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4.3.2 Investigation into the effects of purinergic receptor stimulation on hormone 
release from rat primary pituitary cells 
 
 Following validation of our primary cell cultures, we then went on to identify which pituitary 
hormones would be responsive ATP.  Cells were then treated with a range of ATP doses 
(0.001µM to 1000µM) which had been shown to be stimulatory in other endocrine organs  
[149] and a range of time points (0 to 60 minutes) to assess the effects on ATP secretion. 
4.3.2 .1 The effects of ATP on ACTH secretion from primary pituitary cells 
 
 Figure 4.3 illustrates the effects of increasing concentrations of ATP on the release of ACTH 
from primary pituitary cells in vitro.  For each dose of ATP investigated, an increase in ACTH 
secretion was observed over time. The maximal ACTH secretion was between 120-149,000 
pg/ml for all doses tested. With regard to timeframe, ATP consistently increased ACTH 
secretion from cells at the 7 minute time point onwards. 
 0.001µM ATP did not induce a significant increase in ACTH secretion although it did cause 
a 2 fold increase at 7 and 30 minutes (4.3.A). 0.01µM ATP caused a significant increase at 
the 7 minute time point (P<0.05 vs. control, figure 4.3.B). 0.1µM ATP did not cause a 
significant increase in ACTH, although a 2-fold increase in ACTH release was observed at 
20 minutes (figure 4.3.C). 1µM ATP stimulated a 2-fold rise in ACTH levels at 10 minutes 
(figure 4.3.D). 10µM ATP at the 30 minute time point  has a significant effect on ACTH 
secretion (P<0.05 vs. control, figure 4.1.E). 100µM ATP caused a significant release at the 
time points of 7 (P<0.05 vs. contro1, 4.3F) and 60 (P<0.001 vs. control, figure 4.3F) minutes. 
1000µM of ATP caused a significant increase at 20 (P<0.001 vs. control, 4.3G), 30 (P<0.05,  
vs. control, figure 4.3G) and  60 (P<0.001 vs. control, figure 4.3G) minutes. Results are 
summarised in table 4.3. 
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Figure 4.3 A:  Effect of 0.001 µM ATP on ACTH release from primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (0.001µM) alone for 0, 1, 3, 5, 7,10 ,20, 30 and 60 minutes.  Each experiment 
was repeated at least two times and gave similar results; representative graph shown. Bars represent ± 
S.E.M (n=6). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.3 B:  Effect of 0.01µM ATP on ACTH release from primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (0.01µM) alone for 0,1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each experiment 
was repeated at least two times and gave similar results, representative graph shown. Bars represent ± 
S.E.M (n=6 replicates).    * P<0.05 vs. control.  Data compared one way ANOVA followed by Tukey’s post 
hoc test 
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Figure 4.3 C:  Effect of 0.1µM ATP on ACTH release from primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (0.1µM) alone for 0, 1, 3, 5, 7, 10, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results, representative graph shown. Bars represent ± S.E.M 
(n=6 replicates). Data compared one way ANOVA followed by Tukey’s post hoc test 
 
 
 
 
 
 
 
Time (minutes)
A
C
TH
 (
pg
/m
l)
l)
0 1 3 5 7 10 20 30 60
0
5000
10000
15000
Control
0.1M ATP
C
122 | P a g e  
 
               
 
 
Figure 4.3 D: Effect of 1µM ATP on ACTH release from primary pituitary cells. Cultures (1X105 cells/well) 
treated with ATP (1µM) alone for 0, 1, 3, 5, 7, 10, 20, 30 and 60 minutes.  Each experiment was repeated at 
least two times and gave similar result, representative graph shown. Bars represent ± S.E.M (n=6 
replicates). Data compared one way ANOVA followed by Tukey’s post hoc test 
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Figure 4.3E: Effect of 10µM ATP ACTH from cultured primary pituitary cells treated with  10µM ATP 
Cultures (1X105 cells/well) treated with ATP (10µM) alone for 0,1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each 
experiment was repeated at least two times and gave similar results, representative graph shown. Bars 
represent ± S.E.M (n=6 replicates). * P<0.05 vs. control. Data compared one way ANOVA followed by 
Tukey’s post hoc test. 
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Figure 4.3F:  Effect of 100µM ATP on ACTH release from primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (100µM) alone for 0, 1, 3, 5, 7, 10, 20, 30 and 60 minutes.  Each experiment 
was repeated at least two times and gave similar results, representative graph shown. Bars represent ± 
S.E.M (n=6 replicates). *** P<0.001 vs. control (media only) and (* P<0.05 vs. control).  Data compared one 
way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.3G: Effect of 1000µM ATP on ACTH release from primary pituitary cells. Cultures 
(1X105 cells/well) treated with ATP (1000µM) alone for 0, 1, 3, 5, 7,10 , 20, 30 and 60 
minutes.  Each experiment was repeated at least two times and gave similar results, 
representative graph shown. Bars represent ± S.E.M (n=6 replicates). *** P<0.001 vs. 
control (media only and   * P<0.05 vs. control.  Data compared one way ANOVA followed by 
Tukey’s post hoc test.
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Table 4.3: Effects of ATP (0.001-1000uM) on ACTH (pg/ml) release from rat primary pituitary cells in vitro 
 
 
 
 
 
 
 
 
Data are mean ±SEM of n=12 for each experimental condition. *** P<0.001 vs. control (media only) and (* P<0.05 vs. control). Data 
compared one way ANOVA followed by Tukey’s post hoc test. 
Treatments 
(µM) 
0 1 3 5 7 10 20 30 60 
control 3874± 377 3435± 356 3469±267 4119±584 3738±205 5078±590 3776±451 4182±463 7026±351 
0.001 2883± 215 3789±195 5106±599 8489±1718 6831±785 7317±1206 6405±751 8142±985 6846±683 
0.01 3644± 248 4508±572 5272±512 5401±511 8311±1231* 6124±846 7194±901 7851±1059 7737±418 
0.1 4400± 409 4676±277 6142±727 6849±1017 7363±926 5978±578 8025±860 8396±902 7213±601 
1 5486±526 4756±479 5218±362 5177±412 6934±525 6942±766 7180± 1046 7382±901 9613±773 
10 3998±397 4868±561 5559±596 6010±651 7186±788 5230±690 5305±807 9141±1052* 7253±1179 
100 4823±350 4681±451 5799±493 7197±1072 8555±1082* 5195±664 6665±603 7867±733 13118±1272*** 
1000 3589±565 4807±495 6421±722 7348±858 6825±462 6473±451 13544±2033*** 8959±971* 14749±763*** 
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4.3.2.2 The effects of ATP on GH from primary pituitary cells 
 
 Figure 4.3 illustrates the effects of graded concentrations of ATP on the release of GH from 
primary pituitary cells in vitro.  For each dose of ATP investigated, although none of the 
doses caused a significant increase in GH release, a moderate increase in GH secretion in 
response to ATP was observed over time, with all doses. The maximal GH secretion 
observed was at 7 minutes and was between 892-922 pg/ml for all doses tested. 0.001µM 
ATP did not cause a significant release although maximal release was observed at 7 
minutes with a 24% increase in hormone (4.4.A). 0.01µM ATP caused a 30% increase at 7 
minutes, however it also caused a 69% increase at the 20 minute time point (figure 4.4.B). 
0.1µM ATP caused a maximal increase of GH at 7 minutes, with a 27% increase over basal, 
(figure 4.4.C). 1µM ATP stimulated a peak rise in GH levels at 7 minutes with a 22% 
increase above basal (figure 4.4D). 10µM ATP (figure 4.4.E) and 100µM ATP (figure 4.4F) 
both caused a peak release at  the time  points of 7, with an average 26 % increase 
observed. 1000µM of ATP caused only a marginal increase, peaking at 5 minutes with a 17% 
increase in hormone (figure 4.4.G). Results summarised in table 4.4. 
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Figure 4.4A:   Effect of 0.001µM ATP on GH release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (0.001µM) alone for 0, 1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each experiment 
was repeated at least two times and gave similar results, representative graph shown. Bars represent ± 
S.E.M (n=6 replicates). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.4B:  Effect of 0.01µM ATP on GH release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (0.01µM) alone for 0, 1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each experiment 
was repeated at least two times and gave similar results, representative graph shown. Bars represent ± 
S.E.M (n=6 replicates). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.4 C:   Effect of 0.1µM ATP on GH release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (0.1µM) alone for 0,1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results, representative graph shown. Bars represent ± S.E.M 
(n=6 replicates). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.4 D:   Effect of 1µM ATP on GH release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (1µM) alone for 0,1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results, representative graph shown. Bars represent ± S.E.M 
(n=6 replicates). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.4E: Effect of 10µM ATP on GH release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (10µM) alone for 0, 1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results, representative graph shown  Bars represent ± S.E.M 
(n=6 replicates). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.4 F:   Effect of 100µM on GH release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (100µM) alone for 0, 1, 3, 5, 7, 10, 20, 30 and 60 minutes.  Each experiment 
was repeated at least two times and gave similar results, representative graph shown. Bars represent ± 
S.E.M (n=6 replicates). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.4 G:  Effect of 1000µM ATP on GH release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (1000µM) alone for 0,1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each experiment 
was repeated at least two times and gave similar results, representative graph shown. Bars represent ± 
S.E.M (n=6 replicates). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Table 4.4: Effects of ATP on GH (pg/ml) release in primary pituitary cells  
 
 
 
 
 
 
 
 
 
 
Data are mean ±SEM of n=12 for each experimental condition.  Data compared one way ANOVA followed by Tukey’s post hoc test. 
Treatments (µM) 0 1 3 5 7 10 20 30 60 
control 459±68 248±15.7 236±71 642±50 647±33 459±63 69.4±20 371±29 471± 24 
0.001 369±55 441±54.1 357±76 585±68 855±88 770±137 188±61 503±54 472±22 
0.01 464±95 360±74 449±109 557±45 959±82 509±59 225±61 426±35 382±46 
0.1 535±106 338±38 462±110 655±61 893±90 536±90 246±57 387±23 466±28 
1 423±55 378±67 350±93 737±107 833±83 622±98 171±50 393±31 686±57 
10 437±40 397±57 399±100 810±95 888±57 422±53 149±24 449±46 619±74 
100 363±71 379±77 440±97 821±76 864±119 498±83 222±43 481±82 557±68 
1000 390±89 383±98 461±127 791±56 777±40 456±77 342±2 470±64 644±105 
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4.3.2.3 The effects of ATP on PRL secretion from primary pituitary cells 
 
 Figure 4.5 illustrates the effects of graded concentrations of ATP on the release of PRL from 
primary pituitary cells in vitro.  For each dose of ATP investigated, an increase in PRL 
secretion in response to ATP was observed over all time points investigated. The maximal 
PRL secretion for all doses investigated ranged from 7338-9103 pg/ml. With regard to 
timeframe, ATP consistently increased PRL secretion at 5 min and 20 minutes. 0.001µM 
ATP induced significant hormone release at 20 minutes (P<0.05 vs. control, 4.5.A). 0.01µM 
ATP (P<0.05), figure 4.5 B) 0.1µM ATP (P<0.01, figure 4.5 C) and 1µM ATP (P<0.01, 4.5D) 
caused a significant increase in PRL secretion at 20 minutes. 10µM ATP did not significantly 
increase PRL secretion, although it did induce a 10% increase above basal release at 30 
minutes (Figure 4.1.E). 100µM ATP and 1000µM of ATP also induced a significant increase 
in PRL secretion at 20 minutes (P<0.001 vs. control, figure 4.5.F and G). Results 
summarised in table 4.5. 
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Figure 4.5A:  Effect of 0.001µM ATP on PRL release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (0.001µM) alone for 0,1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each experiment 
was repeated at least two times and gave similar results, representative graph shown. Bars represent ± 
S.E.M (n=6 replicates). * P<0.05 vs. control. Data compared one way ANOVA followed by Tukey’s post 
hoc test. 
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Figure 4.5B:  Effect of 0.01µM ATP on PRL release from cultured primary pituitary cells.  Cultures (1X105 
cells/well) treated with ATP (0.01µM) alone for 0, 1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each experiment 
was repeated at least two times and gave similar results, representative graph shown. Bars represent ± 
S.E.M (n=6 replicates). * P<0.05 vs. control. Data compared one way ANOVA followed by Tukey’s post 
hoc test. 
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Figure 4.5C:  Effect of 0.1µM ATP on PRL release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (0.1µM) alone for 0, 1, 3, 5, 7, 10, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results, representative graph shown. Bars represent ± S.E.M 
(n=6 replicates). ** P<0.01 vs. control. Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.5 D:  Effect of 1µM ATP on PRL release from cultured primary pituitary cells.  Cultures (1X105 
cells/well) treated with ATP (1µM) alone for 0, 1, 3, 5, 7, 10, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results, representative graph shown. Bars represent ± S.E.M 
(n=6 replicates). ** P<0.01 vs. control. Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.5E:  Effect of 10µM ATP on PRL release from cultured primary pituitary cells.  Cultures (1X105 
cells/well) treated with ATP (10µM) alone for 0,1, 3 5, 7, 10, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results, representative graph shown. Bars represent ± S.E.M 
(n=6 replicates). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.5F:  Effect of 100µM ATP on PRL release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (100µM) alone for 0,1, 3, 5, 7, 10, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results, representative graph shown. Bars represent ± S.E.M 
(n=6 replicates).  ** P<0.01 vs. control Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.5G: Effect of 1000µM ATP on PRL release from cultured primary pituitary cells.  Cultures (1X105 
cells/well) treated with ATP (1000µM) alone for 0, 1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each experiment 
was repeated at least two times and gave similar results, representative graph shown.  Bars represent ± 
S.E.M (n=6 replicates). *** P<00.01 vs. control Data compared one way ANOVA followed by Tukey’s post 
hoc test. 
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Table 4.5: Effects of ATP on PRL (pg/ml) release in primary pituitary cells  
 
 
 
 
 
 
 
Data are mean ±SEM of n=12 for each experimental condition. *** P<0.001 vs. control (media only), **P<0.005 vs control and * P<0.05 
vs. control.  Data compared one way ANOVA followed by Tukey’s post hoc test. 
 
Treatments (µM) 0 1 3 5 7 10 20 30 60 
control 5628±1092 9275±771 7364±171 3813±1023 8273±634 5450±1384 1053±100 3488±858 6247±801 
0.001 6623±825 7486±1528 8672±1555 5975±649 7499±1078 8878±1329 2806±350* 8760±1557 5197±352 
0.01 6332±1144 6779±1118 5625±1003 6497±927 7839±1488 6954±1341 3090±339** 7094±1067 6313±429 
0.1 6517±922 7231±1194 6208±967 6519±1088 8248±1788 6136±1625 3253±376** 5092±936 4950±240 
1 8397±1447 9052±1693 6864±1035 7174±1360 8390±1830 7745±1785 3210±371 4760±841 5418±289 
10 6227±1032 7560±1623 6303±983 7541±1416 8694±1898 5372±1289 2201±251** 6766±1198 6750±966 
100 7468±1255 6432±1072 8243±1382 6891±1159 8506±1807 5929±1510 3519±483** 6988± 1758 6723±1110 
1000 5309±1201 6538±1288 6289±858 7339±1193 7068±1396 6727±1570 4709±604*** 6459±1227 6546±555 
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4.3.2 .4 The effects of ATP on TSH from primary pituitary cells 
 Figure 4.6 illustrates the effects of graded concentrations of ATP on the release of TSH 
from primary pituitary cells in vitro.  For each dose of ATP investigated, an increase in TSH 
secretion in response to ATP was observed at each time point investigated. The maximal 
TSH secretion for all doses investigated ranged from 1902-2679 pg/ml. With regard to 
timeframe, ATP consistently increased PRL secretion at 7 min and 10 minutes. 0.001µM 
ATP induced a significant increase in TSH secretion at 10 minutes (P<0.05 vs. control, figure 
4.6.A). 0.01µM ATP induced maximal TSH secretion of 25% above basal at 7 minutes 
(figure 4.6.B). 0.1µM ATP induced maximal TSH secretion of 39% above basal at 10 
minutes (figure 4.1.C). 1µM and 10 µM ATP stimulated a maximal rise in TSH levels at 10 
and 7 minutes, respectively with a 28% increase observed (figure 4.6.D and E). 100µM ATP 
induced a 14% increase in TSH secretion above basal at 7 minutes (figure 4.6F) whereas 
1000µM of ATP induced a significant increase in TSH secretion at 20 (P<0.001 vs. control, 
figure 4.6 G) and 60 minutes (P<0.001 vs. control, 4.6 G). Results summarised in table 4.6. 
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Figure 4.6A: Effect of 0.001µM ATP on TSH release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (0.001µM) alone for 0, 1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each experiment 
was repeated at least two times and gave similar results, representative graph shown. Bars represent ± 
S.E.M (n=6 replicates). * P<0.05 vs. control. Data compared one way ANOVA followed by Tukey’s post 
hoc test 
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Figure 4.6B:  Effect of 0.01µM ATP on TSH release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (0.01µM) alone for 0, 1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each experiment 
was repeated at least two times and gave similar results, representative graph shown. Bars represent ± 
S.E.M (n=6 replicates). Data compared one way ANOVA followed by Tukey’s post hoc test 
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Figure 4.6C:  Effect of 0.1µM ATP on TSH release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (0.1µM) alone for 0, 1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each experiment 
was repeated at least two times and gave similar results, representative graph shown. Bars represent ± 
S.E.M (n=6 replicates). * P<0.05 vs. control. Data compared one way ANOVA followed by Tukey’s post 
hoc test. 
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Figure 4.6D:  Effect of 1µM ATP on TSH release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (1µM) alone for 0, 1, 3, 5, 7, 10, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results, representative graph shown. Bars represent ± S.E.M 
(n=6 replicates). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.6E: Effect of 10µM ATP on TSH release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (10µM) alone for 0, 1, 3, 5, 7, 10, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results, representative graph shown. Bars represent ± S.E.M 
(n=6 replicates). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.6F:  Effect of 100µM ATP on TSH release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (100µM) alone for 0, 1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each experiment 
was repeated at least two times and gave similar results, representative graph shown. Bars represent ± 
S.E.M (n=6 replicates). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.6G:   Effect of 100 ATP on TSH release from cultured primary pituitary cells. Cultures (1X105 
cells/well) treated with ATP (100µM) alone for 0, 1, 3, 5, 7, 10,  20, 30 and 60 minutes.  Each experiment 
was repeated at least two times and gave similar results, representative graph shown. Bars represent ± 
S.E.M (n=6 replicates). *** P<0.001 vs. control. Data compared one way ANOVA followed by Tukey’s post 
hoc test. 
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Table 4.6: Effects of ATP on TSH (pg/ml) release in primary pituitary cells  
 
 
 
 
 
 
 
 
 
 
Data are mean ±SEM of n=12 for each experimental treatment. *** P<0.001 vs. control (media only) and *P>0.05 vs control. Data 
compared one way ANOVA followed by Tukey’s post hoc test. 
Treatments (µM) 0 1 3 5 7 10 20 30 60 
control 1158± 100 1936±182 1646±131 1249±110 1814±119 1333±135 544±52 1309±136 521±29 
0.001 1864±358 1582±265 1823±290 1570±123 1671±178 2679±483* 713±60 2012±420 536±36 
0.01 1618±225 1532±231 1658±222 1620±136 2417±474 1870±179 873±87 1508±257 519±35 
0.1 1456±154 1655±263 1820±232 1590±140 1890±414 2188±343 937±112 1310±212 506±39 
1 1396±170 1839±380 1548±200 1825±203 1842±348 1850±299 863±118 1231±215 478±59 
10 1608±292 1824±274 1652±176 1814±266 2508±368 1239±228 647±72 1706±01 570±71 
100 1753±320 1590±212 1915±267 1720±261 2107±399 1612±348 856±11 1729±367 672±51 
1000 1903±382 1608±301 1902±273 1753±180 1809±332 1566±243 1284±161*** 1771±372 905±57*** 
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4.3.3 Investigating the effect of purinergic receptor activation on secretagogue-
induced hormone release from pituitary cell lines  
Data from the previous experiments indicated that primary pituitary cells responsible for the 
production of ACTH and PRL hormone showed a positive response to ATP treatment (See 
figures 4.3, Table 4.3 and figure 4.5, table 4.5). 
We therefore wanted to assess the effects of ATP on these two pituitary hormones in 
isolation, and utilised two specific in vitro pituitary cell lines to do so.   The mouse 
corticotroph cell line AtT20 D16:16, was used to study the effects ACTH release. This cell 
line had been used extensively by our group [[77]; [150]],   primarily whilst investigating the 
influence of annexin -1 on corticotrophin (ACTH) secretion.  The rat cell, GH3  were utilised to 
look at the effects of ATP on PRL secretion from lactotrophs.  
 Our aim was to identify which of the pituitary cell lines were capable of producing significant 
increases in hormone secretion in response to both the relevant secretagogue and ATP/ATP 
analogues.  Cell lines that were responsive to both stimulants were then investigated further 
with the use of P2X antagonists to attempt to block the secretagogue induced increases in 
hormone secretion. 
4.3.3.1 AtT20 D16:16 corticotroph cells – response to secretagogue (corticotrophin 
releasing factor).  
Previous studies in our group had established that 4 hours was the minimum incubation time 
with which significant increases in secretagogue induced ACTH secretion from ATt20:D16 
cells could be observed [150]. Corticotrophin releasing factor (CRF) is a well-established 
secretagogue for ACTH and our CRF dose response was selected using doses either side of 
concentrations that had previously been shown to be effective (Stefana, Ray et al. 1996). 
Figure 4.7 illustrates the effects of graded concentrations of CRF on the release of ACTH 
from AtT-20 cells in vitro. CRF (0.1-100nM) induced a concentration-dependent increase in 
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ACTH secretion from AtT20 cells, with a significant increase observed with the 100nM CRF 
dose (p < 0.05 vs basal; figure 4.7). 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: The dose dependent effects of CRF (1-100nM) upon ACTH release from AtT20 D16:16 cells 
over 4 hrs. Control (media only) and stimulated groups are a mean of 6 replicates ± SEM. The data are 
representative of two separate experiments. *(P>0.05 vs Control). Analysis was performed by one way 
ANOVA with post hoc comparison using Tukey. 
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4.3.3.2 AtT20 D16:16 corticotroph – response to ATP 
 
Our previous experiments (see Figure 4.7) had identified that 100nM CRF induced a 
significant increase in ACTH secretion from AtT20 cells.  Our preliminary studies also   
showed 100µM ATP to be the lowest dose to induce ACTH release from primary pituitary 
cells (see figure 4.3 and table 4.1). This data, in addition to previous studies within our group 
which demonstrated that CRF is stimulatory at both 4hr and 7hr [150] informed our choice of 
time points to investigate the effects of ATP on ACTH secretion from AtT20 cells.  We also 
extended the time course in our study to include an early (1hr) and late (12hr) time point. 
Figure 4.8 illustrates the effects of ATP, alone and in combination with CRF, on the release 
of ACTH from AtT20 cells in vitro. The corticotroph like AtT-20 cell line responded to CRF at 
all-time points investigated, albeit a significant increase in ACTH secretion was only 
observed at the 1hr time point (p < 0.01 vs basal; figure 4.8 A). ATP alone exerted little 
influence on ACTH secretion from AtT-20 cells, although a non-significant increase was 
observed at 7h. A cumulative effect of CRF and ATP was only observed at the 3h time point 
with a modest, yet significant increase in ACTH secretion observed (p < 0.05 vs basal; figure 
4.8B). At all other time points, CRF alone induced a greater increase in ACTH secretion than 
the combination of CRF and ATP. 
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Figure 4.8: Effects of CRF and ATP on ACTH secretion from AtT20 D16:D16. AtT20 cells 
were treated with ATP (100uM) alone or in combination with CRF (100nM) for 1(A), 4(B), 
7(C) and 12(D)  hrs. The medium from cells (2x 105/well) was collected and ACTH detected 
by RIA. Bars represent means (n=6)± SEM. *p<0.05 vs control **p<0.01 vs control. Data 
represents average of one experiment.  Data compared by one way ANOVA followed by 
Tukey’s post hoc test. 
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hormone) 
Given that AtT20:D16 were not responsive to ATP at the early time points (see figure 4.8 a 
and b), we proceeded to look at the effects of ATP on PRL release using the in vitro model 
of lactorophs, GH3 cells.  Our previous expression profiling studies had shown the cell line 
expresses P2X3, 4 and 7 (see figure 3.2 c and table 3.1). As our group had little experience 
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well-established secretagogue for prolactin [[151];[2]]. A TRH dose response was conducted 
utilising doses and time points (0, 10, 30, 60 and 90 minutes) that previously been shown to 
be effective  [[14];[2]]. 
Figure 4.9 illustrates the effects of graded concentrations of TRH on the release of PRL from 
GH3 cells in vitro.  All doses of TRH induced a significant increase in PRL secretion from 
GH3 cells at 60 and 90 minutes. In addition, 100nM and 1000nM TRH induced a significant 
increase in PRL secretion compared to basal levels at 10 minutes (P<0.05 vs. control).   
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Figure 4.9A: Effects of 1nM  TRH on PRL release from cultured GH3 cells. Cultures (2x105 cells/well) 
treated with TRH alone (1nM), for 0-90 minutes. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control (NT-
media only). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.9B: Effects of 10nM TRH on PRL release from cultured GH3 cells. Cultures (2x105 cells/well) 
treated with TRH alone (10nM), for 0-90 minutes. Bars represent ± S.E.M (n=6). ** P<0.01, *** P<0.001 vs. 
control (NT-media only). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.9C: Effects of 100nM TRH on PRL release from cultured GH3 cells. Cultures (2x105 cells/well) 
treated with TRH alone (100nM), for 0-90 minutes. Bars represent ± S.E.M (n=6). ** P<0.01, * P<0.05 vs. 
control (NT-media only). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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 Figure 4.9D: Effects of 1000nM TRH on PRL release from cultured GH3 cells. Cultures (2x105 cells/well) 
treated with TRH alone (1000nM), for 0-90 minutes. Bars represent ± S.E.M (n=6). ** P<0.01, * P<0.05 vs. 
control (NT-media only). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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4.3.3.5 GH3 lactotroph cell line - response to ATP 
Our previous experiments (Figure 4.9) had identified that TRH induced a significant increase 
in PRL secretion from GH3 cells at 60-90min at all doses tested. We therefore decided to 
investigate the effects of ATP on PRL secretion from GH3 cells over the same timeframe  
Table  4.7 shows the list of ATP analogues, doses and time points investigated 
 
Table 4.7:  Summary of ATP analogues and  time points assessed in vitro 
Cell line 
 
ATP 
analogue 
Dose (µM) Time pints (minutes) 
GH3 ATP, 
BzATP, 
ATPγS 
0.001,0.01,0.1,1,10,100,1000 0,5,10,15,20,30,60 
 
 
Figure 4.10 illustrates the effects of graded concentrations of ATP on the release of PRL 
from GH3 cells in vitro. ATP induced a significant increase in PRL release from GH3 cells at 
all concentrations investigated. A dose dependent increase in PRL secretion in response to 
ATP was not observed, with maximal PRL secretion between 150-250ng/ml for all doses 
tested. With regard to timeframe, ATP consistently increased PRL secretion at 5 min – only 
the 1000uM dose failed to increase PRL release at 5 min. The timeframe for the ATP 
response at each dose is detailed in the table below. 0.001µM ATP induced a significant 
increase in PRL secretion at 5 (P<0.001 vs. control), 10 (P<0.01vs control), 15 (P<0.01vs 
control), 30 (P<0.001 vs. control, figure 4.10A) and 60minutes (P<0.001 vs. control, figure 
4.10.A). 0.01µM ATP induced a significant increase in PRL secretion at 10 (P<0.05 vs. 
control,), 15 (P<0.05 vs. control) and 20 minutes (P<0.001 vs. control)(figure 4.10.B). 0.1µM 
ATP induced a significant increase in PRL secretion at 5 (P<0.05 vs. control), 15 (P<0.05 vs. 
control), 30 (P<0.001 vs. control) and 60 minutes (P<0.001 vs. control) (figure 4.10C). 1µM 
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ATP induced a significant increase in PRL secretion at 5 (P<0.01 vs control), 10 (P<0.05 vs. 
control), 15 (P<0.001 vs. control), 20 (P<0.01vs control ) and 30 minutes (P<0.05 vs. control) 
(figure 4.10D). 10µM ATP induced a significant increase in PRL secretion at 5 (P<0.001 vs. 
control), 15 (P<0.001 vs. control), 30 (P<0.01vs control) and 60 minutes (P<0.001 vs. 
control) (figur4.10.E). 100µM ATP induced a significant increase in PRL secretion at all-time 
points investigated (P<0.001 vs. control)(figure 2.F), whereas 1000µM of ATP only induced a 
significant increase at the 60 minute time point (P<0.001 vs. control)(figure 4.10.G.). Results 
summarised in table 4.8. 
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Figure 4.10A:  Time-course for ATP induced (0.001µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with ATP (0.001µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control 
(NT-media only), ** P<0.01vs control and * P<0.05 vs. control.  Data compared one way ANOVA followed 
by Tukey’s post hoc test. 
5 10 15 20 30 60
0
100
200
300
Control
0.001M ATP
Time (minutes)
P
R
L(
ng
/m
l)
A
***
** **
***
***
166 | P a g e  
 
 
 
Figure 4.10B:    Time-course for ATP induced (0.01µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with ATP (0.01µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control 
(NT-media only), and * P<0.05 vs. control.  Data compared one way ANOVA followed by Tukey’s post hoc 
test. 
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Figure 4.10C:    Time-course for ATP induced (0.1µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with ATP (0.1µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control 
(NT-media only), and * P<0.05 vs. control.  Data compared one way ANOVA followed by Tukey’s post hoc 
test. 
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Figure 4.10D:    Time-course for ATP induced (1µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with ATP (1µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control 
(NT-media only), ** P<0.01vs control and * P<0.05 vs. control.  Data compared one way ANOVA followed 
by Tukey’s post hoc test. 
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Figure 4.10E:    Time-course for ATP induced (10µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with ATP (10µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control 
(NT-media only), ** P<0.01vs control.  Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.10F:  Time-course for ATP induced (100µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with ATP (100µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control 
(NT-media only).  Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.10G:    Time-course for ATP induced (1000µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with ATP (1000µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control 
(NT-media only).  Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.10H and I: Representative dose response graphs for ATP (0.001-1000µM) induced PRL release 
from cultured GH3 cells at 5 and 30 minutes. Cultures (2X105 cells/well) treated with ATP (0.001-1000µM) 
alone for 5 and 30 minutes.  Each experiment was repeated at least two times and gave similar results 
Bars represent ± S.E.M (n=6) *** P<0.001 vs. control (NT-media only),    ** P<0.01vs control and* P<0.05 
vs. control. Data compared one way ANOVA followed by Tukey’s post hoc test. 
173 | P a g e  
 
Table 4.8: Effects of ATP on PRL (ng/ml) release in GH3 cells  
 
 
 
 
 
 
 
 
 
 
Data are mean ±SEM of n=12 for each experimental condition. *** P<0.001 vs. control (media only), **P<0.005 vs Control and  * P<0.05 
vs. control.  Data compared one way ANOVA followed by Tukey’s post hoc test. 
Treatments (µM) 5 10 15 20 30 60 
control 36.87±2.5 39.01± 3.9 77.1 ±3.9 88.25± 22.0 28.61± 1.9 31.11±2.7 
0.001 124.8±10.3*** 113.2±11.9** 114.7±11.7 ** 64.31±4.5 114.7±8.5*** 125.8±31.7*** 
0.01 115.0±8.2 136.4±7.8* 140.3±10.4* 186.7±18.0*** 50.99±4.1 95.02±6.4 
0.1 102.96.0* 101.2±5.8 106.7 ±8.1* 56.25±2.8 156.1±16.6*** 144.0±37.2*** 
1 159.5±8.7*** 139.7±12.5* 214.9±44.2*** 204.5±40.6** 127.4±11.4* 112.5±7.0 
10 157.8±11.5 *** 109.0±9.1 158.8±37.1*** 146.4±1.0 120.4±11.0** 158.8±22.7*** 
100 135.0±6.0*** 136.7±13.1*** 164.0±20.8*** 200.6±10.5 *** 107.5±22.0*** 132.2±9.5*** 
1000 126.2±12.9 122.4±24.1 119.2   ±11 123.8±15.7 167.9±30 313.7±122*** 
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4.3.1.3 GH3 lactotroph cell line - response to ATP analogues: adenosine 5′-[γ-
thio]triphosphate tetralithium salt (ATPΥs) 
At this point, my data demonstrated that ATP induced hormone secretion from primary 
pituitary cultures was most consistently observed with regard to PRL secretion (see figure 
4.5 and summary table 4.5). In addition, PRL secreting GH3 cells demonstrated a consistent 
secretion of hormone in response to an ATP (see figure 4.10 and summary table 4.8). 
Therefore, subsequent work focused on PRL secretion in response to ATP analogues/P2XR 
antagonists. In the first instance, I was interested to investigate the effects of using specific 
ATP analogues on PRL secretion, as has been described previously using primary pituitary 
cells and GH3 cells  [[6][131]]. To this end, we tested the effects of the non-hydrolysable 
analogue adenosine 5′-[γ-thio]triphosphate tetralithium salt (ATPΥs) on PRL secretion from 
GH3 cells. ATPΥ induces a prolonged stimulation of purinergic receptors due to the fact that 
it does not undergo rapid hydrolysis and inactivation, as is the case with ATP.  
Figure 4.11 illustrates the effects of graded concentrations ATPΥ on PRL secretion from GH3 
cells in vitro. ATPΥ across all doses tested was far less effective at inducing PRL secretion 
from GH3 cells compared to ATP.  None of the doses tested significantly increased PRL 
secretion before 30 minutes, in contrast to the consistent stimulatory effect of ATP from 5 
minutes onwards. PRL release from GH3 cells was significantly increased following 
treatment of cells with both 0.001µM ATPΥ and 0.01µM ATPΥ at 60minutes (P<0.001 vs. 
control, figure 4.11A; P<0.01vs control, figure 4.11.B).   0.1µM failed to significantly influence 
PRL secretion (Figure 411.C). 1µM-100 µM ATPΥ induced a significant increase in PRL 
secretion at 30 minutes (*** P<0.001 vs. control figure 4. 11. D-F).  1000µM of ATPΥ had no 
significant effect on hormone release from GH3 cells at any time points investigated (figure 
4.11.G). Results summarised in table 4.9. 
 
 
175 | P a g e  
 
 
 
 
 
 
Figure 4.11A:  Time-course for ATPYs induced (0.001µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with ATP (0.001µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control 
(NT-media only).  Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.11B: Time-course for ATPYs induced (0.01µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with ATP (0.01µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). ** P<0.01 vs. control 
(NT-media only).  Data compared one way ANOVA followed by Tukey’s post hoc test. 
 
 
 
 
 
 
 
Time (minutes)
P
R
L(
ng
/m
l)
5 10 15 20 30 60
0
100
200
300
Control
0.01M ATP
**
B
177 | P a g e  
 
 
 
Figure 4.11C:  Time-course for ATPYs induced (0.1µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with ATP (0.1µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). Data compared one 
way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.11D:  Time-course for ATPYs induced (1µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with ATP (1µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control 
(NT-media only).  Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.11E:  Time-course for ATPYs induced (10µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with ATP (10µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control 
(NT-media only).  Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.11F:  Time-course for ATPYs induced (100µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with ATP (100µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control 
(NT-media only).  Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.11G:  Time-course for ATPYs induced (1000µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with ATP (1000µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). Data compared one 
way ANOVA followed by Tukey’s post hoc test. 
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Table 4.9: Effects of ATP on PRL (ng/ml) release in GH3 cells 
 
 
 
 
 
 
 
 
 
 
Data are mean ±SEM of n=6 replicates for each experimental condition. *** P<0.001 vs. control (media only), **P<0.005 vs 
Control and  * P<0.05 vs. control.  Data compared one way ANOVA followed by Tukey’s post hoc test. 
Treatments (µM) 5 10 15 20 30 60 
0 26.9±1.8 51.4± 12.2 41.7±2.6 44.4± 11.4 23.2± 2.8 15.7±1.8 
0.001 26.8±1.6 37.4± 2.9 42.2±2.8 25.0±2.8 35.1±5.0 94.2±7.2*** 
0.01 25.9±5.9 34.9±4.1 54.0±16.1 28.6±1.6 24.7±1.7 41.0±10** 
0.1 38.6±12.9 48.5±12.3 51.9±9.8 64.0±19.0 25.7±1.9 19.8±1.9 
1 25.9±1.2 30.3±2.0 40.9±10.7 32.7±6.4 66.2±16.9*** 12.7±3.1 
10 39.1±8.6 35.4±10.3 58.8±16.9 33.3±2.5 111±12.5*** 21.4±1.2 
100 35.2±3.3 31.2±3.0 31.5±1.3 59.5±14.0 89.6±2.6*** 27.9±9.4 
1000 33.8±1.1 60.3±18.2 26.6±1.9 51.9±11.5 25.3±2.2 30.5±6.8 
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4.3.1.4 GH3 lactotroph cell line -  response to 3'-O-[4-benzoyl]benzoyl adenosine 5'-
triphosphate (BzATP), a selective P2X receptor agonist. 
In addition to testing non-selective purinergic receptor agonists, we also tested the effects of 
a selective purinergic P2X receptor agonist, 3'-O-[4-benzoyl]benzoyl adenosine 5'-
triphosphate (BzATP) on PRL secretion in vitro.  BzATP has been reported in the literature 
as showing selectivity for P2X receptors and has been shown to augment hormone secretion 
in GH3 cells  in vitro  [[152], [153], [131]].  
Figure 4.12 illustrates the effects of graded concentrations of BzATP on the secretion of PRL 
from GH3 cells in vitro. In general, BzATP appears to be less potent than ATP, with maximal 
PRL secretion in the range of 400-600ng/ml versus 54-78ng/ml compared to ATP alone. 
Maximal secretion of PRL with BzATP usually occurs within the 20-30min time frame with a 
reduction observed at 60 minutes, PRL secretion was not influenced by treatment with 
0.001µM and 0.01µM of BzATP over the 5-60 minute time points (Figures 4.12A and 412.B 
respectively) .0.1-10 µM BzATP induced a significant increase in PRL release at 20 and 30  
minutes with maximal secretion observed at 20 minutes (P<0.001 vs. control, figure 4.12C-
E). This significant increase in PRL secretion was no longer observed at the 60 minute time 
point for each of these doses tested. 100 µM BzATP significantly increases the release of 
PRL when incubated for 30 minutes (P<0.05 vs. control figure4.12 F), although the maximal 
PRL secretion was greatly reduced compared to other doses.  A 1000 µM dose significantly 
increases the release of PRL when incubated for 10 (* P<0.05 vs. control, figure 4.G) 
Results summarised in table 4.10. 
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Figure 4.12A: Time-course for BzATP induced (0.001µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with BzATP (0.001µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). Data compared one 
way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.12B: Time-course for BzATP induced (0.01µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with BzATP (0.01µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). Data compared one 
way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.12C: Time-course for BzATP induced (0.1µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with BzATP (0.1µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control 
(NT-media only).  Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.12D: Time-course for BzATP induced (1µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with BzATP (1µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control 
(NT-media only).  Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.12E: Time-course for BzATP induced (10µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with BzATP (10µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control 
(NT-media only).  Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.12F: Time-course for BzATP induced (100µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with BzATP (100µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). * P<0.05 vs. control 
(NT-media only).  Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.12G: Time-course for BzATP induced (1000µM) PRL secretion from GH3 cells. Cultures (2X105 
cells/well) treated with BzATP (1000µM) alone for 5, 10, 15, 20, 30 and 60 minutes.  Each experiment was 
repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). * P<0.05 vs. control 
(NT-media only).  Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Table 4.10: Effects of BzATP on PRL (ng/ml)  from GH3 cells  
 
 
 
 
 
 
 
 
 
Data are mean ±SEM of n=6 replicates for each experimental condition). *** P<0.001 vs. control (media only), **P<0.005 vs Control and  
* P<0.05 vs. control.  Data compared one way ANOVA followed by Tukey’s post hoc test. 
Treatments (µM) 5 10 15 20 30 60 
0 14.2±10.2 6.8±0.8 14.0±1.5 15.2±1.2 64.4±4.7 13.5±1.8 
0.001 14.1±6.7 22.1±10 26.3±10.8 12.9±0.9 71.6±7.2 13.9±1.9 
0.01 17.6±9.3 13.5±0.8 31.3±8.6 29.6±7.2 57.9±8.8 15.3±0.7 
0.1 8.5±1.2 7.34±2.0 29.6±15.9 78.6±6.0*** 17.4±1.8 15.8±1.9 
1 8.4±1.2 9.1±2.1 12.2±0.6 77.2±4.6*** 24.9±3.1 13.0±2.0 
10 11.1±1.1 19.6±11.6 12.5±0.9 53.4±11.6*** 16.9±2.8 17.8±2.1 
100 22.9±11.2 9.4±1.7 11.0±1.3 19.6±1.9 20.8±2.7 24.3±1.9* 
1000 11.3±1.2 32.4±3.3* 30.2±9.3 26.6±1.7 18.9±3.9 15.5±3.4 
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4.3.4 An investigation into the effects of purinergic receptor antagonism on hormone 
secretion from GH3 cells  
 
The previous section demonstrated the effects of various purinergic receptor agonists on 
hormone secretion within an in vitro model of pituitary lactotrophs, GH3 cells.  ATP 
analogues stimulated PRL hormone release from cells in the following order of 
potency:ATP>ATPγ>BzATP. However, investigation into P2X function is limited by the range 
of purinergic agonists currently available.  Whilst the various agonists utilised induced 
activation of various members of the P2 family (i.e ATP activates both P2Y and P2X; BzATP 
is a P2XR agonist), they are not sufficiently selective to study the significance of individual 
P2XR activation within pituitary cells and the subsequent effect on hormone secretion. 
The aim of the experiments described in this section was to utilise purinergic receptor 
antagonists who were more selective for individual P2XRs in order to assess the functional 
significance of individual P2XRs within the pituitary (see table 4.11). 
We explored the effect of P2X antagonists on secretagogue induced PRL secretion and ATP 
stimulated hormone release. We also examined the ability of ATP to amplify TRH induced 
PRL release from GH3 cells. This effect had been previously described in primary rat 
gonadotrophs, using GnRH and ATP [34]. In the following section we demonstrated a similar 
interaction between ATP and TRH and determined the effects of antagonists on PRL 
release. 
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Table 4.11:  List of purinergic compounds to be investigated in vitro systems  
 
4.3.4.2 The effects of pre-treating cultured GH3 cells with graded concentrations of 
PPADS (1-1000µM) on TRH (1nM) induced PRL secretion 
  
All doses of PPADS tested, with the exception of the 1µM dose, had a significant effect on 
basal release of PRL from GH3 cells (Figure 4.13 A, P<0.001 vs. control and P<0.01 vs 
control). Stimulating cells with 1nM TRH induced a significant increase in PRL release from 
cells (P<0.001 vs control, Figure 4.13 A). These stimulatory effects were significantly 
inhibited by PPADS at all concentrations tested (Figure413 A, P<0.001 vs. control). Results 
summarised in table 4.12 
 
 
 
 
P2X receptor antagonist Target receptor  Doses (µM) 
PPADS P2 receptors (P2X and 
P2Y) 
1, 5, 10, 50, 100, 500, 1000 
TNP-ATP Potent, selective P2X 
antagonist 
0.01,0.05,0.1,0.1, 0.5,1,5 
AF-353 hydrochloride potent antagonist of P2X3 
homotrimers and P2X2/3 
heterotrimers 
0.01,0.05,0.1,0.1, 0.5,1,5 
A-438079 hydrochloride 
hydrate 
selective P2X7 purinoceptor 
antagonist 
0.01,0.05,0.1,0.1, 0.5,1,5 
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Figure 4.13A:  The effects of graded concentrations of P2 receptor antagonist PPADS (1-1000µM) on   
PRL secretion from  cultured GH3 cells  in the presence of 1nM TRH. Cultures (2X105 cells/well) treated 
with TRH (1nM) alone for 30 mins or pre-treated with PPADS for 15mins followed by TRH.  Each 
experiment was repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** 
P<0.001 vs. control (media only) and *P<0.05vs control .  $$$ (P<0.001 vs TRH). Data compared by one 
way ANOVA followed by Tukey’s post hoc test. 
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4.3.4.3 The effects of pre-treating cultured GH3 cells with graded concentrations of 
PPADS (1-1000µM) on ATP (1µM and 100µM) induced PRL secretion 
 
As before, all doses of PPADS tested, with the exception of the 1µM dose, had a significant 
effect on basal release of PRL from GH3 cells (Figure 4.13 B, P<0.001 vs. control and 
P<0.005 vs control). Stimulating cells with 1µM ATP induced a 25% increase in PRL release 
compared to basal secretion, however this was not significant (Figure4.13 B). The 
stimulatory effects of ATP on PRL release was significantly inhibited by all doses of PPADS 
used (figure 4.15,B, P<0.001 vs ATP and P<0.01 vs ATP).  100uM ATP had no significant 
effect on PRL release, but PRL secretion was significantly reduced by PPADS at 5, 10, 100, 
500 (figure4.13 C, P<0.001 vs ATP) and 1000µM (figure4.13 c, P<0.05 vs ATP). 
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Figure 4.13B:   The effects of graded concentrations of P2 receptor antagonist PPADS (1-1000µM) on PRL 
secretion from cultured GH3 cells in the presence of 1µM ATP. Cultures (2X105 cells/well) treated with 
ATP (1µM) alone for 30 minutes or pretreated with PPADS for 15mins followed by ATP.  Each experiment 
was repeated at least two times and gave similar results Bars represent ± S.E.M (n=6). *** P<0.001 vs. 
control (media only) and ** P<0.01vs control .  $$$ (P<0.001 vs ATP) and $$ (P<0.01 vs ATP). Data 
compared by one way ANOVA followed by Tukey’s post hoc test. 
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Figure 4.13C:   The effects of graded concentrations of P2 receptor antagonist PPADS (1-1000µM) on PRL 
secretion from cultured GH3 cells in the presence of 100µM ATP. Cultures (2X105 cells/well) treated with 
ATP (100µM) alone for 30 minutes or pretreated with PPADS for 15mins followed by ATP.  Each 
experiment was repeated at least two times and gave similar results Bars represent ± S.E.M (n=6). *** 
P<0.001 vs. control (media only) and ** P<0.01vs control .  $$$ (P<0.001 vs ATP) and $$ (P<0.01 vs ATP). 
Data compared by one way ANOVA followed by Tukey’s post hoc test. 
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4.3.4.4 The effects of pre-treating cultured GH3 cells with graded concentrations of 
PPADS (1-1000µM) on ATP (1µM) and TRH (1nM) induced PRL secretion 
 
As before, 1nM TRH induced a significant increase in PRL release from GH3 cells (P<0.05 
vs control, figure 4.13 D), whereas 1µM ATP induced a non-significant rise (25%) in PRL 
release.(figure 4.13 D). TRH and ATP in combination, did not induce a significant increase in 
PRL release. PRL secretion was decreased by 1, 5, (figure 4.13D, P<0.05 vs ATP) and 100, 
500 and 1000µM PPADS (figure4.13D, P<0.001 vs ATP). 
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Figure 4.13D: The effects of graded concentrations of P2 receptor antagonist PPADS (1-1000µM) on  PRL 
secretion from cultured GH3 cells in the presence of 1nM TRH  and 1µM ATP. Cultures (2X105 cells/well) 
treated with ATP (1µM) alone for 30mins  or pretreated with PPADS for 15mins followed by ATP.  Each 
experiment was repeated at least two times and gave similar results Bars represent ± S.E.M (n=6). *** 
P<0.001 vs. control (media only) and   ** P<0.01vs control .  $$$ (P<0.001 vs ATP) and $(P<0.05 vs ATP) 
Data compared one way ANOVA followed by Tukey’s post hoc test. 
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4.3.4.5The effects of pre-treating cultured GH3 cells with graded concentrations of 
PPADS (1-1000µM) on ATP (100µM) and TRH (1nM) induced PRL secretion 
 
As before, all doses of PPADS tested, with the exception of the 1µM dose, had a significant 
effect on basal release of PRL from GH3 cells (Figure 4.13E, P<0.001 vs. control and 
P<0.01 vs control). As before, 1nM TRH induced a significant increase in PRL release from 
GH3 cells (P<0.05vs control, figure 4.13E), whereas 1µM ATP induced a non-significant rise 
(25%) in PRL release. TRH and ATP in combination, did not induce a significant increase in 
PRL release. PRL secretion was inhibited with all doses of PPADS tested (Figure 4.13E, 
P<0.001 vs ATP&TRH and P<0.01 vs ATP&PPADS) with the exception of 1000µM PPADS. 
The values for the effect of PPADS on PRL release in vitro  are  tabulated and summarised 
in table 4.11. 
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Figure 4.13E: The effects of graded concentrations of P2 receptor antagonist PPADS (1-1000µM) on PRL 
secretion from cultured GH3 cells in the presence of 1nM TRH and 100µM ATP. Cultures (2X105 cells/well) 
treated with ATP (1µM) alone for 30 minutes or pretreated with PPADS for 15mins followed by ATP.  Each 
experiment was repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** 
P<0.001 vs. control (media only) and   ** P<0.01vs control .  $$$ (P<0.001 vs ATP) and $$(P<0.01 vs ATP). 
Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Table 4.11: A summary of the effects of PPADS on PRL (ng/ml) release from GH3 cells in vitro.  
 
 
 
 
 
 
 
 
 
 
Data 
are mean ±SEM of n=6 replicates for each treatment group. *** P<0.001 vs. control (media only) and ** P<0.01vs control.  $$$ (P<0.001 vs ATP) and $$(P<0.01 vs 
ATP). Data compared one way ANOVA followed by Tukey’s post hoc test. 
 PPADS 
(0µM) 
PPADS 
(1µM) 
PPADS 
(5µM) 
PPADS 
(10µM) 
PPADS 
(50µM) 
PPADS 
(100µM) 
PPADS 
(500µM) 
PPADS 
(1000µM) 
Control 135.1±10.37 87.6±6.9 53.5±6.3*** 45.3±6.8*** 56±4.8 *** 66.3±7.8** 63.2±9.3*** 62.09±13.0*** 
TRH (1nM) 223±28.9 * 76.8±7.7$$$ 46.9±4.5$$$ 69.7±15.7$$$ 61.8±8.5$$$ 51.3±6.9$$$ 46.2±6.7$$$ 55.3±7.6$$$ 
ATP (1µM) 199.4±28.4 46.4±5.8$$$ 49.1±8.1$$$ 55.3±7.1$$$ 114.5±34.$$ 65.5±11.7$$$ 60.5±4.2$$$ 76.4±11.7$$$ 
ATP (100µM) 166.2±19.6 
 
 
121.7±17.4 
66.5±13.2$$$ 78.5±15.0$$$ 104.2±9.8 71.0±13.8$$$ 52.3±15.4$$$ 98.1±22.6$ 
TRH +ATP 
(1µM) 
169.5±22.4 95.2±11.6$ 85.9±21.2$ 109.3±10.1 124.6±12.6 75.19±12.9$$$ 45.03±8.3$$$ 41.9±7.2$$$ 
TRH +ATP 
(100µM) 
170.8±12.9 75.2±9.0$$$ 49.9±9.0$$$ 57.7±7.3$$$ 88.0±17.7$$ 88.9±11.6$$ 83.1±8.4$$ 132.6±26.0 
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4.3.5.1 An investigation into the effects of TNP-ATP on prolactin secretion from 
cultured GH3 cells  
 
 Having demonstrated that inhibition of P2 receptors with PPADS will decrease hormone 
release from GH3 cells, we proceeded to investigate the influence of P2XR inhibition utilising 
the P2X receptor antagonist TNP-ATP. TNP-ATP has been reported to be a potent P2X 
inhibitor in nanomolar concentrations [ [154], [155]].    GH3 cells were incubated with TNP-
ATP for 15 minutes prior to treatment with TRH (1nM), ATP (1µM and 100µM) or TRH and 
ATP combined (1nM TRH +1/100µM ATP). The effects of TNP-ATP on PRL secretion from 
GH3 were determined by RIA. 
 
4.3.5.2 The effects of pre-treating cultured GH3 cells with graded concentrations of 
TNP-ATP (1-5000nM) on TRH (1nM) induced PRL secretion. 
 
TNP-ATP significantly reduced basal PRL secretion from GH3 cells at 1, 50 (figure,4.14A 
P<0.05 vs. control),  10 and 100nM (figure, 4.14A  P<0.01 vs. control ). Stimulating cells with 
1nM TRH induced a significant increase in PRL secretion (P<0.01 vs control, figure 4.6 A). 
These stimulatory effects were significantly inhibited by TNP-ATP at 10, 500, 1000 and 5000 
nM (Figure 4.14A, P<0.01 vs TRH) and 5 and 100nM (Figure 4.14A, P<0.001 vs. TRH). 
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Figure 4.14A: The effects of graded concentrations of P2X receptor antagonist TNP-ATP (1-5000nM) on 
PRL secretion from cultured GH3 cells in the presence of 1nM TRH. Cultures (2X105 cells/well) treated 
with TRH (1nM) alone for 30mins or pre-treated with TNP-ATP for 15mins followed by TRH.  Each 
experiment was repeated at least two times and gave similar results Bars represent ± S.E.M (n=6). ** 
P<0.01 vs. control (media only) and *P<0.05 vs control.  $$$ (P<0.001 vs TRH).and $$(P<0.01 vs TRH). 
Data compared one way ANOVA followed by Tukey’s post hoc test. 
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4.3.5.3 The effects of pre-treating cultured GH3 cells with graded concentrations of 
TNP-ATP (1-5000nM) on ATP (1µM and 100µM) induced PRL release 
 
TNP-ATP significantly reduced basal PRL secretion from GH3 cells at 1, 50 (P<0.05 vs 
control, Figure 4.14B) and 10 and 100nM (figure 4.14, B,   P<0.01 vs. control). Stimulating 
cells with 1µM ATP failed to increase PRL release from GH3 cells whereas 100µM ATP 
induced a significant increase in PRL release (P<0.001 vs. control, Figure 4.14C). The 
stimulatory effect of 100uM ATP on PRL secretion was significantly inhibited by all doses of 
TNP-ATP used (P<0.001 vs. ATP, Figure4.14). 
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Figure 4.14B: The effects of graded concentrations of P2X receptor antagonist TNP-ATP (1-5000nM) on 
PRL secretion from cultured GH3 cells in the presence of 1µM ATP.  Cultures (2X105 cells/well) treated 
with ATP (1µM) alone for 30 minutes or pretreated with TNP-ATP for 15mins followed by ATP.  Each 
experiment was repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). 
**P<0.01 vs. control (media only) and     * P<0.05 vs control.  Data compared one way ANOVA followed by 
Tukey’s post hoc test. 
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Figure 4.14C: The effects of graded concentrations of P2X receptor antagonist TNP-ATP (1-5000nM) on 
PRL secretion from cultured GH3 cells in the presence of 100µM ATP.  Cultures (2X105 cells/well) treated 
with ATP (100µM) alone for 30 minutes or pretreated with TNP-ATP for 15mins followed by ATP.  Each 
experiment was repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). 
**P<0.01 vs. control (media only)      * P<0.05 vs control .  Data compared one way ANOVA followed by 
Tukey’s post hoc test. 
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4.3.5.4 The effects of pre-treating cultured GH3 cells with graded concentrations of 
TNP-ATP (1-5000nM) on ATP (1µM) and TRH (1nM) induced PRL secretion 
TNP-ATP significantly reduced basal PRL secretion from GH3 cells at 1, 50, 100 nM 
(P<0.05 vs control, Figure 4.14D) and 10nM (P<0.01 vs. control, Figure 4.14D). 1nM TRH 
induced a significant increase in PRL release from GH3 cells (P<0.01 vs control, figure 4.14 
D). 1µM ATP failed to increase PRL release from cells. However co-incubation with 1µM 
ATP and 1nM TRH induced a significant increase in PRL release (P<0.001 vs. control, 
Figure4.14 D). The stimulatory effect of TRH both with and without ATP was significantly 
inhibited at all doses of TNP-ATP tested (P<0.001 vs. TRH and ATP, Figure 4.14D). 
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Figure 4.14D: The effects of graded concentrations of P2X receptor antagonist TNP-ATP (1-5000nM) on 
PRL secretion from cultured GH3 cells in the presence of 1µM ATP and 1nM TRH. Cultures (2X105 
cells/well) treated with ATP (1µM) alone for 30mins or pretreated with  TNP-ATP for 15mins followed by 
ATP.  Each experiment was repeated at least two times and gave similar results. Bars represent ± S.E.M 
(n=6). ***P<0.001 vs. control (media only), **P<0.01 vs. control and  * P<0.05vs control . $$$ (P<0.001 vs 
TRH). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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 4.3.5.5 The effects of pre-treating cultured GH3 cells with graded concentrations of 
TNP-ATP (1-5000nM) on ATP (100µM) and TRH (1nM) induced PRL release. 
TNP-ATP had a significant influence on basal PRL secretion from GH3 cells at  1nM (P<0.05 
vs control, Figure 4.6 E) and 10 and 100nM (figure, P<0.01 vs. control, Figure 4.14E). 1nM 
TRH induced a significant increase in PRL release from GH3 cells (P<0.01 vs control, figure 
4.14E). 100µM ATP induced a significant increase in PRL release (P<0.001 vs. control, 
Figure 4.14E). The stimulatory effect of 100uM ATP was significantly inhibited at all doses of 
TNP-ATP tested (P<0.001 vs. ATP, Figure 4.6E). However co-incubation with 100µM ATP 
and 1nM TRH induced a significant increase in PRL release (P<0.001 vs. control, Figure 
4.14E). The stimulatory effect of TRH and ATP was significantly inhibited at all doses of 
TNP-ATP tested (P<0.001 vs. TRH and ATP, Figure 4.14E). The values for the effect of 
TNP-ATP on PRL release in vitro are tabulated and summarised in table 4.12. 
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Figure 4.14E:  The effects of graded concentrations of P2X receptor antagonist TNP-ATP (1-5000nM) on 
PRL secretion from cultured GH3 cells in the presence of 100µM ATP and 1nM TRH. Cultures (2X105 
cells/well) treated with ATP (1µM) alone for 30mins  or pretreated with TNP-ATP for 15mins followed by 
ATP.  Each experiment was repeated at least two times and gave similar results Bars represent ± S.E.M 
(n=6). ***P<0.001 vs. control (media only), **P<0.01 vs. control and * P<0.05vs control. $$$ (P<0.001 vs 
TRH). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Table 4.12: Summary of the effects of TNP-ATP on PRL (ng/ml) release from GH3 cells in vitro.   
 
 
Data are mean ±SEM of n=6 replicates for each treatment group. *** P<0.001 vs. control (media only) and   ** P<0.01vs control.  $$$ (P<0.001 
vs ATP) and $$(P<0.01 vs ATP). Data compared one way ANOVA followed by Tukey’s post hoc test. 
 TNP-ATP 
(0nM) 
TNP-ATP 
(1nM) 
TNP-ATP 
(5nM) 
TNPATP 
(10nM) 
TNP-ATP 
(50nM) 
TNP-ATP 
(100nM) 
TNP-ATP 
(500nM) 
TNP-ATP 
(1000nM) 
TNP-ATP 
(5000nM) 
Control 70.0±14.6* 31.5±5.0 23.8±4.2** 18.4±4.5** 19.4±7.0* 22.4±.7.7 54.5±5.4 52.4±4.5 57.84±3.2 
TRH (1nM) 118.4±11.4** 83.1±6.5 64.6±5.0444 75.0±10.2$$ 96.3±9.9 69.3±4.4$$ 76.9±4.7$$ 75.8±4.4$$ 72.5±6.9$$ 
ATP (1µM) 104.3±10.3 69.1±4.6 53.9±6.8 76.1±5.4 72.4±4.1 86.7±8.4 72.8±6.3 70.1±6.2 97.4±11.4 
ATP 
(100µM) 
185.3±28.0*** 84.6±5.4$$$ 82.8±7.4$$$ 64.3±4.9$$$ 57.3±6.6$$$ 52.3±3.8$$$ 53.2±3.6$$$ 50.3±4.0$$$ 18.4±2.4$$$ 
TRH +ATP 
(1µM) 
159.3±12.9*** 77.2±7.3$$$ 70.9±4.4$$$ 91.5±7.4$$$ 60.2±4.0$$$ 89.8±4.1$$$ 83.6±7.8$$$ 83.0±6.2$$$ 76.1±4.7$$$ 
TRH +ATP 
(100µM) 
206.2±22.8*** 71.8±6.8$$$ 83.3± 7.8$$$ 72.3± 7.5$$$ 81.3±9.2$$$ 73.4±7.0$$$ 79.2±7.0$$$ 86.3±5.3$$$ 82.5±5.4$$$ 
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4.3.5.4 An investigation into the effects of P2X3 inhibitor AF-353 on prolactin release 
from cultured GH3 cells  
 
 We subsequently investigated the effect of blocking individual P2X receptors in order to 
determine the effects of specific receptor antagonism on PRL release from pituitary cells in 
vitro.    The P2X3 receptor antagonist, AF-353 has been characterised both in vivo and in 
vitro as a potent P2X3R inhibitor but it effects on pituitary function are yet to be determined 
[[144],[146] ]. We pretreated GH3 cells for 15 minutes with the P2X3 receptor antagonist AF-
353 and subsequently treated with TRH (1nM), ATP (1µM and 100µM) and TRH and ATP 
combined (1nM TRH +1/100µM ATP). The effects of the compound on PRL secretion from 
GH3 were determined by RIA. 
4.3.5.4.1 The effects of pre-treating cultured GH3 cells with graded concentrations of 
AF-353   (1-5000nM) on TRH (1nM) induced PRL secretion. 
 
All doses of A-353 tested failed to influence basal PRL release from GH3 cells (Figure 
4.15A). Stimulating cells with 1nM TRH induced a significant increase in PRL release from 
GH3 cells (P<0.001 vs control, Figure 4.15A). The stimulatory effects of TRH on PRL 
secretion were significantly inhibited by AF-353 at all concentrations tested ( P<0.001 vs. 
TRH, and P<0.01 vs TRH, Figure 4.15A). 
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Figure 4.15A:  The effects of graded concentrations of P2X3 receptor antagonist Af-353 (1-5000nM) on 
PRL secretion from cultured GH3 cells in the presence of 1nM TRH. Cultures (2X105 cells/well) treated 
with TRH (1nM) alone 30  or pre-treated with AF-353 for 15mins followed by TRH. D= vechile control 
DMSO Each experiment was repeated at least two times and gave similar results Bars represent ± S.E.M 
(n=6). ** *P<0.001 vs. control (media only)   $$$ (P<0.001 vs TRH) and $$(P<0.01 vs TRH). Data compared 
one way ANOVA followed by Tukey’s post hoc test. 
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4.3.5.4.2 The effects of pre-treating cultured GH3 cells with graded concentrations of 
AF-353 (1-5000nM) on ATP (1µM and 100µM) induced PRL secretion 
All doses of A-353 tested failed to influence basal PRL release from GH3 cells (Figure 4.15 
B). Stimulating cells with 1µM ATP induced a significant increase in PRL release from GH3 
cells (P<0.001 vs control, Figure 4.15 B). The stimulatory effects of ATP on PRL secretion 
were significantly inhibited by AF-353 at all concentrations tested (with the exception of the 
5nM dose) (P<0.001 vs. ATP, Figure 4.15A). Stimulating cells with 100µM ATP induced a 
significant increase in PRL release from GH3 cells (P<0.001 vs control, Figure 4.15C). The 
stimulatory effects of ATP on PRL secretion were significantly inhibited by AF-353 at all 
concentrations tested (with the exception of the 100nM dose) (, P<0.001 vs. ATP, P<0.01 vs. 
ATP and P<0.05 vs. ATP Figure 4.15 C). 
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Figure 4.15B: The effects of graded concentrations of P2X3 receptor antagonist Af-353 (1-5000nM) on 
PRL secretion from cultured GH3 cells in the presence of 1µM ATP. Cultures (2X105 cells/well) treated 
with TRH (1nM) alone for 30mins or pre-treated with AF-353 for 15mins followed by TRH. D= vechile 
control DMSO. Each experiment was repeated at least two times and gave similar results. Bars represent 
± S.E.M (n=6). ** *P<0.001 vs. control (media only), $$$ (P<0.001 vs ATP). Data compared one way ANOVA 
followed by Tukey’s post hoc test. 
 
 
0
100
200
300
***
$$$
B
Treatments
ATP  (1M)
AF-353 (nM) -    D 1   5   10  50 100 500 1000 5000 -         1   5   10  50 100 500 1000 5000
 -   -  -   -  -  -    -  -   -   -    +   + + +   + +  + +  +
P
R
L 
S
e
cr
e
ti
o
n
(n
g
/3
0 
m
in
s)
$$$
217 | P a g e  
 
 
 
 
 
Figure 4.15C: The effects of graded concentrations of P2X3 receptor antagonist Af-353 (1-5000nM) on 
PRL secretion from cultured GH3 cells in the presence of 100µM ATP. Cultures (2X105 cells/well) treated 
with ATP (100µM) alone for 30mins or pre-treated with AF-353 for 15mins followed by ATP. D= vechile 
control DMSO. Each experiment was repeated at least two times and gave similar results. Bars represent 
± S.E.M (n=6). ** *P<0.001 vs. control (media only)   $$$ (P<0.001 vs ATP). Data compared one way 
ANOVA followed by Tukey’s post hoc test. 
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4.3.5.4.3 The effects of pre-treating cultured GH3 cells with various concentrations of 
AF-353 (1-5000nM) on ATP (1µM) and TRH (1nM) induced PRL release 
All doses of A-353 tested failed to influence basal PRL release from GH3 cells (Figure 
4.15D).Stimulating cells with 1nM TRH induced a significant increase in PRL release from 
GH3 cells (P<0.001 vs control, Figure4.15D). Stimulating cells with 1µM ATP induced a 
significant increase in PRL release from cells (P<0.001 vs control, Figure 4.15D). However 
stimulating cells with both 1µM ATP and 1nM TRH failed to induce a significant increase in 
PRL release from GH3 cells (Figure 4.15D). Pre-treating cells with inhibitor had no 
significant effect on the PRL release (Figure 4.15 D). 
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Figure 4.15D:  The effects of graded concentrations of P2X3 receptor antagonist Af-353 (1-5000nM) on 
PRL secretion from  cultured GH3 cells in the presence of 1nM TRH and 1 µM ATP. Cultures (2X105 
cells/well) treated with TRH (1nM) alone for 30 mins or pre-treated with AF-353 for 15mins followed by 
TRH & ATP. D=vechile control DMSO.  Each experiment was repeated at least two times and gave similar 
results. Bars represent ± S.E.M (n=6). *** P<0.001 vs. control (media only). Data compared one way 
ANOVA followed by Tukey’s post hoc test. 
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4.3.5.4.4 The effects of pre-treating cultured GH3 cells with graded concentrations of 
AF-353 (1-5000nM) on ATP (100µM) and TRH (1nM) induced PRL release 
All doses of A-353 tested failed to influence basal PRL release from GH3 cells (Figure 
4.15E). 
Stimulating cells with 1nM TRH induced a significant increase in PRL release from GH3 cells 
(P<0.001 vs control, Figure 4.15E). Stimulating cells with 100µM ATP also induced a 
significant increase in PRL release (P<0.001 vs control, Figure 4.15 E). However stimulating 
cells with both 100µM ATP and 1nM TRH caused a marginal but non- significant increase in 
PRL release from cells (Figure 4.15E). The stimulatory effects of TRH and ATP were 
significantly inhibited by AF-353 at 1,10 ( P<0.05 vs. TRH&ATP, Figure 4.15E),  500 and 
1000nM (P<0.01 vs. TRH&ATP, Figure 4.15 E). 5, 50,100 and 5000nM of AF-353 had no 
effect.  The values for the effect of AF-353 on PRL release in vitro are tabulated and 
summarised in table 4.13. 
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Figure 4.15E: The effects of graded concentrations of P2X3 receptor antagonist Af-353 (1-5000nM) on 
PRL secretion from cultured GH3 cells  in the presence of 1nM TRH and 100µM ATP Cultures (2X105 
cells/well) treated with TRH (1nM) and ATP (100um) alone 30  or pre-treated with AF-353 for 15mins 
followed by TRH & ATP.  Each experiment was repeated at least two times and gave similar results Bars 
represent ± S.E.M (n=6). *** P<0.001 vs. control (media only). $$(P<0.01 vs TRH&ATP) and $ (P<0.05 vs 
TRH &ATP) Data compared one way ANOVA followed by Tukey’s post hoc test. 
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Table 4 13 summary of the effects of AF-353  on PRL (ng/ml) release from GH3 cells in vitro.   
 
Data are mean ±SEM of n=6 replicates for each treatment group. *** P<0.001 vs. control (media only) and ** P<0.01vs control.  $$$ (P<0.001 vs ATP) and 
$$(P<0.01 vs ATP) Data compared one way ANOVA followed by Tukey’s post hoc test. 
 DMSO AF-353 
(0nM) 
AF-353 
(1nM) 
AF-353 
(5nM) 
AF-353 
(10nM) 
AF-353 
(50nM) 
AF-353 
(100nM) 
AF-353 
(500nM) 
AF-353 
(1000nM) 
AF-353 
(5000nM) 
Control 94.6±23.3 67.3±7.1 55.3±3.5 57.8±5.4 62.8±4.7 50.9±4.2 43.5±4.6 42.4±6.1 36.5±5.7 52.7±4.2   
TRH 
(1nM) 
----- 142.0±26.8 
*** 
15.3±1.4 
$$$ 
62.2±15.4 
$$$ 
43.7±5.0 
$$$ 
40.4±5.1 
$$$ 
45.9±7.1 
$$$ 
63.4±5.4 
$$$ 
73.0±13.5 
$$$ 
49.1±8.0 
$$$ 
ATP 
(1µM) 
----- 139.5±13.3 
*** 
68.4±11.4 
$$$ 
75.2±11.4 
$$ 
62.2±13.9 
$$ 
47.6±12.3 
$$$ 
38.0±9.1 
$$$ 
63.4±9.8 
$$$ 
51.9±8.0 
$$$ 
64.3±5.2 
$$ 
ATP 
(100µM) 
--- 153.3±26.6 
*** 
66.0±10.6 
$$$ 
58.9±5.6 
$$$ 
69.1±14.7 
$$ 
78.4±10.6 
$$ 
124.6±13.1 80.6±13.4 
$$ 
58.9±10.6 
$$$ 
69.9±17.2 
$$$ 
TRH 
+ATP 
(1µM) 
---- 66.5±4.5 81.6±13.5 47.5±8.3 53.7±5.5 37.3±5.4 55.7±6.4 64.4±6.4 92.2±12.3 76.7±7.8 
TRH 
+ATP 
(100µM) 
---- 125.2±23.3 52.6±8.2 
$ 
72.1±13.8 50.3±17.8 65.1±10.2 81.3±14.0 42.2±3.9$$ 46.1±7.3 
$$ 
80.4±17.9 
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4.3.5.5 An investigation into the effects of the P2X7 inhibitor A-438079 on prolactin 
release from cultured GH3 cells  
 We then proceeded to investigate the influence of specific antagonism of the P2X7 receptor 
on PRL release from GH3 cells in vitro [[156],[157]]. We utilised the P2X7 receptor 
antagonist A-438079 to determine the effect of P2X7 blockade on pituitary function. GH3 
cells were preincubated with A-438079 for 15 minutes prior to treatment with TRH (1nM), 
ATP (1µM and 100µM) or TRH and ATP combined (1nM TRH +1/100µM ATP). The effects 
of the compound on PRL secretion from GH3 were determined by RIA. 
 4.3.5.5 .1The effects of pre-treating cultured GH3 cells with various concentrations of 
A-438079 (1-5000nM) on TRH (1nM) induced PRL release. 
All doses of A-438079 tested significantly reduced the basal release of PRL from GH3 cells 
(P<0.001 vs. control and P<0.01 vs control, Figure 4.16A). Stimulating cells with 1nM TRH 
induced a significant increase in PRL release from cells (P<0.01 vs control, Figure 4.16A). 
The stimulatory effects of TRH were significantly inhibited by A-438079  at all concentrations 
(P<0.001 vs. TRH, Figure4.16 A). 
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 Figure 4.14A: The effects of graded concentrations of P2X7 receptor antagonist A-438079(1-5000nM) on 
PRL secretion from cultured GH3 cells in the presence of 1nM TRH. Cultures (2X105 cells/well) treated 
with TRH (1nM) alone for 30mins or pre-treated with A-438079 for 15mins followed by TRH.  Each 
experiment was repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** 
P<0.001 vs. control (media only) and **P<0.01 vs control.  $$$ (P<0.001 vs TRH). Data compared using 
one way ANOVA followed by Tukey’s post hoc test 
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4.3.3.52 The effects of pre-treating cultured GH3 cells with graded concentrations of 
A-438079 (1-5000nM) on ATP (1µM and 100µM) induced PRL release 
All doses of A-438079 significantly reduced the basal release of PRL from GH3 cells 
(P<0.001 vs. control and P<0.01 vs control, Figure4.16B). Stimulating cells with 1µM ATP 
induced a significant increase in PRL release from cells (P<0.001 vs. control, Figure 4.16 B). 
This effect was also repeated with 100µM ATP (P<0.001 vs. control, Figure 4.16C). The 
stimulatory effects of both does of ATP were significantly inhibited by all doses of A-438079 
tested (P<0.001 vs. ATP, Figure 4.16B and 4.16C). 
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 Figure 4.16B: The effects of graded concentrations of P2X7 receptor antagonist A-438079(1-5000nM) on 
PRL secretion from cultured GH3 cells in the presence of 1µM ATP. Cultures (2X105 cells/well) treated 
with ATP (1µM) alone for 30mins or pre-treated with A-438079 for 15mins followed by ATP.  Each 
experiment was repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** 
P<0.001 vs. control (media only) and **P<0.01 vs control.  $$$ (P<0.001 vsTRH). Data compared using one 
way ANOVA followed by Tukey’s post hoc test 
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 Figure 4.16C: The effects of graded concentrations of P2X7 receptor antagonist A-438079 (1-5000nM) on 
PRL secretion from cultured GH3 cells  in the presence of 100µM ATP cultures (2X105 cells/well) treated 
with ATP (100µM) alone for 30mins or pre-treated with A-438079  for 15mins followed by ATP.  Each 
experiment was repeated at least two times and gave similar results. Bars represent ± S.E.M (n=6). *** 
P<0.001 vs. control (media only) and **P<0.01 vs control.  $$$ (P<0.001 vs TRH). Data compared one way 
ANOVA followed by Tukey’s post hoc test. 
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4.3.3.5.3 The effects of pre-treating cultured GH3 cells with graded concentrations of 
A-438079 (1-5000nM) on ATP (1µM) and TRH (1nM) induced PRL release 
All doses of A-438079 tested significantly reduced the basal release of PRL from GH3 cells 
(P<0.001 vs. control and P<0.01 vs control, Figure 4.16D). Stimulating cells with 1nM TRH 
induced a significant increase in PRL release from cells (P<0.01 vs control, Figure 4.16D). 
Stimulating cells with 1µM ATP induced a significant increase in PRL release from cells 
(P<0.001 vs. control, Figure 4.16D). However combining both secretagogue and ATP 
together failed to significantly influence PRL release (Figure 4.16D). Pre-treating cells with 
A-438079 did significantly decrease the release of PRL from TRH/ATP treated cells 
(P<0.001 vs. TRH/ATP, Figure 4.16D). 
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Figure 4.16D: The effects of graded concentrations of P2X7 receptor antagonist A-438079(1-5000nM) on 
PRL secretion from  cultured GH3 cells  in the presence of 1nM TRH  and 1µM ATP. Cultures (2X105 
cells/well) treated with TRH (1nM) or ATP (1µM) alone for 30mins or pre-treated with A-438079 (for 15mins 
followed by TRH and ATP).  Each experiment was repeated at least two times and gave similar results. 
Bars represent ± S.E.M (n=6). *** P<0.001 vs. control (media only) and **P<0.01 vs control.  $$$ (P<0.001 
vs TRH and ATP). Data compared one way ANOVA followed by Tukey’s post hoc test. 
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4.3.3.5.4The effects of pre-treating cultured GH3 cells with various concentrations of 
A-438079   (1-5000nM) on ATP (100µM) and TRH (1nM) induced PRL release 
All doses A-438079 had a significant effect on basal release of PRL from GH3 cells 
(P<0.001 vs. control and P<0.01 vs control, Figure 4.16E). Stimulating cells with 1nM TRH 
caused a significant increase in PRL release from cells (P<0.01 vs control, Figure 4.16E). 
Stimulating cells with 100µM ATP caused a significant increase in PRL release from cells 
(P<0.001 vs. control, Figure4.16 E). Combining both secretagogue and ATP together did 
have a significant effect on PRL release (P<0.01 vs control, Figure 4.16E). This stimulatory 
effects was significantly inhibited by pre-treating cells with A-438079 at all doses 
investigated (P<0.001 vs. TRH and ATP, Figure 4.16E). The values for the effect of A-
438079 on PRL release in vitro are tabulated and summarised in table 4.14. 
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Figure 4.16E: Effect of increasing doses of the P2X receptor antagonist A-438079 (1-5000nM) on TRH 
(1nM) and ATP (100µM) stimulated PRL secretion from cultured GH3 cells.    Cultures (2X105 cells/well) 
treated with TRH (1nM) alone and/or ATP (100µM)  for 30mins or pre-treated with A-438079 for 15mins 
followed by TRH/ATP.  Each experiment was repeated at least two times and gave similar results. Bars 
represent ± S.E.M (n=6). *** P<0.001 vs. control (media only) and **P<0.01 vs control. . $$$ (P<0.001 vs 
TRH and ATP) Data compared one way ANOVA followed by Tukey’s post hoc test 
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Table 4.14: Summary of the effects of A-438079 on PRL (ng/ml) release 
 A-438079 
(0nM) 
A-438079 
(1nM) 
A-438079 
(5nM) 
A-438079    
(10nM) 
A-438079   
(50nM) 
A-438079 
(100nM) 
A-438079    
(500nM) 
A-438079    
(1000nM) 
A-438079   
(5000nM) 
Control 250.5±34.2 87.2±19.1*** 86.46±17.6*** 52.0±9.8*** 51.3±6.3***   39.2±5.7*** 84.3±16.0*** 138.0±23.4*** 80.3±18.3*** 
TRH (1nM) 370.2±42.8 
** 
55.0±12.4$$$ 59.0±17.4$$$ 100.5±13.6$$$ 80.8±14.8$$$ 56.8±9.7$$$ 59.9±8.1$$$ 69.7±11.7$$$ 67.7±13.1$$$ 
ATP (1µM) 437.1±35 
*** 
166.9±22.4$$$ 102.1±17.1$$$ 108.7±19.7$$$ 63.2±8.7$$$ 109.1±28.8$$$ 54.1±8.2$$$ 73.1±20.0$$$ 85.0±11.7$$$ 
ATP 
(100µM) 
380.2±36.6 
*** 
83.5±21.3$$$ 42.1±7.4$$$ 52.4±8.4$$$ 50.3±11.6$$$ 79.3±14.5$$$ 50.2±7.3$$$ 36.8±6.4$$$ 44.9±6.8$$$ 
TRH +ATP 
(1µM) 
272.0±24.1 54.2±7.4$$$ 63.1±9.3$$$ 57.1±8.7$$$ 81.3±15.7$$$ 65.3±16.2$$$ 128.9±36.7$$$ 55.5±18.5$$$ 66.1±8.0$$$ 
TRH +ATP 
(100µM) 
362.8±37.5 72.5±18.8$$$ 40.0±7.4$$$ 31.8±6.2$$$ 61.1±10.4$$$ 38.5±7.8$$$ 45.8±13.9$$$ 43.8±6.6$$$ 43.8±8.6$$$ 
Data are mean ±SEM of n=12 for each treatment group. *** P<0.001 vs. control (media only) and  ** P<0.01vs control.  $$$ (P<0.001 vs ATP). Data compared 
using one way ANOVA followed by Tukey’s post hoc test. 
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4.4 Discussion 
 
The studies described in this chapter investigated the hypothesis that P2X receptors play a 
key role in the release of pituitary hormone and that treatment with P2XR antagonists would 
significantly influence pituitary function. Our previous data demonstrated that all 7 P2XR 
family members are expressed in the rat pituitary gland (see Chapter 3) and therefore the 
possibility remained that any or all P2XRs may have a role in the regulation of the 
mammalian pituitary gland. This chapter includes data that furthers our understanding of the 
mechanism by which ATP and P2X interact to modulate pituitary function.  
P2X receptors (P2XRs) are a novel class of inotropic receptors which can be found located 
in a range of different tissues of both mammalian and non-mammalian origin. These ligand 
gated ion channels, of which there are seven identified to date (P2X1-7), are activated by 
extra cellular adenosine 5’-triphosphate (ATP), which, when bound to P2XRs affect the 
homeostasis of host cells in the following ways : 1) increase the passage of cations (Na, K,) 
out of the host cell which initials depolarisation, 2) facilitates the passage of calcium ions into 
the cell which further activates internal cellular signalling  and 3) upon prolonged activation,  
dilation of the channel allows unrestricted passage of ions into out the cell [[158],[19]]. In the 
excitable cells of the anterior pituitary, controlled secretion of hormones is driven by 
extracellular calcium/calcium influx [Ca2+]i and occurs in a pituitary subtype specific manner 
[3].The increase in [Ca2+]i stimulates electrical activity within the cell and facilitates larger 
influxes via the activation of voltage-gated calcium channels (VGCCs) which penetrate all 
areas of the cell [[53, 159]].  Rising levels of Ca2+ within the cell stimulate the production of 
inositol triphosphate (IP3) (1, 4, 5) by PLC. IP3 binding to its receptor on the endoplasmic 
reticulum allows the release of calcium from internal stores and aids in elevating cytosolic 
levels of calcium which culminates in pituitary hormone release [[26] [48]]. It has been 
demonstrated that intracellularly located ATP can achieve local concentrations in the 
millimolar range, although there is currently no data concerning ATP concentrations within 
pituitary secretory granules.  Given that the process of secretion is a dynamic process, one 
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could speculate that ATP concentrations would fluctuate dependent on patterns/periods of 
hormone secretion [[160],[161]]. Due to this fact, we tested a wide ATP dose range (0.001-
1000µM) in order to compare hormone secretion across this dose range.  In order to validate 
our primary pituitary culture model we first tested responses to a well know pituitary 
secretagogues in the absence and presence of the relevant receptor antagonist. We utilised 
CRH as our secretagogue and were provided with two potent CRF1 receptor antagonists 
which were developed at Pfizer as anti-depressant agents. CRH induced a significant rise in 
ACTH release from our primary pituitary cultures and both inhibitors caused a significant 
decrease in stimulated ACTH release as expected.  
Several studies have utilised primary cultures to characterise purinergic function in the rat 
pituitary [[75],[96],[64],[34]]. In 2006, Zemkova and colleagues employed primary pituitary 
cultures to demonstrate that ATP amplifies the effect of GnRH on LH secretion via activation 
of P2X2Rs [34] and He and co-workers have demonstrated that ATP stimulation of P2X4 
directly influences PRL release from lactotrophs [75]. 
 In this investigation a mixed population of primary rat pituitary cells were used to assess the 
effects of ATP on the release of a panel of pituitary hormones (ACTH, GH, PRL and TSH). In 
accordance with previous reports, ATP was able to stimulate hormone release from static 
primary cultures [[14], [65]]. We found the order of responsiveness of hormones to all doses 
of ATP used in this study to show the following profile: ACTH>PRL>TSH>GH. Previous 
studies of primary cells responsiveness to ATP had found a similar profile. 81% of 
corticotrophs identified by immunocytochemistry were responsive to ATP, followed by 74 % 
lactotrophs, and sommatotrophs, and 60% of thyrotrophs. [29]. However, this study utilised 
live calcium imaging of Ca2+ ions following a single treatment with 50µM ATP to primary 
cells. Pituitary subtypes were then identified by using antibodies raised against the different 
pituitary hormones. Our study cannot be directly compared with the Villaobos study due to 
differences in rat species used in generating the primary cultures and the functional measure 
of pituitary cell responsiveness to ATP. However, our study did demonstrate that ATP exerts 
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control over pituitary hormone release from cells in a subtype specific manner. Our study 
utilised the high throughput Multiplex system. This novel technique enabled us to directly 
characterize the effects of ATP on the secretion of all pituitary hormones from rat primary 
pituitary cultures in vitro.  Multiplexing analysis has been used in clinical studies to identify 
serum levels of a range of neuroendocrine hormones including ACTH, PRL, GH, 
progesterone and cortisol [[162],[163]].  In vivo, multiplexing assays have been used to 
detect changes in alpha melanocyte stimulating hormone (alpha-MSH) levels in mice. In fact 
the multiplexing immunoassay is so sensitive that it has been used to identify pituitary 
peptide hormones in paraffin embedded sections of tumours, for the purpose of staging 
pituitary adenomas [164]. To our knowledge, this is the first time that a panel of pituitary cells 
have been profiled by this method to measure functional responses to purinergic agonists. 
This allowed us to measure all hormone profiles at once. Therefore our results may reflect 
interactions between pituitary hormones, such as has been documented in rats in vivo )[165].  
A significant finding from this project was that ATP stimulates the release of ACTH from 
primary pituitary cells in vitro (figure 4.3). High dose ATP (100-1000µM) induced a significant 
increase in ACTH secretion compared to basal ACTH release (see figure 4.3, table 4.3). To 
our knowledge, we have shown for the first time that ATP can induce ACTH release from rat 
primary pituitary cells.  There is little evidence to support a role for P2XRs in modulating 
pituitary function, although there is evidence of an effect in the adrenal gland. In cultured 
bovine adrenocortical fasciculata cells, ATP has been demonstrated to potentiate ACTH 
induced glucocorticoid synthesis [166].  A single low dose of ATP (5µM) was able to induce 
cortisol secretion from cells when combined with ACTH, angiotensin II, sodium fluoride and 
forskolin over a one hour period [166]. A recent study reported similar observations using the 
human adrenal cortex cell line NCI-H295R (H295R)[167]. Only P2X5 and P2X7 were 
identified by RT-PCR within this cell line, compared to a wider range of P2Y receptors (P2Y1, 
P2Y2, P2Y6, P2Y12, P2Y13, and P2Y14). It was demonstrated through using the P2Y selective 
agonist 2MeS-ATP, that stimulation of these subsets of the P2 family caused an increase in 
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both calcium mobilisation and glucocorticoid production [167]. Thus, previous studies 
indicating an effect of P2XRs on adrenal function coupled with our data suggest that 
purinergic signalling may have a role in the control of HPA function.  
Interestingly, ATP has been shown to stabilise growth hormone granules in vitro. Interactions 
between ATP in the pituitary cell golgi complex stabilises isolated growth hormone granules 
and facilitates hormone secretion [168]. Previous studies have  also shown that the addition 
of ATP can stimulate the release of GH (and PRL) from isolated secretory granules [169]. 
However, using a mixed population of primary pituitary cells, we were unable to reproduce 
these reported effects. GH showed little response to the addition of exogenous ATP to 
primary pituitary cultures. Both humans and rats release GH hormone from the pituitary in 
episodic bursts, which occur in a pulsatile manner, which is largely GHRH dependent [170]. 
Therefore accurately measuring GH in vitro becomes difficult, as we can only take a “snap 
shot”, which will only depict the phase of release at that time. Also, we also need to take into 
the account the gender differences in the amount of GH released, with females releasing 
more than males [171]. As we used only male rats in our study, combined with the episodic 
pattern of GH secretion may explain the varied basal levels recorded in our investigation for 
GH. 
To our knowledge, this is the first time that TSH secretion in response to ATP has been 
determined in vitro.  With regard to the effect of ATP on pituitary TSH release, 1000µM ATP 
significantly increased TSH secretion at 20 and 60 minutes time point (figure 4.6, table 4.6).  
There is little evidence concerning the effects of ATP on TSH release from the pituitary. 
Studies have demonstrated a regulatory role for ATP in the production of thyroid hormone [1]. 
Using human thyrocytes in primary culture, ATP was observed to cause an increase in 
intracellular calcium which is commonly used as a measure of cellular responses to 
purinergic agonists. [173].  Kumari and co-workers have suggested that adeonsine induced 
P1 receptor activation may contribute to pituitary TSH release [174]. Given the time-point at 
which ATP stimulated TSH release, our data could potentially reflect an influence of 
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adenosine, since P1 receptors and the ectonucleases required for the breakdown of ATP are 
present in the pituitary [127].  
In contrast to the effects on GH and TSH, ATP induced significant increases in PRL release 
from primary pituitary cells in vitro (figure 4.5, table 4.5).  ATP, at all doses tested (with the 
exception of 1µM ATP) stimulated a significant release of PRL from primary pituitary cells at 
the 20 minute time point (figure, 4.5, table 4.5).  This finding is in accordance with previous 
investigations using primary pituitary cells which have demonstrated that ATP induced 
activation of P2 receptors is required for the regulated release of PRL [[6] [175]]. Nunez and 
colleagues demonstrated that stimulating rat primary pituitary cultures with 10µM ATP 
stimulated a significant increase in PRL. This was observed in both male and lactating rats 
[175]. They also demonstrated that enzymatic removal of ATP caused a decrease in both 
basal and TRH induced PRL release [173]. This study employed the reverse haemolytic 
plaque assay to determine and measure responses of single cells to ATP and/or TRH. He 
and co-workers have used isolated  enriched primary rat lactotrophs and measured hormone 
release using cell column perfusion and  RIA to investigate the role of P2 receptors in PRL 
release [65].  This group found ATP to cause both an increase in PRL release and 
intracellular calcium, when treated with 10µM ATP. The column perfusion allowed the group 
to collect samples every minute and immediately assay for PRL responses. Potentially this 
subtle difference in experiment design may account for our differences in response to ATP at 
the earlier time points. However, our study using static mixed population cells and 
multiplexing immunoassay can confirm both these findings and highlights that investigations 
based primarily on the responses to P2 agonists may not be the most efficient measure of 
P2X receptor function in the pituitary gland. In general, the relatively high basal levels of the 
pituitary hormones released from the primary cultures, made it difficult to identify the 
stimulatory effects of exogenously added ATP. This could potentially be due to the loss of 
the hypothalamic regulators such as somatostatin and dopamine which control the levels GH 
and PRL respectively. Dopamine has been shown to inhibit both the release of PRL and GH 
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from normal rat primary cells [176]. Binding of dopamine to the dopamine receptor 2 (D2R) is 
associated with a decrease in the production of cAMP and a decrease in the release of PRL 
from lactotrophs [177]. Potentially, the addition of dopamine would reduce basal levels of 
PRL which might unmask the effects of ATP on hormone secretion.   
With regard to our experiments with the rat primary pituitary cultures, PRL and ACTH were 
the two hormones that were consistently stimulated in response to ATP treatment. In order 
to further investigate the influence of P2XRs on pituitary function, we utilised two pituitary 
cell lines – AtT20:D16s (a corticotroph cell line) and GH3s (a sommatolactotroph cell line). 
Our initial experiments focused on the AtT20 cell line, and we studied the effects of ATP, 
alone and in combination with the relevant secretagogue CRH, on ACTH release. It is 
interesting to note that responsiveness of AtT20 cells to CRF was lower than observed in the 
primary pituitary cultures (figure 4.1 and 4.3). Potentially, intact FS cells, which have been 
demonstrated to facilitate the release of ACTH from corticotrophs in addition to other 
pituitary derived mediators present in the primary culture milieu may have contributed to the 
response to CRF [[78],[178]]. Thus the use of individual pituitary cell cultures is valid in order 
to identify the influence of P2X receptors on hormone secretion in a pituitary cell subtype 
specific manner.  A significant observation that came from the investigations of ATt20:D16s 
was that ATP and CRH co- administration caused a significant increase in ACTH release at 
the 4, 7 and 12hr time point (figure 4.8). Our findings are in accordance with previous 
investigations of P2XR function using this cell line which have also demonstrated that a 
combination of ATP and CRH caused a significant increase in ACTH release from cells 
following 3 hr incubation [61].  Zhao and co-workers used a different subclone of AtT20s 
(AtT20PL cell line) to determine the effects of different purinergic agonists on the expression 
of the pro-opiomelanocortin (POMC) gene and ACTH secretion from cells. RT-PCR 
demonstrated that all P2X receptors, with the exception ofP2X2, and a wide range of P2Y 
(1,2, 4 and 6) and P1 receptors ( A1 A2B A2a) were expressed in these cells. Treatment of 
cells with adenosine (10 and 20µM) or ATP (100µM), alone or in combination with CRH 
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(100nM) caused a significant increase in POMC expression and ACTH release from cells [61] 
. Previous investigations conducted by our group had demonstrated that the maximal effect 
of CRH within AtT20 cells occurred at extended time points (7hr and 12hr) [[150], [150]].  By 
looking at the effects of ATP at these extended time points we were able to show for the first 
time that ATP alone can stimulate ACTH release.   
We also studied the effects of ATP on PRL release from GH3 cells. ATP, at all doses tested, 
significantly increased PRL release from GH3 cells from 5-60 minutes (figure 4.10). This 
evidence is supported by recent studies using electrophysiological techniques to 
demonstrate the responsiveness of GH3 cells to ATP and ATP analogues [[179],[131]].  
Interestingly, the non-hydrolysable ATP analogue, ATPγS (figure 4.11), is less potent that 
ATP at stimulating PRL release from GH3 cells. The major difference between ATP and 
ATPγS, is that the former can be enzymatically cleaved by endogenous endonucleases (see 
figure 1.4), with the breakdown products ADP, AMP or adenosine capable of activating both 
P2 and P1 receptors, whereas the latter is resistant to breakdown and is therefore only 
capable of activating P2 receptors. This suggests that the PRL response to ATP may be, in 
part, mediated by both P2 and P1 receptors. It is important to note the previous studies have 
demonstrated that both P2 and P1 receptors are expressed in the GH3 cell line [[180], 
[66],[127]]. Therefore our results may reflect responses to agonist binding to both subtypes 
of receptors.  Treatment of GH3 cells with BzATP induced a minimal effect on PRL release 
from cells in vitro.  This is unexpected given the fact that BzATP is selective for P2XR 
whereas ATP acts on all purinergic receptors [[181],[152]].  Previous characterisation studies 
of P2X receptors using electrophysiology had demonstrated BzATP to induce Ca2+ influx 
from cells [131].  Chung and Colleagues identified expression of P2X7 in the cell line GH3 by 
RT-PCR and suggested that the P2X7 receptor facilitated the changes in calcium influx 
[131].  Our RT-PCR analysis of GH3 cells is in accordance with this study although our data 
also identified P2X3 and PX4Rs within this cell line (chapter 3). To our knowledge our study 
is the first time that BzATP treatment of GH3 cells has been used to directly measure the 
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effects of P2X receptor stimulation on PRL release. Our results suggest that subsequent 
investigation regarding in vitro characterisation of P2X receptors and hormone release in 
GH3 cells should take a more integrative approach, utilising calcium release and hormone 
secretion when assessing P2X function. In addition, a previous study into the effects of ATP 
on insulin secretion in vitro observed decreases in insulin secretion following BzATP 
treatment [182].This study utilised the hamster derived pancreatic cell line HIT-T15 to assess 
the effect of ATP on insulin release. There is some controversy in the literature regarding the 
effects of purinergic agents on insulin release, whereby ATP has been observed to both 
increase insulin at low doses of ATP and inhibit at higher doses [[149],[182], [124]]. Lee and 
colleagues found 1 hour stimulation of HIT-T15 grown in static culture with 100µM BzATP 
caused a significant decrease in insulin release [182].  Jacques-Silva and co-workers also 
observed a decreased insulin secretion from human islets treated with 50µM BzATP in 
comparison to ATP [124]. In our study, a wide range of doses of ATP (0.001-1000µM) were 
administered to both primary pituitary cells and to our in vitro models, AtT20:D16 and GH3 
cells. In our study, ATP only displayed a positive effect on hormone release in vitro, albeit 
demonstrating a similar profile when compared to the effects of BzATP on GH3 cells. 
 Our data generated utilising P2XR agonists indicated that P2XRs influence PRL secretion 
from GH3 cells, but failed to indicate which specific P2XRs were mediating these effects. In 
order to attempt to identify the importance of specific P2XRs, we studied the effects of 
selective P2XR antagonists on PRL secretion from GH3 cells. Initially, GH3 cells were 
treated with the secretagogue TRH and the native P2XR agonist,  ATP, either alone or in 
combination.  In our study GH3 cells responded to both TRH and ATP in a reproducible 
manner and in accordance with previous studies [ [79], [183],[131], [175]]. In addition, 
coadministration of 100µM ATP with TRH resulted in a consistent potentiation of the effects 
of TRH alone on PRL release from GH3 cells [figures 4.13 to 4.16].  The ability of ATP to 
potentiate the effects of TRH on PRL release has been previously demonstrated in primary 
pituitary cells [175].  In addition, the capability of ATP to potentiate pituitary hormone release 
241 | P a g e  
 
has also been demonstrated in the neurohypohysis [175]. Knotts and colleagues cultured 
primary rat neurohypophysial cells and demonstrated that the electrically stimulated  release 
of vasopressin (AVP) and oxytocin (OT) was potentiated by ATP, most likely via P2X2 and 
P2X3R activation  [[123],[184],[1]]. In our study, the effects of ATP and TRH, alone and in 
combination was significantly reduced by treatment with the non-selective P2R antagonist, 
PPADS (figures 4.13). The capability of PPADS to reduce pituitary hormone secretion has 
also been demonstrated in the neurohypophysis, where AVP release was significantly 
decreased in the presence of the antagonist [[185], [123]]. PPADS has been demonstrated 
to inhibit P2X mediated electrical currents in primary gonadotrophs [34], and decrease 
insulin release following pre-treatment of  cultured primary islet cells from rat and humans 
[[124],[186] ].  The results from our studies are in accordance with this observation, whereby 
PPADS inhibited both TRH and ATP stimulated PRL release form GH3 cells in vitro. Our data 
contributes to the story that functional P2 receptors are expressed in the pituitary and 
regulate hormone release from cells. The selective P2XR inhibitor, TNP-ATP also 
significantly reduced both basal and stimulated PRL release from GH3 cells (figure 4.14).  In 
contrast, the effects of TNP-ATP on PRL release were exerted with nanomolar 
concentrations, compared to PPADS which was only effective at micromolar concentrations 
(figure 4.13-4.14). The fact that our data demonstrates that blockade of P2X receptors 
significantly reduces both basal and stimulated PRL secretion from GH3 cells indicates that 
members of the P2X family play a significant role in hormone release from pituitary cells. 
TNP-ATP mediated blockade of P2X induced hormone release has been demonstrated in 
human keratinocytes  [155]. The release of ATPγs stimulated oxytocin from  cultured  skin 
and epidermis derived keratinocytes was blocked following 5 minute pretreatment with 
100nM of TNP-ATP [155]. Our study has demonstrated through the use of a selective P2XR 
inhibitor that P2X receptors play a significant role in secretagogue and ATP stimulated 
hormone release from GH3 cells in vitro. 
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The data obtained in this present study demonstrates for the first time that inhibition of 
P2X3Rs significantly decreases PRL release (figure 4.15). Investigations of P2X3 R function 
have predominantly focused on the role of this receptor in nociception, and a number of 
other pathophysiological processes [144]. In this setting, AF-353 has been demonstrated, 
using in vivo electrophysiology, to significantly alleviate pain in rat models of bone cancer 
[[146], [144]]. Since its characterisation in 2010, AF-353 has yet to be exploited as an in vitro 
tool for looking at P2XR function, and to our knowledge, this is the first time it has been used 
in vitro to characterise P2X3R function.  AF-353 had no significant effect on basal release of 
PRL from GH3 cells (figure 4.15). This may suggests that basal release of PRL may not 
involve P2X3 channels. Given the limited amount of data on this compound in vitro, one 
cannot draw comparisons with previous investigations. However, in this study we have 
demonstrated that GH3 express mRNA transcript for P2X3 receptors, which are functionally 
expressed in cells and are significantly involved in PRL release. 
All doses of the P2X7R antagonist, A-438079, consistently decreased basal and stimulated 
release of PRL (4.16). In agreement with our study, previous investigations using GH3 cells 
have shown P2X7R to be strongly expressed (chapter 3), and as we have described, P2X7R 
is believed to be the major receptor via which the ATP mediated effect occurs in this cell line 
[131]. Compared to AF-353, A-438079 has been studied more extensively in vitro. A-438079 
treatment of primary rat synaptosomes from the cerebral cortex,  significantly inhibited 
glutamate release from tissues [187].  A-438079 was concluded to be a useful tool in 
determining P2X7 versus non-P2X7  mediated exocytosis of the neurotransmitter glutamate 
[187]. It has also been used to functionally demonstrate P2X7 expression in the rat lacrimal 
gland [156]. Molecular and histological identification of P2X7R in primary lacrimal tissue was 
confirmed by functional studies to determine the effects of P2X7 inhibition on gland 
physiology. Treatment of primary lacrimal gland tissue with A-438079 decreased Bz-ATP 
stimulated calcium influx and peroxidase secretion [156].  
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4.5 Conclusion 
 
In conclusion, the data presented in this section of the thesis confirms that extra cellular ATP 
present within the pituitary cultures is a major driver of basal hormone release. This was 
demonstrated by the marked effects of P2X inhibitors on basal PRL release from GH3 cells. 
Although the timing is not as yet fully clear, our data suggests that this occurs prior to 
secretagogue induced release and is enough to maintain basal levels of hormone. In the 
future, new selective P2X antagonists will become available for the treatment of a range of 
disorders, making it critical that they are investigated in a similar manner, for the possible off 
target effects on normal pituitary function. 
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5. General discussion 
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5.1 Conclusions 
To test the hypothesis that P2X channels mediate the ability of extracellular ATP to modulate 
hormone secretagogue function, we used molecular, biochemical and immunological studies 
on both primary pituitary cells and pituitary cell lines. 
In the proceeding chapters I have confirmed a relationship between P2X receptors and 
normal pituitary function and that P2X receptors may play a role in modulating pituitary 
function. From this work I can conclude the following: 
1. A wide range of P2XRs are present on primary pituitary tissue, and specific pituitary 
cell lines. 
2. Although the timing is not fully clear, our data suggests ATP is secreted prior to 
secretagogue-induced exocytosis, and is present in sufficient concentration to drive 
basal hormone release. 
 
3. Innate pituitary P2X receptors respond to ATP and may be involved in secretagogue 
induced hormone release. 
 
4. Therefore, ATP acts in an autocrine manner to facilitate pituitary hormone exocytosis 
initiated by hypothalamic peptide. 
5.2 Future work  
5.2.1 What is significance of other P2X receptors expressed in the pituitary? : P2X4 
Several studies, utilising both neuronal and non-neuronal cells, have demonstrated that 
activation of P2X4R can induce changes in intracellular calcium concentration and ultimately 
promote the exocytosis of cellular contents. A study by Miklavc and colleagues stated that  
P2X4 activation  mediated  fusion-activated Ca2+ entry (FACE), a stage in calcium signalling 
that proceeds release of cellular contents using  primary rat alveolar type II (ATII) epithelial 
cells [116]. Real time PCR demonstrated P2X4 receptors showed the highest level of 
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expression in ATII cells and western blot confirmed expression of protein. They observed the 
receptor localised in the lamellar bodies (LBs), which are the secretory granules of the cells. 
Calcium induced FACE of LBs to the plasma membrane of ATII cells, a step which proceeds 
exocytosis of contents, was measured using electrophysiology, and was increased following 
application of 100µM ATP. Removal of ATP from ATII cells significantly reduced FACE 
following application of apyrase (300 U/mL, an ATP hydrolytic enzyme). Use of ivermectin 
(IVM), a selective positive modulator of P2X4 receptor caused a significant increase in the 
amplitude of FACE and the study concluded that functional P2X4 receptors regulated cell 
exocytosis [116]. Trang and colleagues, used primary rat cortical microglia, to demonstrate 
P2X4 regulated the release of brain-derived neurotrophic factor (BDNF) from cells [188]. 
Electrophysiology determined a mechanism whereby activation of P2X4 by extracellular ATP 
preceded increases in intracellular calcium which activated Soluble NSF Attachment Protein-
receptor (SNARE) proteins and the release of BDNF. SNARE are membrane bound protein 
complexes required for vesicle fusion and exocytosis of cellular contents [[57],[158]], and 
P2X4 mediated activation of these proteins was found to be essential to the release of BDNF 
from primary rat microglia [188]. Trang and co-workers used inhibition of P2X4 receptors, 
using siRNA to suppress expression of P2X4 in microglia and PPADS and TNP-ATP to 
prevent activation of membrane bound receptors, to investigate the role of the receptor in 
cells. In both cases, they reported a reduction in FACE and subsequent decreased secretion 
of BDNF from microglia [188]. There are similarities in observations reported regarding P2X4 
and calcium controlled release of vesicles containing extracellular material from the cells. 
Our understanding of P2X4 function in the pituitary at present is limited. Zemkova and 
colleges, using q-PCR, found P2X4 to be highly expressed in the rat anterior pituitary. Using 
electrophysiology, this group demonstrated that primary rat pituitary cells responded to IVM 
with an increase in intracellular calcium, and a subsequent dose dependent increase in PRL 
release from pituitary cells [64].  Thus the data presented above linking P2X4 with cell 
exocytosis, coupled with our data and the Zemkova study, suggests that P2X4 may play a 
significant role in the regulation of hormone secretion from pituitary cells. Therefore an 
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assessment of the functional significance of P2X4 expression in the pituitary is a worthy line 
for follow up investigations.  
At present only one P2X4 specific inhibitor is available, the compound 5-BDBD [189].   A 
recent in vitro study using primary guinea pigs cochleas has utilised 5-BDBD to determine 
the extent of P2X4 control of cochlear blood flow - an essential component in the process of 
hearing [190]. Using electrophysiology, applications of 30µM 5-BDBD were observed to 
produce a significant decrease in ATP induced electrical currents in cells. Fluorescent 
calcium imaging was used to document both decreases in free calcium and the dilation of 
capillary vessels supplying blood to the cochlear following treatment of cells with 5-BDBD 
[[189] [190]]. The use of 5-BDBD as an investigative tool to assess P2X4 function in the 
pituitary in vitro has yet to be explored. Therefore in vitro studies testing the effects of 5-
BDBD using the cell models presented in this thesis i.e. pituitary cultures, would extend our 
knowledge of the functional role of P2X4 in the pituitary gland. I would also assess the 
effects of the   inhibitor on calcium release, using a similar method applied by Zemkova and 
co-workers [64], whereby the effects of P2X4 activation were assessed in primary rat 
pituitary cells using single cell calcium measurements [64]. Studying the effects of P2X4 
inhibition on calcium release, which has been demonstrated to be essential to hormone 
release, could then be examined. It would also be useful to examine the P2X inhibitors 
utilised in this thesis with regard to the inhibitory effects on calcium release. This data could 
be integrated with information gained from an assessment of the influence of the inhibitors 
on hormone secretion from primary rat pituitary cells to generate a more complete picture of 
the effect of individual P2XRs on the process of pituitary hormone secretion.   
 
5.2.2 What is the significance of P2X receptors expressed in human pituitary tissue? 
The above methodology could then be applied to determine the role of P2X receptors in 
human pituitary tissue. Jacques-Silva and colleagues have indicated that ATP signalling 
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through P2X3 serves as a positive autocrine signal for insulin release from isolated primary 
human islets cells [124].  Primary cultures of human pituitary adenomas have been used in 
vitro to extend our understanding of the mechanisms underlying pituitary function, and to 
help develop treatments for major pituitary disorders.  Gentillin and co-workers have 
examined the ability of mitotane, an adrenolytic drug used in the treatment of Cushing’s 
disease, to influence pituitary function [191]. Using AtT20/D16v-F2, a mouse corticotroph cell 
line and ACTH-secreting human pituitary adenoma cells, this study identified that mitotane 
acted directly on corticotrophs to influence both ACTH release and cell function [191]. 
Similar studies could focus on the assessment of P2X function in human pituitary cultures 
and the development of primary human cell cultures would also provide a useful in vitro tool 
in the assessment of therapeutic P2X inhibitors prior to clinical trials.  
5.2.3 What are the signalling pathways involved in P2X receptor function and 
activation? 
Our study determined that TRH/ATP evoked secretion of PRL from GH3 cells involved a 
pathway that was inhibited by P2/P2X receptor inhibitors, although hormone release was not 
absolutely dependent on P2XRs. It has been demonstrated that ATP modulation of P2X 
receptors and subsequent calcium influx are responsible for physiological changes across a 
range of cell types. Nishi and colleagues demonstrated that cortisol secretion from the 
human adrenal cortex cell line, NCI-H295R, was increased following ATP treatment and 
directly linked to calcium influx [167]. Treatment of NCI-H295R cells with ATP induce 
transient increases in intracellular calcium influx (as measured by fluorescent calcium 
imaging), which was blocked by the addition of nifedipine, a potent calcium channel blocker. 
A similar effect has been observed in primary rat pituitary cells. As described in Chapter 4, 
Stojilkovic and co-workers have linked ATP activation of P2X receptors with calcium 
mobilisation and hormone release from pituitary cells. In brief, calcium influx through 
activated P2X channels causes depolarisation of the cellular membrane and the generation 
of action potentials which subsequently activate voltage-gated calcium channels which 
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facilitate an increase in intracellular calcium, both via the channels themselves and the 
stimulation of calcium release from the endoplasmic reticulum.  This involves secondary 
intracellular messengers such as DAG and cAMP/PKA. Increased intracellular calcium 
stimulates intracellular mechanisms which ultimately cause hormone exocytosis [[96], [53], 
[6], [96], [62], [192]]. However, the signalling pathway via which ATP and P2X induce 
secretion is still not completely understood. Recent studies have indicated that 
phosphoinositides, which are known to interact with numerous ion channels (e.g TRP, 
NDMA) may also interact with P2XRs. Phospholipids are vital components of the cell 
membrane that allow the cell to adapt to changes in the environment [173]. In a recent 
student by Mo and co-workers, it was found that inhibition of phospholipid signalling in  
primary rat dorsal root ganglion (DRG) neurons significant reduced P2X3 mediated 
responses to ATP[173]. Addition of wortmannin, which inhibits kinases involved in the 
production of phosphoinosides, led to a significant decrease in the ATP stimulated currents. 
A previous study by Bernier and co-workers found that P2X4 receptor function in mouse BV-
2 microglial cells  required  both PIP2 and PIP3  (intermediates in phospholipid production) 
[2]. Treatment of cells with wortmannin led to  ATP only acting as a partial agonist in PI 
depleted conditions[2]. This data suggests that P2X channels operate as part of a larger 
signalling complex [ [194], [195]]. Previous studies have shown that ATP is co-packaged in 
the secretory vesicles of pituitary cells, and ATP is released from both primary and 
immortalised cell lines in vitro [127][124]. In the context of the pituitary, within which we know 
numerous P2X channels are expressed, one could speculate that phospholipid signalling 
and potentially other as yet uncharacterised  proteins may aid in fine tuning P2X channel 
function via local regulation of the receptor. This requires further investigation. 
The pituitary gland is composed of a range of cellular subtypes, the hormone products of 
which interact to maintain homeostasis. Our general overview of how this occurs has been 
described over the last 100 years, but more recent studies, such as the work presented in 
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this thesis, suggest more subtle molecular interactions may also play a crucial role in 
regulating pituitary function. 
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Appendices 1 
 
The general set of the RIAs are shown in table 
 
252 | P a g e  
 
Tube Number  Contents  Description 
1-2 Non-specific binding Contains labelled 
antigen and buffer. 
Used to asses binding in 
assay not to the 
antibody. 
3-4 ½ X Contains half volume of 
labelled antigen  with 
buffer and antibody. 
Used to determine if the 
sensitivity of assay is 
increased with less 
labelled antigen 
5-6 2x Contains twice the 
volume of labelled 
antigen with buffer and 
antibody. Used to 
determine if the 
sensitivity of assay is 
increased with more 
labelled antigen 
7-8 zero Contain labelled 
antigen, antibody and 
buffer. Used to assay 
drift in assay 
9-10 zero  
11-12 Standard 1  
13-14 Standard 2  
15-16 Standard 3  
17-18 Standard 4  
19-20 Standard 5  
21-22 Standard 6  
23-24 Standard 7  
25-26 Standard 8  
27-28 Standard 9  
29-30 Standard 10  
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31-32 Standard 11  
33-34 Zero  
35…….. Samples  
Every 30-50 tubes had a 
zero tube 
---  
Final two tubes Excess antibody Measure of lable quality 
over time 
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Appendices 2 
.1 RT-PCR primer sequences 
 Table   Primer sequence for P2X RT-PCR 
 
RT-PCR control 
 
 
 
 
 
Target Sense (5′-3′) Antisense (5′-3′) bp GenBank 
P2X1 TATGTGGGTGCGAGAGTCAGG TCCTCATGTTCTCCTGCAGG 493 X80477 
P2X2 GCATGGACAGGCAGGGAAAT GGGAAAGGAGATGGCAGGGAAC 689 U14414 
P2X3 CACCATTATCAGCTCGGTGG GTGTGGAAGTGCTTGGTACG 556 X91167 
P2X4 CGTGGCGGACTATGTGATT GTGATGTTGGGGAGGATGTTC 447 X87763 
P2X5 CGCTGGGGAGTCTGTTGTAG TCTCGGTAAAACTCACTC 418    X92069 
P2X6 TCCTTCTTCCTGGTAACCAAC TGTTGTCCCAGGTATCTAAGG 341 X92070 
P2X7 GTGCCATTCTGACCAGGGTTGTATAAA GCCACCTCTGTAAAGTTCTCTCCGATT 354 X95882 
GAPDH CCTGCACCACCAACTGCTTAGC GAGTTGCTGTTGAAGTCACAG 417 X02331 
1        2       3      4      5      6     7      8      9      10    11      12 
1.1 Kb Ladder (Promega) 
2. P2X1 (493 bps) 
3. P2X2 (689 bps) 
4. P2X3 (556 bps) 
5. P2X4 (447 bps) 
6. P2X5 (418 bps) 
7. P2X6 (341 bps) 
8. P2X7 (354 bps) 
9. GAPDH (417 bps) 
10.-Template 
11.-Taq 
12-RT 
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